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Abstract 
Large numbers of Mesenchymal stem/stromal cells (MSCs) are required to 
obtain clinically relevant doses to treat a number of diseases. To economically 
manufacture these MSCs, an automated bioreactor system will be required. This thesis 
describes the development of a scalable closed-system, packed bed bioreactor that is 
suitable for large-scale MSC expansion. The packed bed was formed from fused 
polystyrene pellets that were air plasma treated to endow them with a surface 
chemistry similar to traditional tissue culture plastic. The packed bed was encased 
within a gas permeable shell to decouple the oxygen supply from the bulk nutrient 
flow. This enabled a significant reduction in medium flow rates, thus potentially 
reducing shear and even facilitating single pass medium exchange. The system was 
optimised in a small-scale bioreactor format (total surface area approximately 160 
cm2) with murine-derived green fluorescent protein expressing MSCs, and then scaled-
up to a 2800 cm2 format which successfully expanded 1.12x108 murine MSCs. 
Theoretically this large scale bioreactor could support up to 5.6x107 human MSCs in 
the current format. To demonstrate the bioreactors’ ability to expand primary human 
cells, pre-isolated passage four placental derived MSCs (pMSCs) were expanded in 
the bioreactor. Our bioreactor achieved a 10-fold expansion of pMSCs after a one week 
culture while maintaining their mesodermal tri-linage differential potential. To 
demonstrate the efficiency of our bioreactor, pMSCs were isolated and expanded 
directly onto the bioreactor from digested placental tissue without requiring a pre-
isolation step. These pMSCs also maintained their tri-lineage differentiation potential. 
 
Although the biological function of MSCs was preserved throughout the 
expansion process, MSCs exhibit a reduced cell growth rate in bioreactor expansion 
devices compared to traditional flask cultures. To characterise and understand this 
phenomenon, a two dimensional axial-symmetric model was developed that accounts 
for the influence of glucose and oxygen (essential nutrients) and lactate (a waste 
product) on the cell growth rate, assuming Michaelis-Menten kinetics. The model also 
considered the oxygen diffusion through the gas permeable wall of the bioreactor, 
assuming a constant external oxygen concentration. The model suggested that our 
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design, which allowed for oxygen diffusion through the bioreactor wall, would be 
superior to traditional packed bed bioreactor systems that require a higher medium 
perfusion rate to provide an adequate oxygen supply. The model demonstrated that this 
diffusion concept is scalable in bioreactor systems by adding a central gas permeable 
capillary to increase the oxygen supply as the format increases. Importantly, the model 
predicted that lactate accumulation would have a far greater effect on cell growth than 
the oxygen and glucose concentrations, especially in the small scale bioreactor. 
However, the base model did not accurately predict our experimental results. The 
model was then modified to account for an initial non-uniform cell distribution, to 
represent this a linear cell distribution was modelled in the bioreactor in both the radial 
and vertical directions. This adjustment significantly affected the total cell number, 
and the model more closely agreed with the experimental results. To better fit the data, 
the model was further adjusted to combine the non-uniform cell distribution with a cell 
growth lag phase due to the shock of the seeding process. This simulation output 
matched the experimental data very well. This suggests that the most important 
parameters for achieving optimal cell expansion in the proliferation of MSCs in our 
bioreactor design are efficient initial seeding, achieving as near homogeneous a cell 
distribution as possible, and the gentle handling of the cells during the seeding process. 
 
In summation, our packed bed bioreactor design, which allows the decoupling 
of oxygen from the bulk nutrient flow through wall diffusion, can successfully isolate 
and expand placental derived MSCs. This design was shown to be scalable to a total 
growth area of 2800cm2. Mathematical modelling of this bioreactor design confirmed 
that this design is scalable and supported the hypothesis that a significantly lower flow 
rate can be used, due to the oxygen diffusion through the bioreactor wall, compared to 
a traditional perfusion packed bed bioreactor. The mathematical model also identified 
the importance of cell seeding distribution on the overall final cell numbers and growth 
rate, thereby explaining the significantly reduced cell growth rate observed in the 
bioreactor relative to traditional flask cultures. 
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Chapter 1: Introduction and Literature 
Review 
Mesenchymal stem/stromal/progenitor cells (MSCs) are attractive cell type that 
can be used for cell based therapies that aim to treat a number of diseases or enhance 
innate regenerative processes [1-3]. They are one of the most commonly evaluated cell 
therapy candidates, with 612 clinical trials in tissue regeneration currently registered 
(clinicaltrials.org as of 9 September 2015). MSCs have the potential to home to sites 
of injury [4,5] and the capacity to produce a range of trophic factors that promote tissue 
repair and dampen inflammation [6-8]. Most importantly, MSCs appear to be non-
immunogenic, making them a versatile donor tissue allowing allogeneic donors to be 
used [9-11]. These attributes may enable MSCs to be clinically useful in a diverse 
range of applications, which include improving cardiac function following myocardial 
infarction [12-15], treating non-healing and diabetic wounds [15,16], enhancing 
skeletal tissue repair [17-19], and treating inflammatory diseases such as Crohn’s 
disease and Graft Versus Host disease [20-22].  
 
Bone marrow is the traditional source of MSCs and cells from this tissue are the 
most widely studied and best characterised [23]. However, MSCs can be isolated from 
other tissues, such as placenta, adipose tissue and umbilical cord and they’re becoming 
increasingly well characterized and may be more accessible than bone marrow-derived 
cells [24-26]. However, there are some differences in the phenotype and mesodermal 
differential potential depending on the source [24,26,27]. Regardless of the source, for 
clinical applications a large number of MSCs are required per dose and this may 
exceed 200 million cells [3,16,28,29]. MSC isolation and expansion is traditionally 
achieved using plastic tissue culture flasks and manual culture manipulation, 
increasing the number of flasks at each passage to achieve the required cell number 
[30]. However, the large-scale manual manipulation of tissue culture flasks is not ideal 
for commercial production, as the process is labour intensive, requires a clean room, 
carries a significant risk of contamination and has poor culture condition control [31]. 
MSC isolation and expansion will likely require an automated closed-system 
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bioreactor for commercial translation of these therapies to be routine and economically 
viable. 
 
This thesis focuses on developing a novel packed bed bioreactor that can be used 
to isolate and expand human placental derived MSCs (pMSCs). The following 
literature review covers the basic biology of MSCs, clinical trials using MSCs as a cell 
based therapy highlighting the number of cells used to treat such conditions, the 
technology used to expand MSCs and what culture conditions are required to be 
maintained during the expansion.  
 
1.1 MESENCHYMAL STROMAL CELL CHARACTERISATION 
 
MSCs were first identified from bone marrow mononuclear cells that can 
differentiate down the osteogenic, adipogenic and chondrogenic lineages [32]. 
However, MSCs have been identified and isolated from most fetal, neonatal and adult 
tissue types including placenta, adipose tissue, umbilical cord blood, amniotic fluid, 
dental pulp, skeletal muscle, liver and bone [33-35]. This is attributed to the fact that 
MSCs are perivascular cells and therefore have similar surface markers and cell 
adhesion molecules even though they can be found in different tissues in the body [36-
39]. However, it should be stated that not all pericytes are MSCs [39].  
 
In 2006, the International Society for Cellular Therapy delineated the minimum 
defining criteria as being adherence to tissue culture plastic (TCP), the expression of a 
cluster of differentiation markers CD105, CD73 and CD90, and the absence of CD45, 
CD34, CD14 or CD11b, CD79α or CD19 and HLA class II expression. In addition, 
the cells have to be able to undergo tri-lineage mesodermal differentiation [40]. 
However, selection using these surface markers and plastic adherent cells can result in 
isolation of a very heterogeneous population that is a mix of different committed 
progenitor cells and only a very small fraction of true self renewing cells maybe 
isolated [41]. An extensive list of additional surface markers that are associated with 
MSCs is found in Table 1. Through the isolation of MSCs using the additional markers 
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STRO-1, CD146, VCAM1, CD 271 and CD105 it was demonstrated that this more 
defined population of  cells formed colony forming units in vitro and when 
transplanted into mice could generate a miniature bone organ with bone, cartilage, 
adipocytes and haematopoiesis-supporting stroma [36,42]. The issue with isolated 
MSCs using such markers is that these markers change over time and culture 
conditions, with some markers such as SSEA-4 being induced in in vitro manipulations 
and the use of fetal bovine serum [43]. The marker profile of MSCs is highly transient, 
meaning that there is currently no sole marker or group of markers which are truly 
specific for MSCs. Furthermore, it may not be important to isolate for true stemness 
markers for MSCs to achieve the desired clinical outcomes, but it may be beneficial to 
isolate for markers for a subtype of MSCs that have a desired function, such as the 
CD317 positive subpopulation that has a high immunomodulatory activity, which may 
allow for more predictable clinical outcomes [44].  
 
Table 1: Summary of surface markers for defining and isolating MSC, compiled from [43,45-47] 
Positive Markers Negative Markers 
CD9, CD10, CD13, CD29, CD44, CD49a, 
CD49b, CD49c, CD49e, CD51, CD54, CD58, 
CD61, CD62L, CD71, CD73, CD90, CD102, 
CD104, CD105, CD106, CD119, CD120a, 
CD120b, CD121, CD123, CD124, CD126, 
CD127, CD140a, CD146, CD166, CD271, 
CD317, CCR1, CCR4, CCR7, CXCR5, CCR10, 
VCAM-1, CD166, AL-CAM, ICAM-1, STRO-
1 (CD140b), SSEA-4, HER-2/erbB2 (CD340), 
frizzled-9 (CD349), W8B2, W3D5, W4A5, 
W5C4, W5C5, W7C6, 9A3, 58B1, F9-3C2F1, 
HEK-3D6. 
CD45, CD34, CD14, 
CD11a, CD19, CD86, 
CD80/CD40, CD15, 
CD18, CD25, 
CD31, CD49d, 
CD50, CD62E, 
CD62P, CD117 
 
Although MSCs can be found is almost all vascularised tissues and share similar 
marker profiles, there are distinct differences in their function and ability to 
differentiate, especially in vivo [26,43,48-50]. MSCs isolated from human muscle, 
which expressed some osteogenic features when exposed to bone morphogenetic 
proteins (BMPs) in vitro, did not form bone when transplanted in vivo [51]. Likewise, 
MSCs isolated from human dental pulp that were subsequently transplanted into 
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mouse conditions identical to those used for bone marrow MSCs formed dentin rather 
than bone [52]. Even the reported in vitro tri-lineage potential (bone, cartilage and fat) 
of MSCs correlates poorly with the observed in vivo differentiation capacity of MSCs 
[53,54]. Only 10% of the MSC population is able to form bone, stroma and marrow 
adipocytes in vivo, while the majority of the population are committed progenitors 
[53]. This evidence suggests that a varied class of clonogenic progenitors are found in 
different tissues that are endowed with tissue-specific potency, and that the reported 
multi-lineage potential in vitro could be in fact an artefact of MSC populations being 
a heterogeneous mix of lineage-committed progenitor cells [53]. 
 
Interestingly, MSCs are used successfully to treat a variety of pathologies in 
tissues that are not derived from cells belonging to the osteogenic, adipogenic and 
chondrogenic lineages, including acute myocardial ischemia, stroke, liver cirrhosis, 
amyotrophic lateral sclerosis, graft versus host disease, skin burns and Crohn’s disease 
[55]. Thus, the mechanism by which MSC therapies promote regeneration cannot 
involve direct differentiation into the repair tissue(s) alone, and must facilitate tissue 
regeneration via alternative mechanisms.  
 
1.2 MESENCHYMAL STROMAL CELL MECHANISMS TO REPAIR 
DAMAGED TISSUE 
 
When the perivascular location of MSCs was discovered, the hypothesis was 
proposed that the MSCs would support growth and repair of the surrounding tissue 
through the secretions of cytokines, paracrine and chemokines such as PDGF, ANG-1 
and TGF-β. As such, makes MSCs act as the “injury drug store” of human body 
[8,36,56]. This makes MSCs an ideal candidate for clinical applications in the 
treatment of a variety of congenital and acquired diseases. The mechanisms proposed 
for MSCs as a cell-based therapy in tissue repair is thought to include (I) differentiation 
and transdifferentiation into multiple cell types to repair target tissue through 
autologous transplant, secretion of paracrine factors that promote cell (II)  an 
immunomodulatory effect, (III) survival and proliferation, and (IV) through the ability 
to localise specifically to the injury site (Figure 1) [8,57,58]. However, an additional 
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mechanism has been recently proposed in which mitochondria from MSCs are 
transferred to cells having non-functional mitochondria, which has been hypothesise 
to help promote cardiac tissue repair after infarction [59-61]. This literature review 
here will primarily focus on the first three mechanisms. 
 
 
Figure 1: Observed mechanisms that MSCs repair damaged tissue. Adapted from [33]  
 
1.2.1 Mesenchymal Stromal Cell Differentiation and Transdifferentiation 
 
The most controversial MSC-associated tissue repair mechanism is the MSCs’ 
is their ability to differentiate and transdifferentiate (Figure 1 I) into the target repair 
tissue, as this have been observed to occur in vitro and in vivo animals. The cellular 
process of differentiation occurs when a less specialised immature cell becomes a more 
specialised cell type. However, cells belonging to a specific cell lineage can 
occasionally undergo abrupt changes in phenotype that exhibit phenotypical 
characteristics of a different cell lineage. This process is called transdifferentiation. 
MSCs are multipotent cells that can be induced to differentiate in vitro and in vivo into 
I 
III 
II 
IV 
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mesenchymal tissues (bone, cartilage, tendon muscle, etc.) [40,62-64]. MSCs have 
been reported to trans-differentiate, both in vitro and in vivo in animals, into different 
cell lineages [65-67]. However, the process of MSCs’ transdifferentiation is induced 
in vitro in the presence of growth and transcription factors prior to implantation into 
animals [65-69]. Human MSCs isolated from Wharton’s jelly of the umbilical cord 
were induced to transform into islet-like cell clusters in vitro through a stepwise culture 
in neuron-conditioned media [67]. These islet-like cells secreted insulin and glucagon 
in response to physiological changes in serum glucose when implanted into a diabetic 
rat liver. Human amniotic membrane isolated mesenchymal cells can undergo 
cardiomyogenic transdifferentiation and are able to beat spontaneously through 
cardiomyogenic induction in vitro [70]. MSCs were transplanted into the infarcted 
myocardium of Wistar rats. The MSCs were reported to have transdifferentiated into 
cardiomyocytes in situ and survived for more than 4 weeks after the transplantation 
without requiring immunosuppressant agents. Xenograft of human MSCs from 
adipose or bone marrow applied to a skin wound site in mice and rats can contribute 
to wound repair by transdifferentiating into multiple skin cell types, such as 
keratinocytes and endothelial cells that form vasculature [5,71,72]. 
 
The contribution of differentiation and transdifferentiation to repair tissue 
remains controversial, as only a small number of donor-derived cells can be detected 
in vivo in repair sites in human studies, as little as 0.4% of the total cells injected are 
present after 60 days [56,73-75]. Additionally, there is little available evidence to 
support differentiation and transdifferentiation in humans in vivo [5,33,62]. This 
proposed repair mechanism appears to be limited to autologous donor sources of 
MSCs, as MSCs lose their immune privilege status when they differentiate [76-78]. In 
addition, due to the heterogeneous nature of isolated MSC populations, the reported 
transdifferentiation and differentiation could be due to contamination of different 
lineage progenitor cells [48,53]. Consequently, the beneficial effect of MSCs at the 
site of injury must rely on a mechanism outside of their differentiation capacity alone.  
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1.2.2 Mesenchymal Stromal Cells are Immunosuppressive, but not Immune 
Privileged. 
 
The main mechanism that MSCs promote tissue repair is through the modulation 
of the immune system (Figure 1 II). MSCs secrete a number of immunosuppressive 
and anti-inflammatory cytokines, summarised in Table 2 and Figure 2 that can 
modulate the immune system. MSCs secrete transforming growth factor-β (TGF-β) 
and induce secretions of interleukin-10 (IL-10), both immunosuppressive, that inhibit 
T cell proliferation [79,80]. Interferon-gamma (INF-γ) secretion by MSCs suppresses 
the proliferation of CD4+ and CD8+ T lymphocytes, as well as natural killer (NK) cells, 
but it has no effect on the proliferation of B lymphocytes [81]. Interestingly, the 
suppressive activity of MSCs are not contact-dependent when MSCs are in the 
presence of IFN-γ produced by activated T cells and NK cells in inflammatory 
environments. Even activated B lymphocytes became susceptible to the suppressive 
activity of MSCs when IFN-γ was added exogenously [81]. In another recently 
described mechanism, MCP-1 secreted by MSCs recruit T cells for FasL-mediated 
apoptosis. These apoptotic T cells subsequently triggered macrophages to produce 
high levels of TGF-2, which in turn led to the up-regulation of CD4+ Treg cells and, 
ultimately, led to immune tolerance which could allow allogenic MSCs to persist 
longer [82]. However, this immune damping effect is a double edged sword, in 
response to inflammatory cytokines MSCs become highly immunosuppressive [83]. 
This becomes a problem in the cancer niche as MSCs have been shown to promote 
cancer cell growth and prevent the immune system from attacking the tumour and even 
enhance drug resistance [84-88]. However, no clinical trial using MSC base therapy 
has reported any tumour growth [86].  
 
MSCs are reported to be immune privileged as they express low levels of major 
histocompatibility complex (MHC) class I and do not express MHC class II antigens 
or costimulatory molecules CD40, CD80, and CD86 [89,90]. MSCs’ lack of MHC 
antigen expression permits cells from allogeneic donor sources to be transplanted to 
unmatched recipients with reduced requirements for immune suppressants. This 
characteristic allows for the collection and banking of allogeneic MSCs, which can 
then be used for the treatment of tissue damage when needed. However, some studies 
 8 Chapter 1: Introduction and Literature Review 
report rejection of allogeneic MSCs, raising questions regarding their immune 
privilege status [77,91]. This can be due to the increased expression of MHC antigens 
when the cells are undergoing differentiation or undergoing cell culture expansion [76-
78,92]. Although allogenic MSCs are not as immunogenic as unmatched fibroblasts 
and are reported to persist twice as long as fibroblasts [93], MSCs still activate the 
innate immune system. Through the activation of the complement and coagulation 
cascade following injection the MSCs are quickly killed, this is more notable when the 
MSCs have undergone in vitro expansion [75,94]. Confidence in the idea that MSCs 
are immune privileged has very much diminished since their immune privilege status 
appears largely dependent on the environment and they may just act like antigen-
presenting cells that are able to promote inflammation in vivo [95-98]. 
 
 
Figure 2 Summary of MSCs’ interactions with immune cells. MSCs secrete many soluble factors that 
alter the function and proliferation of the immune cells and regulatory T cells. Adapted from 
[89,99,100]. 
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1.2.3 Mesenchymal Stromal Cells Secrete Soluble Factors that Promote Cell 
Survival, Proliferation and Immunomodulatory Effects 
 
Caplan et al. stated that MSCs are a site-regulated injury "drug store", because 
they migrate to the injury site and secrete soluble cytokines, chemokines and growth 
factors that promote cell survival, proliferation, angiogenesis and modulate the 
immune response (Figure 1 III) [8]. The paracrine factor theory is supported by the 
observation that the addition of a MSC conditioned medium, can in some cases, 
recapitulate the same tissue repair benefits of MSCs. Additionally, MSC conditioned 
media act as a chemoattractant for recruiting macrophages and endothelial cells into 
the wound [101]. Factors released by MSCs include VEGF-1, IGF-1, EGF, nitric 
oxide, hepatocyte growth factor (HGF), keratinocyte growth factor, angiopoietin-1, 
stromal derived factor-1, macrophage inflammatory protein-1a and -1b and 
erythropoietin [101-103]. Tumour necrosis factor-α (TNF-α)-stimulated gene 6 protein 
(TSG-6) is secreted by MSCs that acts as a negative feedback loop to attenuate the 
inflammatory cascade initiated through TNF-α secreted by resident macrophages 
[104-106]. A highly inflammatory environment during skin wound healing causes scar 
formation, MSCs’ secretions of TSG-6 in response to this environment prevents scar 
formation [106]. Additionally, hypoxia common in ischemic tissue enhances the 
production of several factors [102]. Hypoxic conditions also increase MSCs’ paracrine 
secretions in vitro [102]. Additionally, genetic engineering techniques are being 
explored to increase the secretions from MSCs and make the response to the injured 
environment more predictable [107]. Table 2 lists further paracrine factors and extra 
cellular matrix proteins secreted by MSCs that have been reported. These molecules 
secreted by MSCs are important for cell survival, proliferation, neovascularisation 
during tissue repair and wound healing, regulating cell migration, anti-inflammatory 
and immunomodulation [33,55,66,108]. It should be noted that the tissue repair 
abilities of MSCs in the absence of the immune system is very much reduced [109]. 
This suggests that MSCs’ ability to promote tissue repair may be by their 
immunomodulatory secretions reducing inflammation and promoting the natural 
repair mechanisms of the immune system.  
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Table 2 Summary of some of the paracrine factors and extra cellular matrix proteins secreted by 
MSCs. Compiled from [89,101,103,104,110-115] 
Trophic Extra cellular 
matrix 
Immunomodulatory  Chemoattractant  
VEGF Collagen type 1 PGE2  CCL2 (MCP-1)  
bFGF  Fibronectin HLA-G5  CCL3 (MIP-1a)  
IL-6  
 
HGF CCL4 (MIP-1b)  
MCP-1  
 
TGF-b  CCL5 (RANTES)  
HGF  
 
IDO (induced by IFN-
γ)  
CCL7 (MCP-3) 
TGF-β 
 
TSG-6 CCL20 (MIP-3a) 
EGF  
 
Nitric Oxide CCL26 (eotaxin-
3)  
IGF  
 
IL-10 CX3CL1 
(fractalkine)  
SDF-1 
 
PGE2 CXCL1 (GROa)  
Angiopoietin-1  
 
CXCL2 (GROb)  
Macrophage inflammatory protein CXCL5 (ENA-
78)  
Keratinocyte growth factor 
 
CXCL8 (IL-8)  
Erythropoietin  
 
CXCL10 (IP-10) 
PDGF 
  
CXCL11 (i-TAC)  
TPO 
  
CXCL12 (SDF-1) 
 
1.2.4 Mesenchymal Stromal Cell Homing and Migration 
 
MSCs’ therapeutic applications are acclaimed due to the ability of intravenously 
injected MSCs to home to sites of inflammation following injury (Figure 1 IV). In a 
model of multiple organ failure through irradiation of mice, green fluorescent protein 
(GFP)-labelled MSCs were infused and subsequently homed to numerous tissues 
based on the severity of the injury [116]. The migration depended on signals from 
growth factors, and also from chemokines secreted from injured cells and respondent 
immune cells [8,117]. Interestingly, the inflammatory cytokine TNF-α increased the 
sensitivity of MSCs to chemokines such as SDF-1 and IGF, which then induced MSCs 
to migrate to the site of inflammation [118]. In the migration of the MSCs to the injury 
site, the cells first adhere to the vascular endothelial cells mediated by very late 
antigen-4/ vascular cell adhesion molecule-1 (VLA-4/VCAM-1) and display 
coordinated rolling to cross the endothelial barrier to achieve trans-endothelial 
migration [119-121]. The MSCs’ ability to specifically home to injury sites allows a 
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diverse range of options to administer MSC treatment in a clinical setting. Therefore, 
MSCs do not require direct administration to the wound site, but can be infused into a 
patient’s blood stream. However, MSCs lose their homing abilities during in vitro 
expansion, even at early passage numbers [122]. This could explain why, in some 
cases, no homing was observed in vivo; typically less than 1% of the infused MSCs 
reach the target tissue [123,124]. Strategies to engineer improved homing of MSCs 
after expansion are being devised [125,126]. 
 
1.3 CLINICAL APPLICATIONS OF MESENCHYMAL STROMAL CELLS 
 
The reported regenerative and immunomodulatory capacity of MSCs observed 
in vitro and in vivo in animals, is currently being explored in 612 clinical trials 
(clinicaltrials.gov). MSCs are being investigated to treat a wide variety of conditions, 
including acute myocardial ischemia, stroke, liver cirrhosis, graft versus host disease, 
burns, non-healing diabetic foot ulcers and Crohn's disease [55]. One key aspect of 
MSC based therapy is the cell dosages used in clinical trials. Table 3 highlights the 
cell dosages reported in clinical trials to treat different conditions. Another important 
aspect is the cell source, as many of the clinical trials use allogeneic MSCs to treat 
these conditions. This becomes important for the future manufacturing of MSCs as an 
expansion device such as a bioreactor will be necessary to reduce the cost of 
manufacturing to allow these therapies to become more affordable. This following 
section will review the clinical trial results of conditions that rely on MSCs ability to 
promote tissue regeneration through their ability to modulate the immune system and 
secrete paracrines.  
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Table 3 Summary of MSC dosages used in a selection of clinical trials 
Condition Cell 
Dosage 
Cell source Delivery method Ref. 
Articular 
cartilage 
damage 
1-1.5x106 Autologous bone 
marrow MSCs 
Injected into the 
defect  
[127] 
 1.46x107 Autologous Bone 
marrow MSCs 
Injected into the 
defect with 
hyaluronic acid 
[128] 
Severe 
ischaemic heart 
failure 
21.5 x 106 Allogeneic bone 
marrow MSCs 
Intra-myocardial 
injection 
[129] 
Acute 
myocardial 
ischemia 
6x1010 Autologous bone 
marrow MSCs  
Direct injection 
into the 
myocardium  
[130] 
Ischemic 
cardiomyopathy 
2x108 Autologous Bone 
marrow MSCs 
and mononuclear 
bone marrow 
cells 
Transendocardial 
cell injection 
[131] 
Ischemic and 
non-ischemic 
heart failure 
25,75, and 
150 x106  
Allogeneic bone 
marrow MSCs 
Transendocardial 
cell injection 
[132] 
Myocardial 
infarction 
0.5, 1.6 and 
5 x106 
cells/kg 
Allogeneic MSCs Intravenous 
infusion 
[133] 
 1.8 to 2.2 x 
108 cells 
Allogeneic bone 
marrow MSCs  
Intravenous 
infusion 
[134] 
Stroke two dosages 
of 5x107  
Autologous bone 
marrow MSCs 
Intravenous 
infusion 
[135] 
 50-60 x106 
cells 
Allogeneic bone 
marrow MSCs or 
mononuclear cells 
Intravenous 
infusion 
[136] 
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Severe 
traumatic brain 
injury  
6x106 Autologous bone 
marrow MSCs 
Intravenous 
infusion 
[137] 
Hepatic 
fibrogenesis 
30-50x108  Autologous bone 
marrow MSCs 
Intravenous 
infusion 
[138] 
Crohn's disease 1x106 
cells/kg  
Autologous bone 
marrow MSCs  
Intravenous 
infusion 
[139] 
 2x106 
cells/kg  
Allogeneic bone 
marrow MSCs 
Intravenous 
infusion 
[140] 
Graft versus 
host disease 
1.4x106 
cells/kg  
Autologous and 
allogeneic bone 
marrow MSCs 
Intravenous 
infusion 
[141] 
 1,5, or 10 
x106 
cells/kg 
single dose 
or 
additional 
dose after 
two days 
Allogeneic bone 
marrow MSCs 
(MultiStem) 
Intravenous 
infusion 
[142] 
Multiple 
Sclerosis 
1-2 x106 
cells/kg 
Autologous bone 
marrow MSCs 
Intravenous 
infusion 
[143] 
Radiation burn two dosages 
of 1.68x108 
and 
2.26x108 
Autologous bone 
marrow MSCs 
Injection around 
the wound site 
[29] 
Ulcers and acute 
wounds 
1x 106 
cells/cm2 
wound area 
Autologous bone 
marrow MSCs 
 Sprayed on wound 
with fibrinogen 
spray 
[144] 
Diabetic ulcers 
and Buerger’s 
disease 
1x106 
cell/cm2 
wound area 
Autologous bone 
marrow MSCs 
Injection around 
the wound site 
[145] 
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1.3.1 Cardiac Failure 
 
MSCs through their paracrine secretions are reported to stimulate growth of new 
blood vessels and cardiomyocytes [146-149]. It is thought that this functionality of 
MSCs will help repair the damaged heart tissue after myocardial infarcts. In a 
randomised clinical trial of MSC therapy for acute myocardial ischemia, patients 
received either an intracoronary injection of 6x1010 autologous bone marrow MSCs or 
a control vehicle [130]. MSCs significantly increased the left ventricular ejection 
fraction at the three month follow-up following MSC transplantation compared to the 
control group. MSC transplantation was safe, with no deaths or malignant arrhythmias 
reported. A large Chinese study which injected MSCs derived from Wharton’s jelly 
showed significant cardiac function increase over the placebo control [150]. Similarly, 
a more recent phase II trial showed improvement in left ventricular end systolic 
volume, left ventricular ejection force and volume, and increase in myocardial mass 
compared to the placebo [129]. However, there was no significant difference in the 
New York Heart Association functional classification, 6 minute walking test and 
Kansas City cardiomyopathy questionnaire. This suggests that although there was a 
small anatomical improvement with MSC treatment overall there was not a significant 
improvement in the patients’ health. Another recent phase II clinical trial using 
immune selected allogenic MSCs at three different dosages (25, 75, or 150 x106 cells) 
reported similar results [132]. The trial found no difference between any cell dosages 
and placebo for survival probability, MACE-free probability and all-causes of 
mortality. Although they noted that the hospitalisation rate was reduced for the highest 
dosages (p=0.025). The above demonstrates that trans-endocardial injection of 
allogenic MSCs are safe for chronic heart failure patient however no significant or 
strong evidence has been shown of any clinical improvement.  
 
Several other studies have explored the safety and efficacy of MSC transplants 
and evaluated different delivery methods, including direct injection into the affected 
regions of the heart, mobilisation via granulocyte colony stimulating factor (G-CSF), 
and intravenous infusion [134,151-156]. Cell dosages ranged from 107 to 1011 MSCs. 
Most studies showed some improvement in cardiac function with MSC transplant 
compared to control. However, they generally did not significantly improve the 
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patient’s overall health or function. Larger clinical trials are needed. So far the sample 
sizes have been small, there is a wide range of cell dosages, with differences in delivery 
without direct comparisons, and there are considerable differences in the timing of cell 
transplantation after the myocardial infarct. In addition, greater investigation is 
required to find the right phenotypic markers that characterise functional MSCs that 
can promote tissue repair. In the TAC-HFT randomised trial both MSCs (characterised 
by the criteria set out by the ISCT [40]) and bone marrow mononuclear cells 
(mononuclear cells from a Ficoll density gradient) had no difference in clinical 
outcomes between the two cell types. However the MSCs did decrease infarct size and 
increase 6 minute walking distance compared to placebo whereas the bone marrow 
mononuclear cells did not [131].  
 
1.3.2 Stroke 
 
It is thought through the secretion of VEGF and IGF-1 from MSCs would 
promote angiogenesis and activate the endogenous neural cells to further express more 
VEGF, EGF and bFGF to promote neural cell growth [8,157]. A clinical trial was 
performed that recruited patients for up to 2 years after having a stroke. The subjects 
were treated with an intravenous infusion of 50-60 million autologous bone marrow 
MSCs (isolated from plastic adherents) or mononuclear cells (isolated from a Ficoll 
density gradient). There was no difference in outcomes observed with functional MRI 
and DTI and clinical scores, only the Barthel Index (ability to perform activities of 
daily living) showed a statistically significant improvement for those given the 
mononuclear cells [136]. They observed that the MSCs that underwent expansion 
performed worse than the mononuclear cells. This is consistent with the observed loss 
in some phenotypic functions after long term culture of MSCs [158].  
 
A longitudinal open-label, observer blinded clinical trial, studied autologous 
MSC transplants in stroke patients (two dosages of 5x107 cells two weeks apart 
transplanted through intravenous infusion) and followed the patients up to 5 years 
[135]. This study concluded that the procedure is safe with no adverse effects 
following MSC treatment, and it demonstrated an improvement in functional recovery 
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(p=0.046) and a decrease in mortality. However, the treatment group was small 
(N=16), this was not a randomised trial and the hazard ratio between the MSC group 
and the control group was insignificant. This brings into doubt the claim of a decrease 
in mortality and will require a larger sample size and randomisation of the treatment 
groups to remove any biases.  
 
1.3.3 Neural and Spinal Cord Repair 
 
Following a spinal cord injury there is an influx of inflammatory immune cells 
into the injury site, this is a necessary part of the tissue regeneration process. However, 
this can cause secondary damage to the tissue surrounding the original injury site that 
can continue for days and weeks following the injury and which can lead to cavitation 
and cyst formation [159,160]. It is thought that the immunomodulatory function of 
MSCs will help prevent this from happening and that the paracrine secretion from the 
MSCs will help the tissue regeneration process [161]. A nonrandomised clinical trial 
was conducted which injected, via lumbar puncture, autologous bone marrow MSCs 
into the cerebrospinal fluid, of 11 patients. 20 patients were in a control group who 
underwent a traditional treatment method [162]. None of the patients experienced 
adverse reactions, although headaches and tingling were reported by some of the 
patients who were treated with the MSCs, after 24-48 hours. Although 45% of the 
patients treated with the MSCs showed a marked recovery compared to only 15% of 
the control group, this was found to be not statistically significant. Other trials reported 
similar side effects. In one clinical trial where autologous bone marrow MSCs plus 
granulocyte-colony stimulating factor were injected into the area surrounding the 
spinal cord injury, fevers were reported [163]. While others studies reported fevers and 
myalgia [66]. Although all these trials show an improvement in clinical function, none 
of these results were statistically significant.  
 
It is also thought that the immunomodulatory function of MSCs would help in 
acute neuro-inflammation after a traumatic brain injury. A phase I clinical trial was 
conducted, children were treated with an intravenous infusion of 6x106 cells/kg 
autologous bone marrow mononuclear cells in addition to the standard treatment 
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protocol for a traumatic brain injury. A control group who did not receive any cell 
therapy was also followed [137]. This trial showed a statistically significant increase 
in clinical performance in those children who were given cell therapy and less 
intensive treatment was required compared to the control group. Most significant was 
that the requirement for intracranial pressure monitoring was half the time of the 
control group. A trial using four dosages over intervals of 5-7 days of 1x107 allogeneic 
umbilical cord MSCs injected into the subarachnoid space via lumbar puncture and 
followed up 6 months after treatment showed an improvement in the functionality 
using the Fugl-Meyer Assessments and Functional Independence Measurement over 
the control group [164]. However, the control group received no medical or surgical 
treatment whatsoever, hence it is difficult to draw a conclusion. This makes the 
improved MSC injection result suspect. The control group must undergo a standard 
treatment to truly demonstrate if MSCs improve clinical outcomes. Longer follow up 
periods are required to see if these outcomes result in better recovery of the patients. 
Larger randomised clinical trials are needed to confirm that this is a viable strategy to 
improve treatment for traumatic brain injuries.  
 
1.3.4 Crohn’s Disease and Multiple Sclerosis 
 
The reported immunomodulatory and anti-inflammatory properties of MSCs 
make them ideal for treating inflammatory diseases such as Crohn's disease. Crohn’s 
disease is a chronic inflammatory disorder of the gastrointestinal tract. In a pilot study 
of eight patients, autologous bone marrow MSCs were infused intravenously at a dose 
of 1x106 cell/kg body mass. In five of the patients, the Crohn's disease activity index 
scores improved, with the clinical response observed in three patients at week 6 [139]. 
In another study, ten patients with fistulising Crohn's disease were treated with 
autologous bone marrow MSCs [165]. The MSCs were injected into the lumen and the 
wall of the fistula tracks. There was complete closure of the fistula track in seven of 
the ten patients after twelve months, with a reduction of Crohn's disease and perianal 
disease symptoms and healing of the rectal mucosa. In a more recent study, patients 
received between 8-10x106 cells/kg weekly for four weeks of allogeneic bone marrow 
MSCs with a primary end point, the Crohn’s Disease Activity Index was below 150 
indicating remission [140]. Twelve patients had a clinical response, 50% of all patients 
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went into clinical remission and seven patients had endoscopic improvements. 
However, no placebo or control group was used in these studies which reduce their 
clinical significance. 
 
Multiple sclerosis is an inflammatory disease that causes destruction of the 
myelin sheaths of the neurons. MSCs have the potential to treat multiple sclerosis 
through their immunomodulatory function by inhibiting pathogenic T and B cell 
responses and the secretion of neuroprotective and pro-oligodendrogenic molecules to 
promote tissue repair [166-168]. However, the most robust clinical trial that had a 
randomised study and had a placebo control group showed no difference between 
placebo and 1-2x106 cells/kg of bone marrow MSCs intravenously infused in all 
clinical scores of the number of gadolinium-enhancing lesions with no difference in 
the frequency of TH1 cells in the blood [143].  
 
1.3.5 Graft Versus Host Disease 
 
Graft versus host disease (GVHD) is a severe life threatening complication with 
allogeneic haemopoietic stem cell (HSC) transplants. The immunomodulatory aspects 
of MSCs have been used in the clinical situation to help reduce the incidence and 
severity of GVHD. In a Phase II clinical study, 1.4x106 MSC/kg body weight were 
transplanted into patients who had suffered steroid resistant severe and acute GVHD 
after they underwent a HSC transplant [141]. Both MSCs from autologous and 
allogeneic sources proved effective therapy for these patients with refractory chronic 
GVHD. Other small pilot studies have confirmed their benefit [169-171]. It has also 
been reported that HSC engraft faster when co-transplanted with MSC [141,172]. 
However, due to the high cost of the treatment, other methods will be used first to treat 
GVHD when more traditional steroid treatments fail. Even then it appears that MSC 
therapy is only effective in less severe and less intensively treated cases of GVHD 
[173]. However, more recent studies suggest that overall survival is not improved by 
MSC therapy compared to placebo over the long term [22]. It has also been reported 
that MSCs were ineffective in patients with prolonged GVHD with lower lymphocyte 
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counts [174]. This suggests that a functioning immune system is required for effective 
control of GVHD by MSCs.  
 
1.3.6 Mesenchymal Stromal Cell role in Enhancing Wound Healing 
 
There are a number of in vitro and animal studies that outline the mechanisms in 
which MSCs promotes wound healing [71,72,101,110,175,176]. The pro-
inflammatory mediators interferon-γ (INF-γ), tumour necrosis factor-α (TNF-α) and 
interleukin-1β (IL-1β), which are released from the wound during the inflammation 
phase, firstly promote migration of MSCs to the wound site; secondly, they activate 
regulatory functions in MSCs to modulate the immune response thereby attenuating 
the immune response to injury through the secretion of TSG-6[104,115]. In addition, 
the inflammatory wound environment stimulates COX 2 activity in MSCs, 
upregulating prostaglandin E2 (PGE2) and transition in wound environment in favour 
of dermal regeneration [177]. The shift to anti-inflammatory cytokine expression 
promotes wound fibroblasts to upregulate matrix metallopoteinase (MMPs) expression 
and down regulates the expression of various collagen types [178,179]. This results in 
a less dense fibrotic granulation tissue in the wound bed. The secretions of basic 
fibroblast growth factor (bFGF), vascular endothelial growth factor-A (VEGF-A) and 
adrenomedullin from MSC’s promote proliferation of microvascular endothelial cells 
[180,181], vascular stability [182] and the development of a long lasting functional 
vascular network [183]. In addition, MSCs secrete a number of cytokines and growth 
factors that have antifibrotic properties, including hepatic growth factor (HGF), IL-10 
adrenomedullin and MMP-3 [101,184-186]. These cytokines promote the turnover of 
the extra cellular matrix, keratinocytes proliferation and inhibition of myofibroblast 
differentiation [187-190]. Therefore, MSCs promote generation of well vascularised 
granulation tissue, enhance re-epithelialisation of the wound and attenuate the 
formation of fibrotic scar tissue. 
 
A number of pilot studies have been conducted using MSCs to treat a variety of 
non-healing wounds in humans [16,29,144,145]. A Chilean man with a severe 10 cm 
diameter radiation burn was treated with MSCs after a conventional excision and skin 
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autograft and rotation flap had failed. A combined approach of numerical dosimetry-
guided surgery with injection of 168x106 autologous expanded MSCs followed by a 
second 226x106 MSCs 39 days after the operation, to provide a source of trophic 
factors to promote tissue regeneration [29] resulted in a favourable clinical outcome. 
The lesion healed in 6 months, and no recurrence was observed during the 11 month 
follow-up.  
 
In a second trial, MSCs were used to treat chronic non-healing wounds (diabetic 
ulcers). An autologous biograft composed of fibroblasts and 3x106 MSCs on a 
biodegradable collagen membrane was placed directly in the wound site, whilst MSCs 
were injected into the edges of the wound being covered with the biograft [16]. The 
wound steadily decreased in size, increased in vascularisation of the dermis, and 
increased in dermal thickness after 29 days. These in vivo data, coupled with in vitro 
skin equivalent models, suggest that MSCs could be beneficial in the treatment of 
chronic wounds [16]. Other trials that treated diabetic foot ulcers and critical limb 
ischemia with intramuscular injections of peripheral blood or bone marrow MSCs (cell 
dosage ranging 3x107 to 3x109 cells) reported similar results with improved blood 
flow, new vessel formation and rescue of the ischaemic limb [191-194].  
 
A fibrinogen and thrombin gel spray was trialled to apply autologous bone 
marrow MSCs to treat acute surgical wounds after removal of skin cancer (n=5) and 
on chronic non-healing foot ulcers (n=8) [144]. A strong correlation was observed 
between the number of cells applied (greater than 1x 106 cells per cm2 wound area) 
and the subsequent decrease in the chronic wound size. 
 
A study was conducted in India with 24 patients with diabetic foot ulcers or 
Buerger disease. Autologous bone marrow derived MSCs were injected into the wound 
site at a concentration of 1x106 cell/cm2 and a control group was treated with a standard 
wound dressing. The wound area reduced from 5 cm2 to 1.5 cm2 in patients with foot 
ulcers, and patients with Buerger showed a decrease in the diseased area from 7.3 cm2 
to 2 cm2 after 12 weeks. There was no significant size reduction in the control group 
[145].  
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The clinical trials using MSCs to treat non-healing wounds generally show 
statistically significant results. This could partly be due to the topical application of 
the MSCs rather than by intravenous injection which is known to activate the innate 
immune system [11,75]. As the MSCs remain viable for longer in these wound sites 
and are able to function as an “injury drug store” widely reported in popular media [8]. 
However, many of these trials lack control groups or placebo controls. In addition, in 
all the trials there is great variability in the MSC functionality even when they have 
been characterised. With the increasing failure of clinical trials to demonstrate that 
MSC therapy is effective, it is hard to be uncritical of the science involved and many 
researches in the stem cell field have been starting to question the methods used in the 
MSC therapy field [56,195]. This criticism is even stronger with the clinical results in 
trials repairing mesodermal tissues of bone and cartilage when the addition of MSCs 
to scaffolds made little difference in the tissue repair, even when the scaffold or bone 
chips were sufficient to promote repair [196]. In addition, many of these clinical trials 
used intravenous infusions, it has been shown that the majority of the MSCs are 
embolised in the lungs which can cause endothelial damage [56,105,197]. As the true 
surface marker and phenotype that makes up a true MSC is yet to be discovered, the 
populations that are being used are very heterogeneous. In addition, donor tissue type 
and culture conditions have a significant impact on the function of MSCs [26,158,198-
203]. To add to the complexity of the problem the understanding of how MSCs 
respond to an inflamed environment is really unknown. It is worrying that there are 
reports that when MSCs respond to the highly inflamed cancer niche they result in 
supporting the growth of the cancer by damping the natural immune response 
[87,204,205]. This indicates that the minimum criteria for MSCs [40] requires 
updating in order to have better standardisation across all laboratories. In addition, 
better in vivo animal models are needed as rodent models are far more efficient in 
undergoing wound repair than humans [206-208].  
 
1.4 EX VIVO EXPANSION OF MESENCHYMAL STROMAL CELLS FOR 
CLINICAL USE 
 
The clinical results reveal very little evidence of the reported benefits of MSCs. 
This has created a heated debate regarding moving ahead with clinical trials on these 
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new cell therapies as it is considered that this is too far ahead of the current available 
science [56,195]. However, one observation is clear that the number of MSCs required 
to treat wounds and other clinical conditions is in the order of 2x108 cells per dose (see 
Table 3). Cell expansion is therefore required to enable MSCs to be used as cell-based 
therapy to treat such conditions, as only small numbers of MSCs can be isolated from 
bone marrow. Using traditional methods in tissue culture flasks is not viable because 
of the large surface area required to expand cells just to produce a single dose. This 
method is time intensive, requires skilled technicians to maintain the cell culture and 
needs a clean room for the clinical expansion, thus making this a very expensive 
therapy [89,209]. 
 
Assuming that two million MSCs can be manufactured in a T175 flask, a single 
cell dosage of 2x108 cells will require 100 T175 flasks, which is 1.75 m2 of surface 
area just for a single dose. However, it would be ideal to expand at least 10-100 cell 
dosages from a single donor source to develop an allogeneic bank of cells and have 
significant benefits with respect to product validation and consistency, and reducing 
production costs [210]. Surface area is the key limiting factor to achieve 100 cell 
dosages, as this will require 175 m2, which is 10,000 T175. This is not viable without 
an efficient automated bioreactor system. Even from a non-invasive source such as 
placenta, which weighs approximately 500 g, only enough MSCs can be isolated to 
provide cells for 2 dosages after one passage in culture. However, using a bioreactor 
system to expand placental derived MSCs over four passages is hypothetically enough 
to make 7000 dosages [210].  
 Chapter 1: Introduction and Literature Review 23 
 
Figure 3 Bioreactor geometry and mass transfer diagrams indicating mass transfer for various bioreactor 
geometries: (A) Media is mixed by a magnetic impeller. (B) Media inside a rotating wall bioreactor has 
the same angular velocity as the wall. (C) Bag cultures on a rocker generate a wave motion which mixes 
cell suspension and medium. (D) Plug flow is maintained throughout the bed to generate uniform 
perfusion. (E) Cells are generally grown on the extra capillary space either in suspension or in a gel 
scaffold; media is perfused in the intra capillary space to provide nutrients and oxygen through the 
semipermeable wall. Taken from [211].  
 
The expansion and differentiation of stromal cell populations under controlled 
conditions remain a major technical challenge. This is due to the complex kinetics of 
the heterogeneous nature of MSC populations, the transient nature of the 
subpopulations of interest, the lack of surface markers and multiple interactions 
between culture parameters; such as growth factor concentration, nutrient 
concentration, dissolved oxygen tension, cell–cell interactions or providing a large 
surface area for cell attachment and growth [212]. When the nutrient, glucose, is 
considered, high glucose medium (25 mM) results in a 40% reduction in the 
confluence compared to low glucose medium (5.5 mM) because high glucose has an 
effect on MSCs colony formation and differentiation [213-217]. This suggests that a 
low glucose concentration is required to maintain the stemness of the MSCs during in 
vitro expansion. However, supplying extra glucose through higher flow rates is limited 
by the fact that a low shear stress of 0.015 Pa has been reported to up-regulate the 
osteogenic pathways in human bone marrow MSCs [218-221]. This issue becomes 
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even more complex because of the limited solubility of oxygen (0.2 mM) in the 
medium. A tight balance is needed between providing adequate nutrients and oxygen 
to the MSCs while removing waste products such as lactate or lactic acid which affects 
the culture pH whilst maintaining a low shear stress on the cells [222]. This becomes 
increasingly difficult when it has been shown that hypoxic conditions are far better in 
maintaining stemness of MSCs [199,200,202,203,223]. Suppling oxygen at this low 
concentration by the medium perfusion alone would be very difficult to control [224]. 
 
Table 4 Advantages and disadvantages of bioreactor systems [31,209,212,218,219,224-232]. 
Bioreactor Type Advantages Disadvantages 
Wave bag Gentle mixing, low shear stress, 
easy scale up 
Expensive, more suited 
to cell suspensions than 
microcarrier cultures. 
Stirred tank Supports high density cell cultures, 
easy to scale up, can support 
differentiation and microcarriers, 
can act as a cell delivery system or 
cells can be encapsulated to protect 
from shear 
High shear, difficult to 
harvest cells. 
Hollow fiber Low shear stress, easier control on 
the cell microenvironment 
Difficulty in scale up and 
heterogeneous 
environment due to 
oxygen and nutrient 
gradients. 
Packed bed 
bioreactor 
Lower shear than stirred tank, 
provides 3D microenvironment to 
allow special organisation of cells, 
proliferation and differentiation 
can be regulated, can be used in 
tissue formation 
Difficult to harvest cells, 
shear stress can be an 
issue at high flow rates 
for high density cultures. 
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Bioreactors need to be tailor suited to meet the requirements of MSC culture and 
need to be optimised for the mass transport of oxygen, nutrients and waste elimination 
[227]. The large scale expansion of MSCs has the additional criteria of providing a 
large surface area for cell attachment. This could be done by using roller bottles or 
multiple plates such as CellFactory (Thermo Scientific Nunc) and CellSTACK 
(Corning). However, these approaches are only suitable for low dosages and small 
patient numbers [233]. In addition, roller bottles and multiple plates are very labour 
intensive and difficult to equip with online monitoring for process control, thus a 
bioreactor system providing large surface area for cell attachment is required. Figure 
3 highlights bioreactor geometry that can provide large surface area for cell attachment 
and growth by either incorporating micro-carriers or making use of the bioreactor 
geometry and Table 4 highlights the advantages and disadvantages of these different 
bioreactor systems.  
 
1.4.1 Wave Bag Bioreactors 
 
The simplest designed bioreactor is a wave bag bioreactor, which simply consists 
of a gas permeable bag sitting on top of a rocker to gently induce wave and undertow 
in the semi-closed vessel. This bioreactor layout has some advantages, including 
purchasing of pre-sterilised parts, good heat transfer, aeration and oxygen monitoring. 
In addition, the bioreactor can be adapted to a batch, fed-batch, continuous perfusion 
configuration [234]. They also perform as well as stirred tank bioreactors without the 
high shear [235]. There are a number of commercially available wave bag bioreactors 
through GE Healthcare and Sartorius Stedim Biotech that are disposable and come 
pre-sterilised with the desired medium, making wave bag bioreactors ideal for 
production of cells under GMP. A wave bag bioreactor was used to isolate placental 
derived MSCs through an automated process, demonstrating a process to automate 
MSC isolation and expansion in one device is possible [210]. However, there are a few 
problems with this system; sampling, monitoring and controlling the system is not as 
simple as other bioreactor systems, and the cost of a single disposable bag is quite high 
[212]. Also, when growing adherent cells, it is difficult to get even seeding of cells 
onto the carriers leading to over confluence on some beads and some beads devoid of 
any cells. 
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1.4.2 Stirred Tank Bioreactors 
 
The most widely used configuration is the stirred suspension bioreactor. This 
bioreactor can be made to operate in a batch, fed-batch or continuous configuration. 
Stirred suspension bioreactors are appealing for the large scale production of stem cells 
as concentrations of 106-107 cells/mL can be attained [236]. Cells can be cultured in a 
single cell suspension, as aggregates, or on microcarriers in order to attain high cell 
densities. The cell density can be increased significantly with the use of porous 
microcarriers which also protect the cells from the high shear stress as they are able to 
grow inside the pellets [237]. However, it is very difficult to harvest the cells from the 
pores making porous microcarriers only suitable for when the cells are not the product. 
Stirred suspension bioreactors have been used for a number of years with a wide range 
of models and components commercially available, facilitating this bioreactor use in a 
wide variety of applications [212]. MSCs have been cultured in aggregates as well as 
on microcarriers in stirred suspension bioreactors [238-240]. MSCs grown in 3D 
aggregates do not grow rapidly, however they do maintain stemness and differentiation 
capacity better than 2D cultures [238]. When growing MSCs, seeding is far more 
difficult with microcarriers compared to other cell types [241]. In addition, growth rate 
of MSCs on the microcarriers was generally less than MSCs grown on 2D tissue 
culture plastic and expansion of microcarriers in xeno-free culture media has been 
demonstrated [228,239-242]. There are many commercial bench top scale bioreactors 
available including Mobius® Cell Ready (Merck Millipore) and BIOSTAT® 
UniVessel (Sartorius Stedim Biotech) that have been used to expand MSCs [31,243-
246] 
 
A similar concept to the stirred suspension bioreactor is the rotating wall 
bioreactor. Instead of an impeller agitating the medium, the wall of the bioreactor 
rotates to mix the media leaving the particles suspended in "free fall" [247]. Rotating 
wall bioreactors are reported to have a positive effect on osteogenic differentiation of 
MSCs [248,249]. However, due to the nature of the mechanics, the system is complex 
and not easily scalable. 
 
 Chapter 1: Introduction and Literature Review 27 
One of the major problems with stirred suspension bioreactors is that, although 
homogenous conditions are achieved by stirring the media, it becomes increasingly 
difficult to maintain homogenous conditions as the bioreactor is scaled up, requiring 
an increase in the speed of the rotor. This can cause hydrodynamic shear stress due to 
mechanical agitation, which is harmful to the cells [250]. Due to hydrodynamic shear 
to keep the microcarriers in suspension, stirred suspension bioreactors are not ideal for 
expanding large number of cells due to heterogeneous culture conditions and micro-
eddies induced by the rough external surface of macroporous carriers damaging the 
cells [224]. 
 
1.4.3 Hollow Fibre Bioreactors  
 
Hollow fibre bioreactors offer an increase in surface area to volume ratio 
compared to other bioreactors. Hollow fibre bioreactors consist of two compartments: 
a vessel that normally contains cells (extracapillary space) and a semipermeable 
membrane capillary through which media is perfused (intracapillary space), see Figure 
3F. These membranes generally have a low molecular weight cut off <10 kDa; this 
allows micronutrients such as glucose and oxygen to diffuse freely through the 
membrane, but larger molecules such as proteins cannot [251]. The hollow fibres 
provide nutrients and eliminate waste products from the cells in a manner which is 
analogous to blood vessels in vivo [252]. However, in tissue engineering applications 
the cells are maintained in a gel scaffold in the extra capillary space, which hinders 
perfusion leading to concentration gradients [253,254]. One of the major problems 
with growing cells in the extra-capillary space is recovery of the cell product after 
expansion if they have been grown in a scaffold. It has been qualitatively shown that 
MSCs can effectively grow in the extra-capillary space suspended in a gel. However 
the researcher could not remove the cells to get a quantitative measure of the expansion 
[68]. This result suggests that growing MSCs in the extra-capillary space is not an ideal 
way of using a hollow fibre bioreactor to expand cells for a clinical cell based therapy 
application.  
 
 28 Chapter 1: Introduction and Literature Review 
1.4.4 Packed Bed Bioreactors 
 
Packed bed bioreactors provide a very large surface area to volume ratio. This 
bioreactor is simply a vessel with immobilized scaffold arranged in a column where 
the cells are seeded and adhere to the packed bed. Media is perfused axially to provide 
nutrients, including oxygen. A packed bed bioreactor containing 500 μm diameter 
beads in a bioreactor volume of approximately 400 mL can provide approximately 3 
m2 of surface area. By simply decreasing the bead size down to 100 μm (a common 
commercial microcarrier size) the surface area that this volume of bioreactor can 
provide is 14 m2, which equates to 8 cell dosages of 2x108 cells [236].  
 
Packed bed bioreactors are widely used in the fermentation industry as they 
provide a low foaming and low shear environment, however they are not yet widely 
used in cell therapy [227]. However, these sorts of perfusion devices are more 
commonly used for tissue engineering purposes especially for bone [255]. Uniform 
flow (plug flow) must be maintained through the column to prevent unequal 
distribution of flow that will result in nutrient and oxygen gradients within the packed 
bed [211]. In addition, as flow is applied axially through the pack bed, there is a 
concentration gradient of nutrient and oxygen along the length of the reactor. No 
design has developed a solution of spatial concentration gradient within a packed bed 
bioreactor. Simply increasing the flow rate is not ideal, as it will induce a high 
hydrodynamic shear on the cells adhering to the packed bed. Haematopoietic 
progenitor cells have been expanded in packed bed bioreactors using a stromal cell 
support layer with limited success [256,257]. MSCs have been expanded on glass 
spheres in a packed bed, and all the necessary information to scale up such a packed 
bed bioreactor has been provided [218]. Another packed bed bioreactor using Fibra-
Cell disk (Eppendorf) as the packing material was able to expand MSCs and produce 
4.15 x 108 cells with no detriment on to the MSC’s characteristic [258]. However, an 
increased flow rate (>3x10-4 m/s) resulted in a decrease in the growth rate [218,226]. 
This greatly limits the size of the bioreactor due to oxygen concentration restraints. In 
addition, similar to microcarrier stirred tank bioreactors, cell harvest is difficult. 
However, the surface of these microcarrier or scaffolds plays a large role in modulating 
the phenotype of cells growing on these surfaces [238,259-263]. 
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1.5 SUMMARY AND THESIS STRUCTURE 
 
For MSCs based therapy to become affordable and routine, an automatable 
bioreactor system is required to produce the large number of cells used in a single dose 
for clinical applications. A packed bed bioreactor is required to achieve the large 
surface area to volume ratio to grow adherent cell type such as MSCs on. However, to 
provide adequate amounts of the limiting metabolite oxygen to the MSCs, a high flow 
rate of the medium is required. This higher velocity can cause shear stress on the cells, 
resulting in delamination and cell death [218]. This limits scale-up potential of 
traditional packed bed bioreactors as the flow rate is determined by oxygen 
concentration which is in limited supply. To counteract this, a packed bed bioreactor 
that incorporates a gas permeable wall made from PDMS that allows gas diffusion 
radially into the bioreactor was developed. This allows for a decoupling of oxygen 
from the bulk nutrient flow through the radial diffusion of oxygen. We hypothesize 
that this novel design allows for a lower median flow rate, as oxygen is no longer the 
limiting metabolite in the perfused medium. This allows for greater scale up potential 
and better control over the microenvironment as the flow rate can be optimised for 
other soluble factors and nutrients that are at a higher concentration than oxygen.  
 
To explore and develop this bioreactor design, murine derived bone marrow 
MSCs were initially used. In Chapter 2, the design process is demonstrated by 
exploring the use of different scaffold materials of glass and plasma treated 
polystyrene for the bioreactor in a 1.5 cm diameter by 7.5 cm bioreactor providing 160 
cm2 of surface area. Furthermore, to demonstrate the scale-up potential of this 
bioreactor design, a 5 cm diameter by 12 cm length scaffold providing 2830 cm2 of 
surface area was used to expand the murine bone marrow MSCs.  
 
In Chapter 3, to demonstrate the application of the packed bed bioreactor design 
and to confirm that MSCs can maintain their phenotype during expansion in the 
bioreactor compared to tissue culture flasks, the packed bed bioreactor was used to 
isolate and expand MSCs from digested human placenta.  
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To further develop the bioreactor design and more importantly help explain the 
results observed in Chapters 2 & 3, in Chapter 4, a 2D axisymmetric finite element 
model was developed that included the effects of oxygen, glucose and lactate 
concentration on the cell growth rate. This model was solved using the finite element 
software COMSOL. For ease of the reader, this Chapter follows a different format 
from the other experimental Chapters with a combined results and discussion section 
to give better understanding of the thought processes involved for the model 
development. 
 
In Chapter 5, the work of this thesis is summarised and the future directions of 
this work is outlined. 
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Chapter 2: Design and Development of 
Packed Bed Bioreactor with a 
Gas Permeable Wall 
MSC populations will require in vitro expansion in order to generate clinically 
relevant cell numbers to be used as a cell based therapy. Many promising therapies 
require single or multiple doses of approximately 2 x 106 cells/kg [3]. For MSC-based 
therapies to become a routine and economically viable treatment approach, the most 
efficient and cost effective method for their large-scale manufacture will require an 
automated closed-system bioreactor.  
 
Bioreactor designs used for MSC expansion include micro-carrier suspensions 
in spinner flasks, stirred tank reactors, and perfusion reactors, such as fixed/packed 
beds or hollow fibre bioreactors [68,226,231,258]. Simple microcarrier suspension 
cultures achieve a large surface area for adherent cell culture. However, there is no 
connectivity between individual microcarriers, and empty micro-carriers do not 
contribute to the total surface area available to the culture. As a result, some micro-
carriers rapidly reach confluence, whilst others remain empty; this requires frequent 
passaging to overcome localized space limitations [231,264]. Packed bed bioreactors 
potentially solve both problems by providing a continuous and connected surface to 
allow the cells to migrate between pellets. 
 
The packed bed bioreactor described here contains scaffold that was constructed 
from air plasma modified polystyrene pellets to which promote cell attachment similar 
to commercial tissue culture polystyrene (TCP) [265]. This surface modification is 
required as many polymers used as a scaffold for cell growth are hydrophobic and 
exhibit low surface energy, which leads to inefficient cell attachment, spread and 
proliferation [263,266-268]. However, surface modification to improve the surface 
cell affinity can be achieved in a number of ways [269]. Wet chemistry methods are 
commonly used, such as sodium hydroxide treatment to hydrolyse the polymer surface 
[259,270,271] or alternatively, acids such as sulfuric, or chromic acids, to oxidise the 
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surface to increase the hydrophilicity [272,273]. However, these reactions are 
nonspecific, and these surface modifications are inconsistent and heterogeneous with 
respect to polymers with different molecular weight, crystallinity or tacticity 
[274,275]. The modifications condition are also harsh and can degrade the polymer, 
resulting in a loss of mechanical properties and the chemical reagents generate 
hazardous chemical waste [275,276]. Alternatively, peroxide oxidation, ozone 
oxidation and γ- and UV-radiation can be applied to add functional groups. However, 
this also leads to degradation of the polymer, and the desirable modifications are non-
permanent [277-280].  
 
 
Figure 4 The reaction between polystyrene and oxygen plasma on surfaces results in a variety of 
chemical groups and breaking of the chain back bone or opening of benzene rings (not shown) that 
results in a more hydrophilic surface. Adapted from [281]. 
 
Plasma surface modification is a superior method to add functional groups to the 
surface to improve the hydrophilicity of a surface without changing the bulk properties 
of the material [269,282,283]. This method uses non-thermal plasma sustained in 
oxygen, air, nitrogen or ammonia without the need for damaging solvents [265,284]. 
Surface modification is regulated by the pressure, power, time, gas flow rate and the 
gas used [274,285]. Oxygen, nitrogen and ammonia plasma add oxygen and amine 
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functional groups, respectively, while carbon dioxide gas can introduce carboxyl 
groups [286]. Polymers such as polystyrene exposed to the corona discharge react to 
the highly energetic oxygen ions, which oxidise and graft to the surface polystyrene 
chains (Figure 4) that result in the surface becoming hydrophilic and negatively 
charged. These characteristics allow vitronectin and fibronectin (cell attachment 
proteins found in serum) to coat the surface and provide better surface properties for 
cell attachment [273,281]. In contrast, gases, like helium and argon discharges 
generate free radicals, which can later be cross-linked to oxygen-containing groups 
when exposing the surface to oxygen or air [269,283]. Plasma treatment provides a far 
more homogeneous surface modification without degradation of the polymer 
compared to wet chemistry methods.  It is also able to modify scaffolds with small 
pore sizes and particles of 500 µm in size [269,274,287,288], which is important for 
the research described here. However, plasma surface modification is sensitive to 
contaminates that cause undesirable reactions, especially with the more exotic gases 
[274]. In addition, the multiple parameters that must be optimised for the plasma 
surface modification creates difficulty in reproducing the results at a laboratory scale 
[289]. In Appendix 1the methodology for testing plasma modified surfaces is 
demonstrated.   
 
An additional issue in expansion devices is the mixing or perfusion of the medium to 
enable nutrient exchange and prevent concentration gradients. The shear stress arising 
from mixing or medium perfusion must be carefully modulated, as this can 
compromise MSC stemness characteristics during expansion [219,220]. As the 
maximum perfusion flow velocity cannot exceed 3 x 10-4 m/s without compromising 
the growth rate [218]. This greatly limits the scalability, as both soluble nutrients and 
oxygen must be supplied by medium perfusion alone. 
 
The bioreactor design described here overcome these problem by incorporating 
a gas permeable polydimethylsiloxane (PDMS) shell, which decouples the bulk 
medium perfusion from the supply of oxygen. This allows a reduced perfusion flow 
rate or even a single pass medium supply circuit to be used. Bubble formation within 
the bioreactor caused by pressure drops and temperature changes across the bioreactor 
was prevented by pressurizing the waste reservoir to 2 PSI. The system was optimised 
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using an immortalized murine MSC population that expresses green fluorescent 
protein (GFP-mMSC). This allowed for easier imaging of the cells on the bioreactor 
using fluorescent microscopy and also reduced complications due to primary human 
cells such as donor specific changes. Data from earlier prototypes was also included 
to demonstrate the design process, moving from a glass bead packing material to the 
plasma treated polystyrene scaffold.  
 
2.1 METHODS 
 
2.1.1 Single Pass Small-Scale Bioreactor Design 
 
This system contained a 1.5 cm diameter by 7.5 cm long scaffold providing a 
total surface area of 160 cm2, connected to a single pass circuit (Figure 5 A). This was 
made from either plasma treated 2.5 mm polystyrene pellets (Figure 5 C) or serum 
coated glass 3 mm beads. A 5 mm thick polydimethylsiloxane (PDMS, Dow Corning, 
MI, USA) tube was moulded to just fit the polystyrene scaffold with an additional 1 
cm head space to function as a bubble trap. Perfused medium was driven by a syringe 
pump (New Era Pump Systems Inc., NE-1800, Farmingdale, NY, USA) that was 
maintained outside of the incubator. Medium was perfused first through a 30 cm length 
of 16 mm diameter silastic tubing (Cole-Parmer, IL, USA) to enable conditioning of 
the medium before it entered the bioreactor flow cell. The rest of the tubing set was 
constructed of 1.6 mm Masterflex PharMed BPT tubing (Cole-Parmer, IL, USA). 
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Figure 5 (A) Process flow diagrams of the single pass small-scale 160cm2 bioreactor and (B) 
recirculating perfusion for the large-scale 2800 cm2 bioreactor. (C) Picture of 160 cm2 left and 2800 
cm2 right bioreactor scaffolds made from 2.5 mm polystyrene pellets (scale bar is 10 mm). (D) 2800 
cm2 bioreactor inside the incubator. 
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2.1.2 Recirculating Large-Scale Bioreactor Design 
 
A recirculating system was implemented as shown in the process flow diagram 
(Figure 5 B). The large-scale bioreactor was a 5 cm diameter by 12 cm scaffold, 
providing a total surface area of 2800 cm2, encased in a 5 mm thick PDMS tube. The 
peristaltic pump (Watson Marlow Alitea, 403V/VM 4, Stockholm, Sweden) was 
located outside the incubator. A single 3 mm diameter Masterflex PharMed BPT 
tubing passed through the peristaltic pump and was expanded into two 30 cm lengths 
of 1.6 mm diameter silastic tubing to allow conditioning of the medium for the inlet. 
This was then further expanded into the four 1.6 mm inlet holes into the bioreactor. 
Medium then left the bioreactor via the four 1.6 mm outlet holes, reducing firstly into 
two 30 cm lengths of 1.6 mm diameter silastic tubing and finally one 3 mm diameter 
Masterflex PharMed BPT tubing into the reservoir (Figure 5 D). 
 
2.1.3 Large Surface Area Scaffold 
 
Scaffolds were constructed from 2.5 mm in diameter by 3 mm length fused 
cylindrical polystyrene pellets (a generous gift from Paul Reynolds of Styron, PA, 
USA) or 3 mm serum coated glass beads. The polystyrene pellets were fused together 
by passing Acetone through a mould with a 1.5 cm diameter and 7.5 cm in length for 
the small-scale and a 5 cm diameter and 12 cm in length for the large-scale. The surface 
area of the scaffold was calculated by using the mass of the column and the volume 
estimate was confirmed by measuring the void volume (0.47).  
 
Details of the plasma reactor used to treat the polystyrene scaffolds have been 
reported previously [290]. In brief, the plasma reactor was loaded with the untreated 
scaffold columns, sealed and pumped under vacuum to a base pressure of 7x10-3 mbar. 
Air was then introduced into the reactor at a flow rate of 4 cm3/min, while the chamber 
was rotating at approximately 10 revolutions per minute. Plasma was ignited at 50 W 
for a total period of 10 minutes.  
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2.1.4 Prevention of Bubble Formation in Bioreactor System 
 
To prevent bubble formation due to pressure drop and temperature changes in 
the system, the system was pressurised with air at 2 PSI (13.79 kPa) using a low 
pressure two stage gas regulator (Gascon Systems, Thornbury, Vic, Australia) and a 
pressure safety valve set at 2 PSI (Generant, Butler, NJ, USA).  
 
2.1.5 Bioreactor Sterilisation. 
 
The bioreactors were sterilised overnight with a reactor volume (~6.2 ml for 
small scale and ~110 ml for large scale) of 70% ethanol. The ethanol was drained and 
the bioreactor was washed 2 reactor volumes (~ 12.4 ml for small scale and ~220 ml 
for large scale) of PBS (Gibco). The bioreactor was left overnight to allow the ethanol 
to leach out of the PDMS wall. This is because PDMS is known to absorbed small 
molecules [291]. The bioreactor was washed with one reactor volume of PBS and 
drained ready to be connected to the tubing circuit and injection of cells. The reservoir 
and tubing circuit was sterilised by autoclave. For the glass scaffold the bioreactor, 
reservoir and tubing circuit was autoclaved together.   
 
2.1.6 Air Plasma Treated Polystyrene Scaffold Characterisation 
 
Surface analysis was carried out using Axis Ultra DLD spectrometer (Kratos, 
Manchester UK.) using a monochromatic Al Kα X-ray source operating at 225 W, 
which corresponds to an energy of 1486.6 eV. The area of analysis was 0.3 x 0.7 mm 
and an internal flood gun was employed to minimize the charging of the samples. The 
survey spectra were collected at a dwell time of 55 ms with 160 eV pass energy at 
steps of 0.5 eV with three sweeps. The collected data were then analysed and processed 
using CasaXPS (ver.2.3.16 Casa Software Ltd. ®) utilizing Shirley baseline correction. 
To compensate for the charging effects, the C-C peak was offset to 284.8 eV in all 
spectra. Finally, all atomic percentages were mathematically rounded to one digit after 
the comma.  
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2.1.7 Cell Culture 
 
Green fluorescence protein labelled mouse mesenchymal stromal cell line (GFP-
mMSCs, generous gift from Mater Medical Research Institute (MMRI)) were 
originally isolated from the bone marrow of UBI-GFP/BL6 mice by MMRI in 
accordance with The University of Queensland Animal Ethics Committee, previously 
published and described in [292,293]. The GFP-mMSCs were maintained in DMEM 
10% FBS and incubated in standard cell culture conditions (37°C and 5% CO2).  
 
2.1.8 Comparison Cell Growth Rate of Glass Packing Material and Tissue 
Culture Plastic 
 
Round glass cover slips with the surface area of 1.9 cm2 (the same surface area 
as a 24 well plate) were used. The cover slips were sterilised overnight in 70% ethanol 
before being rinsed with PBS (Gibco) and placed into 4 wells of a 24 well plate. The 
cover slips were coated in 200 µl of FBS overnight. A total of 8 plates were prepared, 
one for each time point (days 1 through 7) and one plate for attachment. Each plate 
utilised 4 wells containing the serum coated glass and 4 wells that were tissue culture 
plastic. The wells were seeded with 1000 cell/cm2 of green florescence protein labelled 
mouse mesenchymal stromal cells (GFP-mMSC) with 0.5 mL of DMEM 10 % FBS 
and incubated in standard cell culture conditions (37 ⁰C, 5 % CO2). At each time point, 
a plate was removed from the incubator, the medium was removed and the well was 
washed with PBS. The cells were then fixed with 100 µL of 4 % paraformaldehyde 
(PFA, Sigma) for 20 minutes, and the PFA was removed from the wells. The wells 
were then washed twice with 200 µL PBS before being stained with 100 µL of 300 
nM DAPI hydrochloride (Invitrogen) for 15 minutes. The wells were washed twice 
again with 200 µL PBS before being observed under a florescent microscope (Nikon 
Eclipse, 4x objective lens). The numbers of cells per well were obtained by 
photographing the bottom of each well, and scanning the entire well surface. The 
nuclei were counted in each image by ImageJ (version 1.45), first by highlighting the 
nuclei by adjusting the threshold (adjust -> threshold), then by making a binary of the 
highlighted nuclei (process -> binary -> make binary). Any particles that were 
touching were automatically separated using the watershed algorithm (process -> 
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binary -> watershed). The nuclei were counted automatically using the “analyse 
particle” function, excluding particles smaller than 100 pixels2 (analyse -> analyse 
particles).  
 
2.1.9 Comparison of Air Plasma Treated Polystyrene and Commercial Tissue 
Culture Plastic on Cell Growth Rate and Attachment. 
 
Non-tissue culture treated polystyrene 60 mm Petri dishes (Sigma-Aldrich) were 
plasma treated in the same manner as the polystyrene scaffolds above. To assess cell 
attachment, the air plasma treated Petri dishes and T75 flask (Nunc) were seeded at 
2000 cells/cm2 with GFP-mMSCs in DMEM 10% FBS. This cell density was used 
instead of 1000 cells/cm2, so that enough cells to provide an accurate count using flow 
cytometry method. The cells were permitted to attach for one and half hours in standard 
cell culture conditions. The adhered cells were detached and then counted on an FC 
500 flow cytometer (Beckman and Coulter, USA) using flow cytometry counting 
beads (Beckman and Coulter, USA). To compare the growth rate, plasma treated Petri 
dishes and T75 flask were seeded with GFP-mMSCs at a density of 1000 cells/cm2 
and incubated for 3 days in DMEM 10% FBS. The cells were then harvested and 
counted via flow cytometry as described above. 
 
2.1.10 Packed Bed Bioreactor Seeding Method. 
 
1000 cells/cm2 was seeded into the bioreactor suspended in DMEM 10% FBS. 
To distribute the cells evenly, the bioreactor was placed on a tube rocker roller set at 5 
RPM for 10 minutes, followed by 5 minutes of rest in an incubator (37°C and 5% CO2) 
this process was repeated for 3 hr. After this process was completed the pump was 
switched on for perfusion experiments.  
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2.1.11 Expansion of GFP-mMSCs in the Packed Bed Bioreactor 
 
The 160 cm2 bioreactor was seeded at 1000 cells/cm2 (25,685 cells/ml) of GFP-
mMSCs suspended in DMEM 10% FBS as described in 2.1.10. As a 2D control, GFP-
mMSCs were seeded at a density of 1000 cells/cm2 (5,833 cells/ml in 30 ml of 
medium) in T175 flasks (Nunc). The GFP-mMSCs were grown either under static 
conditions (no continuous perfusion with the media exchanged every two days) or 
perfusion (5 mL/day) in the bioreactor. The cell numbers were quantified every two 
days by replacing the medium with a 1:50 dilution of AlamarBlue in DMEM 10% FBS 
medium and incubated for three hours. The reacted AlamarBlue medium was replaced 
with fresh DMEM 10% FBS and the culture was continued. The fluorescence signal 
of the AlamarBlue in medium was measured in a plate reader (FLUOstar Omega, 
BMG Labtech, Germany) using excitation and emission filters of 544 and 590. To 
infer the cell numbers a cell titration of 0 to 16,000 cell/ml in a 96 well plate (n=8 
wells) was analysed. 
 
2.1.12 Packed Bed Bioreactor Harvest and Harvest Efficiency 
 
The bioreactor was washed with one reactor volume (~6.2 ml for small scale, 
~110 ml for large scale) of PBS and replaced with one reactor volume of 0.05% 
Trypsin EDTA (Gibco). The Bioreactor was then incubated (5% CO2 and 37⁰C) for 
15 minutes. The detached cells were removed by first draining the Trypsin solution 
and then pumping through three reactor volumes (~19 ml for small scale, ~330 ml for 
large scale) of DMEM 10% FBS and removing the remaining medium in the reactor. 
Live cell numbers were determined by an automated cell counter (Bio-Rad TC20, CA, 
USA) using Trypan Blue. This number was compared to the AlamarBlue result to 
estimate the percentage of live cells removed from the bioreactor.  
 
2.1.13 Packed Bed Bioreactor Imaging 
 
For direct imaging of the GFP-mMSCs attached to the 160 cm2 column at the 
end of culture, the column was removed and fluorescence microscopy (Nikon Eclipse 
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Ti-u with a Nikon Digital Sight Ds-Qimc camera, Japan) was used to image GFP 
expressing cells. 
 
To image the whole bioreactor using the IVIS Imaging System 200 series 
(Caliper, PerkinElmer, MA, USA), the cells were fixed with 4% paraformaldehyde for 
1 hour. The PFA was drained from the bioreactor and washed with two reactor 
volumes PBS. The scaffolds were stained with a reactor volume 10 µg/mL propidium 
iodide in PBS (PI, Invitrogen) for 10 minutes. As the IVIS detection filters are in the 
red spectrum so the GFP signal could not be detected. In addition, this process was 
needed for the detection using IVIS primary human MSCs. The bioreactor was then 
washed with a reactor volume PBS and stored on ice prior to imaging. As negative 
controls, bioreactors containing no cells underwent the same fixing and staining 
process. The bioreactors were imaged with an excitation filter of 520 nm and an 
emission filter of 620 nm. The thresholds were adjusted to remove background auto 
florescence.  
 
2.1.14 Scale-up of GFP-mMSC in Bioreactor 
 
The 2800 cm2 bioreactor was seeded at 1000 cells/cm2 (~25,455 cells/ml) with 
GFP-mMSCs suspended in DMEM 10% FBS using the injection port. The T175 flasks 
functioned as a 2D control. The same seeding procedure as per section 2.1.10 was 
followed. The reservoir was filled with 250 mL of DMEM 10% FBS to give a total 
medium volume of 360 mL in the circuit (bioreactor volume 110 mL). The medium 
was pumped in the recirculating circuit at 0.5 mL/min. A 1 mL medium sample was 
taken from the injection port each day. In addition, at the end of the culture period an 
additional 1mL sample was taken from the bulk medium in the reservoir. Glucose and 
lactate concentrations were quantified by the Mater Hospital Pathology laboratory. At 
the end of expansion, the cell numbers were quantified by the AlamarBlue method. 
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2.1.15 Statistics 
 
Results are expressed as means and standard deviations of four biological 
replicates unless stated otherwise. Differences were determined by T-test using SPSS 
statistics (ver 17, SPSS Inc, Chicago) and values of p ≤ 0.01 were considered 
significant. 
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2.2 RESULTS 
 
2.2.1 Glass Bioreactor Development 
 
Glass was first chosen as a packing substrate, as it allowed for easier sterilisation. 
As PDMS, silicon tubing and glass are all autoclavable materials, the entire bioreactor 
and tubing circuit could be autoclaved before each bioreactor run, simplifying the 
sterilisation process. Historically, glass was commonly used for tissue culture before 
the advent of tissue culture plastic, so FBS coated glass was believed to be a suitable 
matrix for bioreactor design. To be certain, the growth rates of GFP-mMSCs on both 
glass and TCP were compared. There was no significant difference in cell number after 
a week’s expansion between the glass cover slip and traditional TCP (Figure 6 A). 
However, in a 3D scaffold configuration in the bioreactor there was a problem with 
achieving cell expansion. This was due to the cells delaminating from the surface so 
that the surface coverage of the serum coated glass beads became very patchy (Figure 
6 D, E, F & G). This was so dramatic as to cause areas in the bioreactor to have no 
cells present and there was a very heterogeneous cell distribution overall (Figure 6 B 
& C). This demonstrated that unmodified serum coated glass was unsuitable as a 
scaffold material and the alternative of plasma modified polystyrene was explored. 
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Figure 6 (A) Comparison of cell density of mouse GFP-mMSC between glass and tissue culture plastic 
(TCP), mean + SD of n=4. (B & C) IVIS images of two separate glass packed bed bioreactors containing 
mouse GFP-mMSC stained with PI. Fluorescence intensity ranges from low (dark red) to high (yellow). 
The bright spot in C is due to autofluorescence of a large deposit of silicon glue. (D, E, F & G) 
Fluorescence microscopy images of GFP-mMSC growing on glass beads.  
 
2.2.2 Plasma Treated Polystyrene Scaffold Characterisation 
 
The rotary air plasma treatment greatly increased the charged oxygen groups on 
the surface on the polystyrene pellets (Figure 7 A), providing a similar growth surface 
chemical composition to commercial TCP [265]. However, high amounts of silicon 
and oxygen contamination in the untreated polystyrene were detected. This was likely 
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because the PDMS mould used to make the scaffold is known to leach unreacted 
polymer which contains silicon and oxygen [294].  
 
 
Figure 7 (A) Surface composition of the air plasma treated polystyrene scaffold determined by XPS, 
commercial TCP based on literature value [265]. (B) Cell density of GFP-mMSC attachment after one 
and half hours, initially seeded at 2000 cells/cm2 in a 60 mm plasma treated petri dish or a T75 flask 
control (n=4, mean + SD). (C) The growth after 3 days of culture of GFP-mMSC seeded at 1000 
cells/cm2 in a 60 mm plasma treated petri dish or a T75 flask control (n=6, mean + SD).  
 
The attachment and growth of GFP-mMSCs were compared, on our plasma 
treated surface in 2D and commercial TCP. Less than half of the 2000 cells/cm2 seeded 
attached to the plasma treated surface after one and half hours (Figure 7 B). However, 
after 3 days the cell number on the plasma treated surface was equivalent to 
commercial TCP (Figure 7 C). Following this observation, the seeding period for the 
bioreactor experiments was extended to 3 hours to allow more robust cell attachment.  
 
2.2.3 GFP-mMSCs Expansion in Small-scale Packed Bed Bioreactor 
 
The GFP-mMSCs growth rate in the bioreactor was significantly (p<0.01) less 
than the 2D controls under both static and perfusion conditions (Figure 8 A & B) with 
the doubling time of 30.19±0.6 hr and 26.48±0.49 hr respectively for static conditions 
and 27.18±0.8 hr and 24.59±0.53 hr respectively under perfusion conditions (5 
mL/day). The doubling time was calculated by ln(2)/max growth rate assuming 
logarithmic cell growth. The cells were harvested from the bioreactor with an 
efficiency of 84%±11% with a cell viability of 71%±15% (Figure 8 C). 
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Figure 8 (A) The fold expansion of GFP-mMSCs seeded at 1000 cell/cm2 in four bioreactor (BR) under 
static conditions and, (B) under 5 mL/day perfusion, compared to four T175 flask controls (2D). (C) 
Cell harvest recovery and viability from the bioreactor undergoing 5mL/day perfusion.  
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The roller method of seeding greatly increased attachment efficiency with only 
1.89% of the total injected cells not attaching to the scaffold after 24 hours (Figure 9 
A). This is approximately 13% more cells attached to the scaffold using the roller 
method as compared with the static method of injecting the cells and allowing them to 
attach with no other manipulations. The cells formed a monolayer on the fused pellets 
and maintained a spindle-like morphology. In addition, the cells were observed to 
display normal MSC morphology and where grow across the connection between the 
beads (Figure 9 G, H, I, J). IVIS imaging used the fluorescent intensity of the PI stained 
cells to estimate the global distribution of cells within the bioreactor. Under both static 
and perfusion conditions, fluorescence intensity was homogeneous within the scaffold 
(Figure 9 B & C), suggesting that the cells could be homogeneously distributed in the 
scaffold using the roller seeding method when compared to the static method where 
there was a higher fluorescent intensity at the inlet (Figure 9 D, E & F). 
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Figure 9 (A) Seeding efficiency of using the roller method compared to just injecting the cells and 
allowing them to attach under static conditions, (n=4, mean + SD, * p<0.01). (B) IVIS imaging of the 
fluorescent intensity of PI stained GFP-mMSCs in the bioreactor under static and (C) 5 mL/day 
perfusion conditions after roller seeding method. (D, E & F) IVIS images of static expanded GFP-
mMSCs using the static seeding method. IVIS images are a red (low) / yellow (high) heat map of 
fluorescent intensity. (G, H, I & J) Fluorescent microscopy showed that the GFP-mMSCs attached to 
the scaffold after cell expansion using the roller seeding method (scale bar is 500 µm,).  
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2.2.4 Scale-up of the Packed Bed Bioreactor 
 
GFP-mMSCs were used to demonstrate the scale up potential of a larger 250 mL 
vessel that provided 2800 cm2 of growth surface. The bioreactor was able to expand 
up to 1.12x108 GFP-mMSCs. However, cell growth was significantly slower in the 
bioreactor than in the 2D controls, with doubling times of 21.5 ± 0.1 hr and 20.8 ± 0.4 
hr respectively (Figure 10 A). The medium perfusion rate was increased to 0.5 mL/min 
from the small-scale experiments to provide adequate glucose to the cells. The glucose 
levels were nearly depleted in the bioreactor and the reservoir by day 5 (Figure 10 B), 
suggesting either that the medium must be changed every three to four days or that a 
larger medium reservoir is required to prevent glucose concentration dropping by half. 
The IVIS imaging showed heterogeneous fluorescence intensity, implying that the 
seeding method is not as robust when scaled-up to the large-scale bioreactor compared 
to the small-scale bioreactor (Figure 10 C, D, E & F). 
 
 
Figure 10 (A) The fold expansion of GFP-mMSCs in a scaled-up bioreactor under 0.5 ml/min perfusion 
with T175 flask control (n=4, mean + SD, * p<0.01). (B) Glucose and lactate levels in the bioreactor 
(n=3, mean + SD). (C, D, E & F) IVIS imaging of the fluorescent intensity of PI stained GFP-mMSCs 
in the bioreactor.  
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2.3 DISCUSSION 
 
Packed or fixed bed bioreactors like many other bioreactor designs, rely either 
on the perfusion or mixing of the medium to provide the two limiting metabolites, 
glucose and oxygen. Due to the low oxygen solubility, the perfusion or mixing rates 
must be high enough to meet the oxygen demand of the expanding cells and to prevent 
depletion and significant concentration gradients [31,218]. Such high perfusion rates 
can potentially cause shear stress on the cells, which has been shown to reduce cell 
growth rate and induce differentiation. A shear stress of 0.015 Pa has been reported to 
up-regulate osteogenic pathways in human bmMSCs [218-221]. Our bioreactor 
employed a gas permeable wall to decouple the oxygen supply from the bulk medium 
perfusion, resulting in lower flow rates and putatively decreasing the shear stress to 
which the cells were exposed. In addition, the lower medium volume required for 
tissue culture would the reduce flow rate, representing a significant cost saving. Please 
refer to Chapter 4 and Appendix 11 for a thorough analysis of momentum transfer in 
the bioreactor that shows that the flow rate used in the experiments is below the 0.015 
Pa threshold that induces differentiation.  
 
The Glass packing material as was commonly used for tissue culture before the 
advent of tissue culture plastic (TCP), so glass was believed to be a suitable scaffold 
for bioreactor design. In 2D expansion experiments there is no difference in a glass 
surface and TCP GFP-mMSC growth rate (Figure 6A). However, the cells were easily 
delaminated from the surface which made glass very unsuitable, in addition, 
movement of the beads during the seeding process could damage and kill the cells 
(Figure 6 G, H, I & J). It was decided to move to a scaffold of fused polystyrene pellets 
that was plasma treated. An air plasma treated polystyrene surface provided a 
comparable surface to commercial grade tissue culture plastic (Figure 7 A), and the 
growth rate was comparable to commercial TCP (Figure 7 C). However, the overall 
growth rate of the GFP-mMSCs growing in the bioreactor in static and perfusion 
conditions was less than the traditional flask expanded cells (Figure 8 A & B). 
Although, medium perfusion enhanced the growth rate, which is consistent with 
literature observations [226,228,231,295]. Similarly, when the bioreactor was scaled 
up to a larger 5 cm diameter by 12 cm in height, there was a decrease in the growth 
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rate of the cells growing in the bioreactor compared to the tissue culture flask. 
However, difference between the two growth rates was less with a higher flow rate 
providing more nutrients in the bioreactor compared to the lower flow rate used in the 
small 160 cm2 bioreactor (Figure 10 A). Nevertheless, this result supports the 
hypothesis that suppling oxygen diffusion through the wall is scalable and can use a 
flow rate that is lower than what has been previously been published 
[226,228,231,295].  
 
This impaired bioreactor growth rate relative to traditional tissue culture flasks 
could be attributed to surface chemistry and geometry of the scaffold or to the method 
used to seed the bioreactor. As the growth on the plasma modified petri dishes was the 
same as commercial TCP and the GFP-mMSC maintain their spindle like morphology 
on the bioreactor scaffold (Figure 9 G, H, I & J). This suggests that the impaired growth 
rate observed in the bioreactor could not be entirely attributed to chemical differences 
in surface composition. The inefficiencies in the cell seeding process and geometry 
can also strongly affect the growth rate. A noticeable uneven cell distribution was 
observed in the scale up bioreactor (Figure 10 C, D, E & F). The geometric features of 
the bioreactor scaffold surface could alter the contact inhibition characteristics of cell 
colonies, which would be likely to reduce the observed growth rate. However, due to 
the size of the pellets used in the scaffold being large, the surface would appear 2D at 
a cellular level. Which greatly reduces the contact inhibition effect due to curved 
surfaces and the 3D orientation of the scaffold during cell expansion. Despite this,  the 
geometric features of the scaffold can affect the collision rate during seeding, defined 
as the rate at which cells contact the scaffold, would be greatly reduced on these 3D 
structures in dilute cell suspension [264]. Of the many bioreactor seeding methods 
reported in the literature, no method was completely efficient [218,296-298]. The best 
method achieved ~85% cell attachment with 85% uniformity [299,300]. The roller 
seeding method was fare more efficient with 98% of the cells attaching and the static 
method achieved an efficiency of 87%. 
 
 Chapter 4 explores this reduced growth in the packed bed bioreactor by 
modelling the bioreactor in a 2D axisymmetric model, which was developed to explore 
the effect of nutrient concentrations and cell seeding distribution on the overall cell 
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growth rate. Furthermore, the model was used to aid future scale up designs by 
modifying shape and demonstrated that by decreasing particle size this bioreactor 
design was able to produce greater than 2x108 cells at a lower medium flow rate than 
has been previously been reported [226,228,231,295].  
 
The next Chapter discusses the use of this bioreactor to isolate and expand MSCs 
from human placenta to further demonstrate the flexibility of this bioreactor and its 
use as a potential single closed system isolation and expansion device for MSCs. 
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Chapter 3: Bioreactor Application: Isolation 
and Expansion of Placental 
Derived Cells on a Packed Bed 
Bioreactor 
The most widely studied and best characterized MSCs are derived from bone marrow 
(bmMSCs) [23]. However, MSCs can be isolated from other tissues that may be more 
accessible than bone marrow-derived cells, these include placenta, adipose tissue and 
umbilical cord [24-26]. The placenta is a particularly attractive source of MSCs, as a 
single placenta (500-700 g tissue) is sufficient for manufacturing several thousand 
units of allogeneic MSCs once expanded [231]. Furthermore, placental tissue can be 
harvested aseptically during a Caesarean section with no added risk to the mother or 
child. Placental-derived MSCs (pMSCs) are reported to behave similarly to bone 
marrow derived MSCs (bmMSCs) in many respects [26,301]. However, pMSCs may 
be only partially immunogenic and less immunomodulatory relative to bmMSC and 
do appear to have a reduced differential potential down the oestrogenic linage [26,49].  
 
MSCs have been reported to promote repair of non-healing wounds and ulcers 
[302]. MSCs secrete a number of soluble factors that promote cell growth, survival 
and have an immunomodulatory effect [8,101,303]. Nevertheless, tissue repair is not 
only enhanced by injecting the MSCs, but also supported by injecting the MSC 
conditioned media alone [101,110,175,238,303], despite the observation that the 
overall half-life of secreted proteins in the conditioned media is less than by injecting 
MSCs directly [304]. However, intravenously injected MSCs are mainly captured in 
the lungs and are also attacked by the innate immune system through the complement 
and coagulation cascade, preventing the MSCs from reaching their desired location 
[75,94]. This suggests that the topical application of MSCs conditioned media would 
be ideal method for wound repair. 
 
It was demonstrated in Chapter 2 that decoupling the oxygen supply from the bulk 
medium flow by allowing oxygen diffusion through the wall could support GFP-
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mMSC growth. However, as the growth rate was reduced in the bioreactor compared 
to traditional tissue culture flask, it was necessary to confirm if this had any effect on 
the MSCs’ ability to differentiate. Primary human placental derived MSCs were used 
to investigate if there were any detrimental effects in growing human MSCs in our 
bioreactor. In order to demonstrate the flexibility of the bioreactor, pMSCs from 
digested placenta were isolated directly onto the bioreactor. In addition to, exploring 
the effects isolating and expanding pMSCs in the packed bed bioreactor on the cell 
stemness, a comparison of the functional difference between placental and bone 
marrow derived MSCs in their ability to differentiate and to promote cell growth was 
investigated. By using the human keratinocyte cell line, HaCaT, growth response to 
conditioned medium of the MSCs from the two tissue sources at different passages, to 
examine the effect of long term culture on MSCs phenotype.  
 
3.1 METHODS 
 
3.1.1 Bioreactor set-up 
 
The bioreactor was set up in a single pass circuit system described in 2.1.1 & 
2.1.4, using the same plasma treated polystyrene scaffold described in 2.1.3. 
 
3.1.2 Cell Culture 
 
Placenta was obtained from full term elective Caesarean sections with written 
consent from the patients and ethics approval from the Queensland University of 
Technology’s Human Ethics Committee (1000000938). The method used to isolate 
pMSCs from the placenta has previously been reported [231,305], the resultant product 
was <1% CD45+ and >90% CD73+/CD105+. Briefly, 10 g of placental tissue cut into 
5 mm cubes (pieces) was digested in a 50 mL falcon tube with DMEM low glucose 
(Invitrogen), 100 Units/mL Collagenase I (Worthington) and 2.5 µg/mL DNase I 
(Roche) that was incubated at 37 °C for 2 hours on a shaker (250 RPM). The cell 
supernatant was passed through a 70 µm cell strainer (BD Falcon) and was centrifuged 
at 400 g for 5 minutes. The supernatant was removed and the cell pellet was 
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resuspended in PBS, and mononuclear cells were then isolated using a Ficoll-Paque 
(GE Healthcare) density gradient at 400 g for 30 minutes. The mononuclear layer was 
collected and washed with PBS and finally the cells were resuspended in low glucose 
DMEM supplemented with 10% fetal bovine serum (Thermofisher), 100 units/mL 
penicillin, and 100 µg/mL streptomycin (Life Technologies) (referred to as DMEM 
10% FBS from here on) and seeded into a single T175 flask. The cells were then 
incubated in 20% oxygen, 5% CO2 at 37 °C for 24 hours to allow adherent cells to 
attach. The flask was washed and fresh medium was added. The flask was placed into 
a hypoxic incubator (2% oxygen and 5% CO2). This process was standardised in our 
group for MSC isolation procedures [202]. The medium was replaced twice a week 
until the monolayer was 80-90% confluent before passaging. The pMSCs were 
harvested and cryogenically stored after passage one.  
 
To isolate bone marrow MSCs, human bone marrow aspirates were obtained 
from volunteer donors. Written consent and ethical approval for these studies was 
granted by the Mater Health Services Human Research Ethics Committee (Ethics 
number: 1541A) and the Queensland University of Technology Human Research 
Ethics Committee in accordance with the Australian National Statement on Ethical 
Conduct in Human Research. Every 5 ml bone marrow aspirate was diluted to 35 ml 
with Phosphate buffer saline (PBS, Invitrogen). The mononuclear cells were isolated 
using Ficoll-Paque (GE Healthcare) density gradient at 400g for 20 minutes. The buffy 
layer was removed and washed in PBS and re-suspended in low glucose DMEM 
(Invitrogen) supplemented with 10% fetal bovine serum (Thermofisher), 100 units/mL 
penicillin, and 100 µg/mL streptomycin (Life Technologies), referred to as DMEM 
10% FBS from here on, and seeded into a single T175 flask (Nunc). The cells were 
then incubated in 20% oxygen, 5% CO2 at 37 ⁰C for 24 hours to allow adherent cells 
to attach. The medium was then replaced with fresh medium and the flask was placed 
into a hypoxic incubator (2% oxygen and 5% CO2 at 37 ⁰C). The medium was replaced 
twice a week until the monolayer was 80-90% confluent before passaging. 
 
HaCaT keratinocyte cell line were maintained in low glucose DMEM 
(Invitrogen) supplemented with 10 % FBS and 100 units/mL penicillin 100 µg/mL 
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streptomycin and incubated in standard cell culture conditions (37 ⁰C, 20 %O2 and 5 
%CO2).  
 
3.1.3 Placental and Bone Marrow Conditioned Medium 
 
To make conditioned media, 10,000 cells/cm2 of pMSCs or bmMSCs were 
seeded onto a 6-well plate in 5 mL of DMEM 10 % FBS. The cells were left to attach 
for four hours, after which the media was removed and the wells were washed with 5 
mL of PBS to remove any residual serum proteins. 5 mL of XVIVO 15 or DMEM 
(low glucose, Invitrogen) cell culture media supplemented with 100 units/mL 
penicillin 100µg/mL streptomycin (is referred to as DMEM) was added to the well. 
The cells were then incubated up to 48 hours in hypoxic conditions (2 % oxygen, 5 % 
CO2) in a humid atmosphere at 37 ⁰C. The medium was removed and centrifuged at 
500 G for 5 minutes to remove the cell debris and stored at -20⁰C. 
 
For the cell aggregate condition medium, 60,000 cells where added to a 48 well 
plate with microwell technology developed in the Doran Lab, that contains 600 
microwells/cm2 suspended in 0.5 ml XVIVO 15 [306,307]. After 48 hours incubation 
in hypoxic conditions, the media was removed, centrifuged at 500 G for 5 minutes to 
remove cell debris and stored at -20⁰C. For use in the growth experiments the 
conditioned media was diluted to 5 ml so that the cell concentration would be the same 
as the monolayer conditioned media. 
 
The concentrated condition media followed the same procedure as the 
monolayer conditioned media in the 6 well plates above. After 48 hr of conditioning, 
the media was removed and centrifuged at 500g for 5 minutes. The media was then 
dialysed with a 12 kDa (Sigma) cut off for 48 hours changing the deionised water 
every 6 hours for the first 24 hours and every 12 hours for the last 48 hours. 5ml 
aliquots of the dialysed media were lyophilised (Christ Alpha 1-2 LDplus). The 
lyophilised media was stored at -20⁰C and resuspended in 2.5 ml XVIVO 15 for 
experiments to give a 2x concentration conditioned media. 
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3.1.4 HaCaT growth in response from MSC conditioned media 
 
To gauge MSC conditioned medium capacity to enhance cell growth, HaCaTs 
were seeded at 1000 cells/cm2 in a 96 well plate, and the cells were left to attach for 4 
hours in DMEM 10 % FBS. The medium was then removed, and the wells were 
washed three times with PBS to remove any residual serum proteins. 100 µL MSC 
conditioned medium, positive control of the 10% FBS supplement DMEM or XVIVO 
and a negative control of serum free XVIVO 15 or DMEM. The cell number was 
quantified on day 4 and 6 using AlamarBlue comparing the relative florescence to cell 
number standard on a plate reader (BMG labtech). The media was changed every 2 
days. The HaCaTs were grown in normoxic conditions.  
 
3.1.5 Pre-Isolated pMSCs Expansion in the Packed Bed Bioreactor 
 
The 160 cm2 scaffold bioreactor was seeded through the injection port with 1000 
cells/cm2 of passage four pMSCs suspended in DMEM 10% FBS, using the same 
seeding process, culture conditions and 2D controls as the expansion of the GFP-
mMSCs in section 2.1.10 & 2.1.11. However, in the perfusion experiment the cell 
numbers were quantified by AlamarBlue at the end of the culture, in the method 
outlined in 2.1.11. The cells were then harvested (2.1.12) and characterised by tri-
lineage mesodermal differentiation capacity (3.1.7). The cell distribution was observed 
by IVIS imaging described in 2.1.13. 
 
3.1.6 pMSC Isolation and Expansion in the Packed Bed Bioreactor 
 
The placental tissue was digested by the same method outlined in the pMSC 
isolation and cell culture section above. Instead of a density gradient, the filtered cell 
suspension from the 10 g of starting tissue was seeded into the bioreactor or into a 
T175 flask using the same seeding method outlined in the GFP-mMSC expansion 
(2.1.11). After 24 hours, the cell suspension was removed, the medium was replaced 
and the flow rate was adjusted in the bioreactor to 5 mL/day. Once the pMSC colonies 
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were observed (between day 10 and 14) in the T175 flasks, the cells were harvested in 
both the bioreactors and flasks and reseeded into the same bioreactor or flask to 
continue the expansion process. The cell number was monitored using the AlamarBlue 
method. The cells were harvested once confluence was achieved and characterised by 
tri-lineage differentiation capacity. 
 
3.1.7 Tri-Linage Mesodermal Differentiation 
 
Osteogenic differentiation was achieved by culturing 25000 cells/cm2 pMSCs in 
24 well plate with 2 ml of induction medium containing high glucose DMEM 
(HGDMEM, Invitrogen) supplemented with 10% FBS, 10 mM β-glycerol phosphate 
(Sigma-Aldrich), 100 nM Dexamethasone (Sigma-Aldrich) and 50 µM L-ascorbic 
acid 2-phosphate (Sigma-Aldrich). The calcium deposits were visualised by first fixing 
the cells with 4% PFA and washing twice with 2ml of PBS before staining with 1ml 
2% AlizarinRed S (Sigma-Aldrich) incubating for 5 minutes before washing 2ml of 
de-ionised water until it runs clear and the calcium deposits where observed under a 
microscope. Alkaline phosphatase (ALP) activity was quantified with p-nitrophenyl 
Phosphate (Sigma-Aldrich) following manufactures instructions, measuring the 
absorbance at 405 nm after a 30 minute incubation at room temperature protected from 
light.  
 
Chondrogenesis was induced using cultures of 200,000 cell pellets grown in 1 
ml HG DMEM supplemented with 110 μg/mL sodium pyruvate (Invitrogen), 10 
ng/mL recombinant human Transforming Growth Factor β1 (TGF-β1, Peprotech), 100 
nM dexamethasone, 200 μM ascorbic acid 2-phosphate, 40 μg/mL L-proline (Sigma-
Aldrich) and 1% ITS-X (Invitrogen). Every two days 75% of the chondrogenic 
medium was changed, the collected medium was stored at -20°C for subsequent 
glycosaminoglycan (GAG) analysis. GAG was visualized by staining frozen sections 
of the cell pellets with 0.5% Alcian Blue (Sigma-Aldrich). GAG was then quantified 
by first digesting the pellets in 2 mg/ml papain (Sigma) solution and then staining with 
1,9-Dimethyl-methylene blue zinc chloride double salt (Sigma-Alrich) and the 
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absorbance was measured at 590 nm and compared to a standard made from shark 
chondroitin sulphate (Sigma) to quantify the GAG. 
 
Adipogenic differentiation was induced over 2 weeks with HGDMEM 
supplemented with 10% FBS, 10 µM insulin (Invitrogen), 1 µM dexamethasone, 200 
µM indomethacin (Sigma-Aldrich) and 500 µM 3-isobutyl-1-methyl-xanthine (Sigma-
Aldrich) in a 24 well plate seeded at 25000 cells/cm2. Lipid droplets were visualised 
by staining with 0.2% Oil Red O (Sigma-Alrich) of 4% PFA fixed cells. The lipids 
were quantified with an abiogenesis detection kit (Abcam) following the 
manufacturer’s protocol. 
 
The DNA was quantified by PicoGreen dsDNA Reagent Kit (Invitrogen) 
following the manufacturer’s protocol.  
 
3.1.8 Statistics 
 
Refer to section 2.1.15. 
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3.2 RESULTS 
 
3.2.1 Difference in tri-lineage Differentiation Potential of bmMSCs and pMSCs 
 
Figure 11 (A) Tri-lineage potential of pMSC and bmMSC was assessed by staining and visualising the 
lipid droplets (Oil Red O, adipogenic), bone nodules (Alizarin Red, osteogenic) and GAG in the pellet 
(Alcian blue, chondrogenic). (B) The levels of triglycerides were measured to indicate the degree of 
adipogenic differentiation. (C) The activity of ALP was measured to indicate the degree of osteogenic 
differentiation and (D) the chondrogenic differentiation was assessed by the level of GAG present in 
the pellet. *indicated p<0.01 with n=4 in all conditions.  
 
To understand the functional difference between bmMSCs and pMSCs, their 
capacity to undergo tri-lineage differentiation must be assessed. The two types of 
MSCs underwent 2 weeks of induction under adipogenic, osteogenic and 
chondrogenic conditions. By visualising the bone nodules and GAG expression by 
staining the lipid droplets a significant decrease in the differentiation capacity of 
pMSC compared to bmMSCs was easily observed (Figure 11 A).  Under adipogenic 
induction conditions, bmMSCs produced significantly more lipid droplets, confirmed 
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by the near doubling of the triglycerides present in the well (Figure 11 B). More and 
larger bone nodules were observed in bmMSCs under osteogenic induction than the 
pMSCs, which was confirmed by a 10-fold increase in ALP expression levels in 
bmMSCs (Figure 11 C). The bmMSCs also produced a larger pellet with twice as 
much GAG produced (Figure 11 D), strongly suggesting that there is a difference 
between the biological functions of MSCs from these two tissue types. For the 
purposes of potential wound healing applications, it is necessary to determine if this 
biological difference also affects the ability of these two types of MSCs to induce 
HaCaT growth using the conditioned media. 
 
3.2.2 Difference in pMSC and bmMSC conditioned media on HaCaT growth 
 
To explore the effect of long term culture on pMSC and bmMSC and the 
difference in the two cell types’ ability to promote HaCaT growth conditioned medium 
made from increasing passage number was made. The conditioned medium was 
produced in hypoxic conditions as maintains the MSCs and improves the secretion of 
trophic factors to promote cell growth [199,201,203,238]. In Appendix 2 demonstrate 
the rational for the conditioning time for the medium and the use of the medium type. 
It was found that there was no link in passage number and MSCs’ ability to promote 
HaCaT growth (Figure 12A). In the case of pMSCs, all except passage 10 promoted 
HaCaT growth above XVIVO 15 medium. On the other hand, for bmMSC only 
passage 3 and 6 was effective in increasing HaCaT growth significantly over the 
negative control (XVIVO 15). When taking the average of the cell density achieved 
by the pMSCs and bmMSC there was no significance difference between the two 
tissue types in the ability to promote HaCaT growth. However, no consistency in the 
result was achievable on top of donor variations, which made it impossible to 
determine if there was a true difference between the MSC tissue source on the length 
of culture (Appendix 3).  
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Figure 12 (A) HaCaT growth in response to MSC conditioned medium of different passage number 
after 4 days (n=4). (B) Average HaCaT density achieved for pMSCs and bmMSCs from Figure 12A 
removing the outliers of bmMSC p8 & 10 and pMSC p10 (n=4). * Significant (p<0.01) increase over 
XVIVO 15 negative control. 
 
To see if any nutrient depletion was playing a role in the inconsistent results or 
improve the growth response of HaCaTs, the conditioned medium was concentrated 
by dialysis to remove the nutrients but still keep the proteins. The dialysate was then 
lyophilised and resuspended to a higher concentration. It was found that this process 
actually reduced the ability of the conditioned medium to promote growth when 
concentrated three times (Figure 13 A). The one times concentration conditioned 
medium did provide some benefit, when it was made for the bmMSC conditioned 
medium and only resuspended 1x, however this did not have a significant 
improvement on the unmodified conditioned medium. As aggregates have been shown 
to better maintain the stemness of MSCs [238,306-308], Conditioned medium from 
cell aggregates was explored. The MSC cell aggregates did improve HaCaT growth 
compared to negative control, however there due to inconsistency it was impossible to 
determine a significant improvement in aggregate conditioned medium to traditional 
conditioned medium ability to promote cell growth (Figure 13 B & Appendix 3).  
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Figure 13 (A) HaCaT growth in response to concentrated conditioned medium after 6 days. (B) HaCaT 
growth in response to cell aggregates after 6 days. * Significant (p<0.01) increase over XVIVO 15 
negative control, # significant (p<0.01) increase in HaCaT growth over traditional conditioned medium. 
 
3.2.3 Human Placental MSCs Expansion in Small-Scale Packed Bed Bioreactor 
 
To demonstrate that the bioreactor had no effect on pMSCs ability to undergo 
mesodermal differentiation, pre-isolated passage 4 human pMSCs were expanded 
under static and perfusion conditions in the small packed bed bioreactor. The doubling 
time of bioreactor expanded cells took longer than the 2D controls (T175 flask), 
63.5±1.5 hr and 43.7±1.5 hr, respectively for static (Figure 14 A) and 49.2 ± 2.6 hr and 
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37.9 ± 0.9 hr, respectively for perfusion (Figure 14 B). A single end point 
quantification protocol after seven days of expansion was adopted in the perfusion 
experiments, due to the disruption caused to the cells by taking a measurement every 
two days. This had a better impact on the MSCs expanded in the bioreactor growth, 
resulting in reduced differences in the doubling times between perfused bioreactor 
grown cells and the 2D controls. IVIS images of pMSCs expanded under perfusion 
conditions displayed an even fluorescent intensity from the scaffold suggesting a 
homogeneous distribution of cells (Figure 14 C).  
 
 
Figure 14 (A) pMSC expansion in the small-scale 160 cm2 bioreactor (BR) in static and (B) 5 mL/day 
perfusion (n=4 mean + SD), with the 2D controls (2D). (C) IVIS imaging of PI stained pMSCs under 
perfusion conditions. IVIS images are a red (low) / yellow (high) heat map of fluorescent intensity.  
 
The cells were characterised by mesodermal tri-lineage differentiation. No 
differences were observed between the bioreactor expanded cells in both static and 
perfusion conditions and the corresponding 2D controls when stained with Oil Red O, 
AlizarinRed S or Alcian Blue (Figure 15A). There was no difference in the 
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triglycerides amount and ALP activity (Figure 15B & C). However, there was 
significantly less GAG production in the cells expanded in the bioreactor under static 
conditions relative to the 2D control (Figure 15D).  
 
 
Figure 15 (A) Two week tri-lineage differentiation induction of bioreactor expanded pMSCs and 2D 
controls down the adipogenic (Oil Red O, 10x, scale bar is 100 µm), osteogenic (Alizarin Red, 5x, scale 
bar 500 µm) and chondrogenic (Alcian Blue, 10x, scale bar 500 µm) lineages. Quantification of (B) 
triglycerides (n=4, mean + SD), (C) ALP activity (n=4, mean + SD) and (D) GAG production (n=4, 
mean + SD). * indicates p<0.01. 
 
3.2.4 Isolation and Expansion of Placental MSCs Directly in a Small-Scale 
Packed Bed Bioreactor 
 
pMSCs were isolated from 10 g of digested placenta directly onto the bioreactor 
and were expanded under 5 mL/day perfusion. The growth rate of pMSCs was slower 
in the bioreactor compared to the 2D controls (Figure 16 A). The pMSC colonies was 
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observed to becoming confluent after 13 days of culture in the T175 flasks (2D 
controls) and at this point the cells were re-seeded back into the same flask or 
bioreactor, and the expansion was continued. At day 18 the 2D controls reached 
confluence and were harvested and characterised by tri-lineage differentiation to 
determine if isolation and growth had an effect on the pMSCs phenotype. The 
bioreactor pMSCs’ cultures were harvested at day 22.  
 
 
Figure 16 (A) Cell growth of pMSCs isolated directly from a placenta in the 160 cm2 packed bed 
bioreactor undergoing 5 mL/day perfusion (n=4, mean + SD). On day 13, the cells were redistributed 
back into the same flask or bioreactor. # indicating no 2D control result was measured as the flasks were 
harvested on day 18. (B) Two week tri-lineage differentiation induction of bioreactor expanded (BR) 
pMSCs and 2D controls down the adipogenic (Oil Red O, 10x, scale bar is 100 µm), osteogenic 
(Alizarin Red, 5x, scale bar 500 µm) and chondrogenic (Alcian Blue, 10x, scale bar 500 µm) lineages. 
Quantification of (C) triglycerides (n=4, mean + SD), (D) ALP activity (n=4, mean + SD) and (E) GAG 
(n=4, mean + SD) production compared to its matching 2D control. * indicates p<0.01. 
 
The qualitative differential potential of the osteogenic, chondrogenic and 
adipogenic lineages were similar as shown by staining between the bioreactor 
expanded pMSCs and the 2D controls (Figure 16 B). However, when quantified 
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
BR 2D
G
A
G
 (
µ
g)
/D
N
A
 (
µ
g)
E
0
0.05
0.1
0.15
0.2
0.25
BR 2D
A
b
so
rb
an
ce
/D
N
A
 (
u
g)
D
0
2
4
6
8
10
BR 2D
Tr
ig
ly
ce
ri
d
e
s 
p
e
r 
W
e
ll 
(n
M
)
C
*
0
5,000
10,000
15,000
20,000
25,000
Day 13 Day 18 Day 22
C
e
ll 
D
e
n
si
ty
 (
ce
lls
/c
m
2 )
A
2D Control
Bioreactor
#
2D
BR
Adipogenic Osteogenic ChondrogenicB
*
*
  
Chapter 3: Bioreactor Application: Isolation and Expansion of Placental Derived Cells on a Packed Bed 
Bioreactor 67 
(Figure 16 C, D & E) there was a significant difference in ALP activity between 
bioreactor isolated and expanded cells compared to the 2D controls. 
 
3.3 DISCUSSION 
 
Although MSCs sourced from different tissue types have similar surface marker 
profiles, there is a difference in their epigenetic and genetic expression which affects 
their mesodermal differentiation capacity [26,49,50,309-311]. In our experimentation 
there was a significant reduction in the mesodermal differentiation capacity of pMSCs 
compared to bmMSCs (Figure 11). However, the conditioned medium from pMSCs 
and bmMSCs both promote HaCaT cell growth with no significant difference between 
the two donor tissues (Figure 12B). An explanation is that the secretome of MSCs 
from different tissue sources are similar [311,312]. However, the results were 
inconsistent and we could not definitively prove that conditioned medium could 
promote HaCaT growth and that there was a difference with varying the culture times 
when the experiments were repeated. 
 
It was thought that if the medium was dialysed so that cytokines secreted could 
be concentrated this could improve the result by allowing the medium to be replaced 
with fresh medium while still having the secreted MSC cytokines. This resulted in a 
reduction in the HaCaT growth rate and if it did improve the growth rate it was no 
better than the unmodified conditioned medium (Figure 13 A). This could be the effect 
of continued storage at 4 degrees and also the changes in PH and ionic concentrations 
during the dialysis with the secreted cytokines losing function [313,314].  
 
Another way the MSC conditioned medium can be improved is through culturing 
the MSCs in aggregates thereby helping to maintain their stem cell like features and 
this may help to improve their secretome profile [238,306,307]. It was found that the 
aggregate conditioned medium did improve HaCaT growth compared to the negative 
control (Figure 13 B). However, it was not better than the traditional culture method 
and the degree it improved the HaCaT growth compared to the negative control was 
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not consistent. Although, the aggregate conditioned medium was more likely to 
improve HaCaT growth consistently by some degree in repeated experiments 
compared to the traditional 2D culture conditioned medium that resulted in 
inconsistent results. This suggested that methods which better select or pre conditioned 
the MSCs for desired function could result in more consistent results.  
 
The growth rate of the pMSCs in the packed bed bioreactor was less than that in 
the traditional tissue culture flask (Figure 14 A & B) a result that was similar to the 
growth rate of the GFP-mMSCs growing in the bioreactor in Chapter 2. Nevertheless, 
the growth rate observed in our packed bed bioreactor was similar to human MSC 
expansion in other bioreactor devices [226,228,231,295]. This indicates that the reduce 
growth rate observed in the bioreactor is not unique. A number of contributing factors 
could be the cause of the reduce growth rate: initial seeding distribution, seeding 
efficiency and nutrient concentration. These effects are explored in Chapter 4. In 
addition, it has been reported that cell can detach from 3D cultures during cell division 
[315]. However, this occur only during in high cell densities and high shear situations, 
neither criteria is met in our bioreactor system.  
 
It was noticed that the pMSCs were far more sensitive to the quantification 
process every two days, and because of this only a single time point was measured for 
the perfusion expansion. It was difficult to transfer the bioreactor with the tubing 
circuit between the incubator and tissue culture hood for cell quantification and this 
disruption impacted negatively on the pMSCs. The use of AlamarBlue method was 
required to quantify the cell number due to the harvesting method is only 84%±11% 
efficient with a cell viability of 71%±15% (Figure 8 C). This will add artefact into the 
calculation of the growth rate in comparison to the 2D controls. In chapter 4, the model 
was used predict cell death because of the manipulation of the bioreactor during the 
media exchange for the cell quantification by AlamarBlue, and this contributed to the 
stunted growth in static conditions that was observed experimentally. 
 
Despite the significant decrease in the growth rate in our bioreactor, the pMSCs 
maintained the capacity to differentiate down the osteogenic, adipogenic and 
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chondrogenic lineages. No differences in tri-lineage differentiation were observed 
under the perfusion expansion protocol (Figure 15 B, C & D). However, the GAG 
production in the static bioreactor-expanded cells diminished relative to the 2D 
controls. As preconditioning MSCs to a higher oxygen concentration reduces their 
capacity to differentiate down the chondrogenic lineage, reduced GAG production 
could be explained by a higher oxygen concentration present in the bioreactor 
compared to the traditional tissue culture flask [201,203]. The liquid layer in a 
traditional tissue culture flask offers greater resistance to oxygen diffusion resulting in 
a lower concentration of oxygen at the cell layer [316]. MSCs in the bioreactor located 
at the liquid-wall interface were exposed to a far higher oxygen concentration. 
Normoxia conditions are not ideal as for maintain MSCS which have been shown to 
prefer are more hypoxic 5% O2 atmosphere [199-203,223]. However, it was uncertain 
if oxygen diffusion alone would be enough to prevent oxygen depletion in the centre 
of the bioreactor without performing high level modelling in Chapter 4, so to prevent 
this artefact the bioreactor and flask isolation and expansion experiments were 
performed in normoxia. 
 
To further characterise the bioreactor’s effect on MSCs’ stemness, and to 
demonstrate the flexibility of the design, pMSCs were isolated from a digested 
placenta directly into the bioreactor. The pMSCs produced from this protocol 
maintained their potential to differentiate down the adipogenic, osteogenic and 
chondrogenic lineages (Figure 16 B). However, the bioreactor-expanded cells 
exhibited greater ALP activity than the analogous traditional tissue culture flask 
expanded pMSCs (Figure 16 D). During isolation, large amounts of red blood cells 
and other debris from dead cells could not be removed and remained within the 
bioreactor column. As dead cells have been reported to contribute to, and possibly 
even induce, osteogenesis in bmMSCs [317], such debris could pre-condition 
bioreactor-isolated pMSCs toward osteogenic differentiation. The manual syringe 
driven process used in this experiment made removing the cell debris from the 
bioreactor difficult. A steady flow rate was difficult to achieve using this manual 
method, so the flow rate was kept low to avoid detaching the cells from the scaffold. 
Automated medium flow in future generations of the bioreactor will help prevent this 
build-up of cell debris, as a controlled continuous flow will allow higher flow rates 
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without detaching the cells from the scaffold. An increased flow rate used in the 
expansion process in the scaled-up bioreactor will also actively remove cell debris. 
 
Although the growth rate of pMSCs in the bioreactor was less than the cells 
grown on tissue culture plastic, the few extra days required for MSCs to reach 
confluence in the packed bed bioreactor represents an acceptable trade-off to have the 
potential for an automatable method to digest, isolate and expand pMSCs in a single 
closed bioreactor system. An isolation/expansion process based on our design, 
although performed manually here, could be easily automated [231]. Thus, a single 
automated bioreactor imbedded with an automated isolation protocol might be 
developed to digest, isolate and expand pMSCs for clinical use with single procedure 
in a completely closed system. Failure of the rotatory plasma reactor and time 
limitations, needed for plasma modification in the larger columns meant that scale up 
of the pMSC isolation and expansion could not be done. However, in the following 
chapter, the scale up of the device is explored based on parameters from MSCs. The 
model developed was used to further aid scale-up designs and improve the culture 
methods used for the bioreactor. In addition, the model was used to help explain the 
reduced growth rate observed in the bioreactor compared to the traditional flask 
cultures. 
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Chapter 4: Explanation of Experimental 
Results, and Further Design and 
Development: Modelling 
Mesenchymal Stromal Cell 
Growth in a Packed Bed 
Bioreactor  
Oxygen is the limiting metabolite in bioreactors due to its low solubility in cell 
culture medium, and thus is the most difficult to adequately supply through perfusion. 
As the newly developed bioreactor no longer relies solely on oxygen supplied by the 
medium perfusion, the flow rate can be greatly reduced to control only the glucose 
supply. This significantly decreases the shear stress on the cells that could induce 
differentiation, which is detrimental for the manufacture of MSCs for cell based 
therapy. Although the bioreactor achieved similar MSC growth rates to other 
bioreactors reported in literature [226,228,231,295], the growth rate of the MSCs in 
our bioreactor was significantly less than in traditional tissue culture flasks. It was 
hypothesised that three factors could have affected the bioreactor cell growth rate: (a) 
The supply of the nutrients oxygen and glucose was inadequate, leading to significant 
concentration gradients in the scaffold, (b) The lower flow rate ineffectually removed 
the waste product, lactate [318,319], (c) A homogenous cell distribution was not 
achieved in the scaled-up bioreactor. Initial heterogeneous cell distribution during 
seeding might affect the growth rate and thus and final cell number. 
 
A mathematical model was developed to evaluate the three hypotheses and direct 
future experiments. Many scaffold perfusion models have been reported for cell 
expansion on a scaffold for tissue engineering purposes, and models designed to 
investigate cell growth that focus on nutrient concentration [320-322] and perfusion 
devices [323-326] formed the basis of our theoretical treatment. Based on previous 
experimental work [323], Lewis et al. modelled the interaction between oxygen 
profiles and cell distribution in a cartilaginous tissue construct [322]. Their cell growth 
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and uptake description were based on early tumour models [320,327] using Michaelis-
Menten kinetics for cellular uptake of oxygen. However, their model did not consider 
cellular migration on the solid substrate or advective phenomena. Their simulation 
predicted a high cell proliferation around the outside of the scaffold with a region of 
hypoxia in the centre. Zhao et al. [326] showed the importance of perfusion on MSC 
growth on a polyethylene-terephthalate scaffold in a perfusion bioreactor, achieving 
four times the cell density compared to those achieved in static culture conditions. The 
2D oxygen concentration profile model suggested the importance of perfusion, with 
far less depletion of oxygen within the scaffold and lower oxygen gradient compared 
to the static culture. However, the cell growth rate in their model was constant, the 
effects of oxygen concentration or cell migration on the cell density were not 
considered. Coletti et al. [324] developed a far more comprehensive 2D axis of 
symmetry model that included advection and the diffusive transport of oxygen. The 
culture medium flow within the bioreactor was modelled in two ways as there was of 
a channel around the scaffold in the centre of the bioreactor. The medium flow outside 
the scaffold was described by the Navier-Stokes equation for an incompressible fluid, 
while the flow through the scaffold was described by the Brinkman’s extension to 
Darcy’s Law. The cellular nutrient uptake was modelled using Michaelis-Menten 
kinetics. The cellular growth rate was assumed to be given by the Contois equation, 
which takes into consideration the nutrient concentration and the cell density. 
However, cell migration effects were ignored. Chung et al. [328] further developed 
this bioreactor model that used Michaelis-Menten kinetics for cellular uptake of 
nutrients, as well as a modified Contois equation for the cellular growth, to include 
cell migratory terms. They also explored the effect of scaffold permeability and 
porosity on cell growth. In their model, the cell growth causes a reduction in scaffold 
pore size that changed the flow through the scaffold and increases shear. This reduction 
in nutrient supply to the cells impacts the growth rate. Shakeel et al. [329] reduced the 
complexity of the fluid dynamic system by neglecting the inertial forces of the fluid 
flow since the Reynolds number is small and used Darcy’s Law to describe the fluid 
flow through the scaffold [330]. Their model suggested that both shear stresses and 
reduction in pore size compromised cell growth [325,329]. They also investigated the 
importance of the initial seeding density distribution on the final total cell number by 
modelling all the cells as either a central circle or along the walls of the scaffold.  
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The above models accounted for the effect of only one limiting metabolite (either 
oxygen or glucose) on the cell growth rate. However, the low flow rate used in the 
bioreactor design used here required exploring the effect of both oxygen and glucose 
on the cell growth rate. In addition, the lower flow rate reduced the removal rate of the 
waste product lactate, which is known to reduce the growth rate of cells [318,319]. 
The Monod model of mammalian cell growth describes the limiting effect of 
insufficient oxygen and glucose concentrations plus the inhibitory effect of lactate 
accumulation [331-333]. However, accounting for complexities of cell metabolism can 
be difficult. For example, the rate of consumption of glucose and the rate of production 
of lactate can simply be related mathematically by the stoichiometric yield of lactate-
to-glucose. However, the metabolism of cells and their growth rate increases under 
perfusion conditions, with glucose consumption and lactate production increasing 
greatly compared to static conditions. The yield of lactate-to-glucose decreases under 
perfusion conditions, suggesting an increase aerobic respiration from the MSCs 
preferred anaerobic respiration, possibly associated with the increased oxygen supply 
due to perfusion which prevents regions of hypoxia [326]. In addition, nutrient 
consumption or waste production can be influence by cell morphology and density on 
scaffolds or cytokines levels in the medium. Example of this is normal cell culture 
conditions the oxygen uptake rate for MSCs is approximately 98 fmol/cell/hr, in the 
absence of TGF-β the levels reduce down to approximately 12 fmol/cell/hr [334]. 
 
In most bioreactors designs, the medium perfusion is the sole source of oxygen. 
To prevent oxygen depletion and maintain homogenous nutrient concentration in these 
devices, the flow rate must be increased as the cell numbers grow. To decouple the 
oxygen supply from the bulk medium flow, oxygen can by supplied by diffusion 
through interwoven gas permeable fibres in a hollow fibre bioreactor [229] or through 
a micro-bioreactor wall made of a gas permeable polymer [335]. Kim, et al. [336] 
modelled the oxygen pressure drop in a microfluidic device where the only source of 
oxygen was through a diffusive PDMS wall. The 2D diffusive model explored the role 
of the thickness of the PDMS on cellular density and the time taken for the oxygen to 
reach equilibrium in the medium. Depending on the cellular uptake rate, it is possible 
for the cell density to be affected by a wall thickness greater than 5 mm with an 
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effective diffusion time of 26 minutes, suggesting that diffusion resistance becomes 
high for a microfluidic scale device.  
 
This Chapter describes a 2D axis symmetric model for MSC growth in the 
packed bed bioreactor. The work modelled oxygen, glucose and lactate transport in a 
porous media and their effects on cell growth in the scaffold. The model includes the 
effects of oxygen transport through the gas permeable wall of the bioreactor. Using 
this model, the effect of nutrient concentration and initial cell distribution on cellular 
growth rate, to help explain the observed reduction in growth rate in the bioreactor 
compared to traditional tissue culture flasks was explored. Furthermore, the effects of 
scale-up of our bioreactor was investigated by increasing the vessel dimensions and 
decreasing the particle size of the packed bed, thus increasing the scaffold surface area. 
The finite element solver package COMSOL was used to solve the model equations 
numerically. 
 
4.1 DEVELOPMENT OF THE MATHEMATICAL MODEL 
 
4.1.1 Model Description 
 
It was assumed that the cells are initially seeded with a uniform density in the 
porous scaffold. The scaffold with a radius R1 and a length L, consists of a randomly-
packed bed of polystyrene cylinders with 2.5 mm diameter by 3 mm in length. It was 
assumed that the pore size in the scaffold is not changed significantly by the presences 
of a confluent cell layer, as such the porosity and permeability of the scaffold remains 
constant. This is because the cell thickness is at most 1-2 µm compared to the scaffold 
pore size that could be greater than 1 mm, meaning that the cell layer has negligible 
reduction of the pore size. The fluid (cell culture medium) is assumed to be viscous, 
incompressible and Newtonian. It is pumped into the scaffold at the boundary z=0 and 
leaves at boundary z=L as shown in Figure 17. The fluid is pumped at a constant 
volumetric flow rate Q. The fluid contains oxygen and glucose which is consumed by 
the cells. A small amount of lactate is present initially in the cell culture medium 
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associated with the addition of foetal bovine serum. The bioreactor wall is made from 
a gas permeable polymer of a thickness R2-R1, polydimethylsiloxane (PDMS), which 
provides for the radial diffusion of oxygen through the bioreactor wall. The oxygen 
solubility in the PDMS is greater than that of the medium. 
 
 
 
Figure 17 (A) Axis of symmetry diagram of perfusion bioreactor with a gas permeable wall. This allows 
oxygen to diffuse radially into the bioreactor. The radius of the PDMS cylinder is denoted by R2, the 
radius of the scaffold volume of the bioreactor is denoted by R1 and the length is denoted by L. In the 
equation development the radial coordinate was denoted by r and the longitudinal coordinate by z 
(measured from the inlet). (B) The experiments were also performed in a batch configuration where the 
medium was replaced every two days, however oxygen could still diffuse through the wall. (C) 
Traditional packed/fixed bed bioreactor where all the nutrient and oxygen are provided by medium 
perfusion alone. (D) Further enhancement of the design by the incorporation of a central capillary with 
outer wall radius Rw and lumen Rc in the centre of the reactor provides an additional oxygen source.  
 
The base model equations stated in the next section were adjusted to explore a 
batch configuration (Figure 17B), and they were used to compare our bioreactor design 
to a traditional packed bed reactor (Figure 17C). For scaling-up the bioreactor, it may 
be beneficial to provide additional sources of oxygen through gas permeable 
capillaries. The model was further modified to simulate this situation with a central 
gas-permeable capillary providing oxygen (Figure 17D). 
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4.1.2 Development of Model Equations 
 
The model leads to five partial differential equations. The first characterises the 
fluid flow through the porous material with velocity (U) driven by the pressure (P). 
The second is a mass balance for the convective and diffusive transport of the nutrients; 
oxygen (CO) and glucose (CG), and the waste product lactate (CL). The third equation 
represents the cell density (N) that includes terms describing the proliferation and 
migration within the scaffold. 
 
Fluid Flow Through the Scaffold 
 
The fluid velocity through the bioreactor scaffold is small, so that inertial forces 
can be neglected, thus the fluid flow can be regarded as a flow through a porous media 
given by Darcy’s Law. This relates velocity to the interstitial pressure as a function of 
the material permeability (K*) and the fluid dynamic viscosity 𝜇. 
Given by 
 
 𝑼 = −
𝐾∗
𝜇
∇𝑃, (1) 
where 
𝐾∗ =
𝑑𝑝
2Φ3
180(1 − Φ)2
. (2) 
 
Assuming that the cells do not occupy a significant fraction of the scaffold pore 
space, the permeability (K*) is taken to be constant and is defined in terms of the 
particle diameter equivalent to a sphere (dp) and the scaffold porosity (Φ) [330]. The 
continuity equation the fluid which was taken to be incompressible is 
 
 ∇. 𝑼 = 0 . (3) 
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The following boundary conditions are applied. As the fluid is viscous, there is 
no slip along the bioreactor wall, and axisymmetric flow was assumed, so that 
 
 
{
𝑼𝒓 = 0
𝑼𝒛 = 0
 at r=0 and R1, 0<z<L. (4) 
 
The flow at the entrance leads to 
 
 𝐔𝒛 =
𝑄
𝜋𝑅1
2 at 0<r<R1, z=0, (5) 
 
where Q is the constant fluid flow rate (cm3/hr). 
 
Development of Nutrient Conservation Equation 
 
The cells require oxygen and glucose to survive and proliferate. Lactate is 
produced through the metabolism of glucose and other metabolites and inhibits cell 
survival and proliferation. The transport equation for the nutrients is in terms of 
advection, diffusion and consumption of glucose and oxygen and production term for 
lactate. Both glucose (CG) and lactate (CL) have similar conservation of mass equations 
and boundary conditions. However, as lactate is a product of glucose metabolism, the 
lactate production rate was related to glucose consumption rate by simply multiplying 
by the lactate yield from glucose (YL/C) [318,319,331]. The following transport 
equations was obtained: 
 
 𝜕𝐶𝐺
𝜕𝑡
= 𝐷𝐺∇
2𝐶𝐺 − ∇. (𝑼𝐶𝐺) −
𝑉𝑚𝑎𝑥,𝐺𝑁𝐶𝐺
𝐾𝑚,𝐺+𝐶𝐺
, (6) 
and 
 𝜕𝐶𝐿
𝜕𝑡
= 𝐷𝐿∇
2𝐶𝐿 − ∇. (𝑼𝐶𝐿) + 𝑌𝐿/𝐶
𝑉𝑚𝑎𝑥,𝐺𝑁𝐶𝐺
𝐾𝑚,𝐺+𝐶𝐺
. (7) 
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The consumption of glucose can be assumed to be modelled using Michaelis-
Menten kinetics. This is a function of the maximum uptake/production rate (Vmax,I, 
mM.hr-1.cell-1), the Michaelis-Menten constant (Km,I, mM), the cell density (N, 
cells/cm3) and the concentration (Ci). The diffusion coefficient must be modified to 
account for the restriction to diffusion associated with a bioreactor that contains non-
gas-permeable pellets that retard the overall diffusion. This modification is defined by 
the voidage (𝜀), tortuosity (𝜏) and the free diffusion coefficient (Dm,i). The tortuosity 
is defined in (9) as a function of the porosity and the sphericity (𝜑) of the particles 
[337]. The sphericity of non-spherical particle is given by (10) as a function of the 
number of the particles per unit volume of the packed bed (n), the porosity, and the 
surface area to volume ratio (a) of the packed bed. Defined by 
 
𝐷𝑖 =
𝜀
𝜏
𝐷𝑚,𝑖, 
 
(8) 
where 
𝜏 =
1.23(1−𝜀)
4
3
𝜀×𝜑2
, 
 
(9) 
and 
𝜑 =
(36×𝜋×𝑛(1−𝜀)2)
1
3
𝑎
. (10) 
 
A constant concentration of glucose and lactate at the inlet (11) and that there is 
no longitudinal diffusive flux at the outlet (12) and the at reactor wall (13) was 
assumed. The symmetry condition gives a zero flux for all species at r=0 (14). In 
summary, these are given by 
 𝐶𝑖 = 𝐶𝑖𝑛,𝑖 at z=0, 0<r<R1, (11) 
 
 𝜕𝐶𝑖
𝜕𝑧
= 0 at z=L, 0<r<R1, (12) 
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 𝜕𝐶𝑖
𝜕𝑟
= 0 at r=R1, 0<z<L, (13) 
 
 𝜕𝐶𝑖
𝜕𝑟
= 0 at r=0, 0<z<L. (14) 
 
Oxygen conservation leads to two equations, one to define the oxygen 
concentration, in the scaffold (15) and the other for the oxygen diffusion in the wall 
(16), these are given by 
 
 𝜕𝐶𝑂,𝐴
𝜕𝑡
= 𝐷𝑂∇
2𝐶𝑂,𝐴 − ∇. (𝑼𝐶𝑂,𝐴) −
𝑉𝑚𝑎𝑥,𝑂𝑁𝐶𝑂,𝐴
𝐾𝑚,𝑂+𝐶𝑂,𝐴
 for 0<r<R1 (15) 
 
 𝜕𝐶𝑂,𝐵
𝜕𝑡
= 𝐷𝑃𝐷𝑀𝑆∇
2𝐶𝑂,𝐵 for R1<r<R2 (16) 
 
For expression 15 the boundary conditions are set as no flux through inlet and 
outlet wall with constant concentration of oxygen at the outer wall. This is defined as 
the solubility of oxygen in PDMS (SPDMS, mM) 
 
 𝜕𝐶𝑂,𝐵
𝜕𝑧
= 0 at z=0, L, R1<r<R2, (17) 
 
 𝐶𝑂,𝐵 = 𝑆𝑃𝐷𝑀𝑆 at r=R2, 0<z<L. (18) 
 
At the interface between the wall and the scaffold, continuity of the diffusive 
flux (19) and a change in concentration due to the difference in solubilities (21) was 
required. The solubility of oxygen in the fluid is denoted by SM (mM). The boundary 
conditions are 
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 𝐷𝑂
𝜕𝐶𝑂,𝐴
𝜕𝑟
= 𝐷𝑃𝐷𝑀𝑆
𝜕𝐶𝑂,𝐵
𝜕𝑟
 at r=R1, 0<z<L (19) 
and 
 𝐶𝑂,𝐴
𝑆𝑀
=
𝐶𝑂,𝐵
𝑆𝑃𝐷𝑀𝑆
 at r=R1, 0<z<L (20) 
 
Within the scaffold itself, the inlet fluid pumped is oxygenated, there is no 
diffusive flux at the outlet and at the axis of symmetry (25). 
 
 𝐶𝑂,𝐴 = 𝑆𝑀 at z=0, 0<r<R1, (21) 
 
 𝜕𝐶𝑂,𝐴
𝜕𝑧
= 0 at z=L, 0<r<R1, (22) 
 
 𝜕𝐶𝑂,𝐴
𝜕𝑟
= 0 at r=0, 0<z<L. (23) 
 
Development of Cell Growth Equation 
 
The local cell density changes over time, due to proliferation and the cells are 
free to migrate on the pellets of the scaffold. The proliferation rate is taken to be a 
logistic kinetic form with maximum cell density (Nmax, cell/cm
3) and an intrinsic 
growth rate (k, hr-1) [320]. The growth rate dependence is taken as a Monod kinetic 
equation that is dependent on the nutrient concentrations (Ci), maximum growth (Kmax, 
hr-1) and the Michaelis-Menten constants (KG, KO and KL, mM) [321,331]. The 
migration is governed by the diffusion coefficient (DN) and the cell density, so that 
 
 𝜕𝑁
𝜕𝑡
= 𝑘𝑁 (1 −
𝑁
𝑁𝑚𝑎𝑥
) + 𝐷𝑁∇
2𝑁, (24) 
where 
 𝑘 = 𝐾𝑚𝑎𝑥(
𝐶𝐺
𝐾𝐺+𝐶𝐺
𝐶𝑂,𝐴
𝐾𝑂+𝐶𝑂,𝐴
𝐾𝐿
𝐾𝐿+𝐶𝐿
). (25) 
 
The boundary condition for the cell growth is derived as follows. The cells 
cannot leave the scaffold and r=0 axis of symmetry. To obtain 
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 𝜕𝑁
𝜕𝑧
= 0 at z=L and z=0, 0<r<R1, (26) 
and 
 
 𝜕𝑁
𝜕𝑟
= 0 at r=R1, 0<z<L, (27) 
with  
 𝜕𝑁
𝜕𝑟
= 0 at r=0, 0<z<L. (28) 
 
Shear Stress 
 
The shear stress (𝜎, Pa) acting on the cells can be estimated from the Darcy 
velocity (U), porosity (ε), tortuosity (τ), viscosity (µ) of the medium and the pore 
diameter of the packed bed (DH) as follows 
 
 𝜎 =
8𝜇𝜏‖𝑈‖
𝐷𝐻𝐾∗
, (29) 
 
The pore diameter is a function of the voidage and the particle diameter [338] so 
that 
 𝐷𝐻 =
2𝜖𝑑𝑝
3(1−𝜀)
. (30) 
 
4.1.3 Initial Conditions and Parameters 
 
Initially the cells are seeded with a uniform density of 1000 cells/cm2, which 
must be converted to cells per unit volume by multiplying the surface area to volume 
ratio (a).  
so that 
 𝑁(𝑟, 𝑧, 0) = 𝑁𝑖 at 0<r<R1 and 0<z<L.  (31) 
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It is assumed that the medium and the PDMS are initially in equilibrium with the 
atmospheric oxygen concentration so that 
 
 𝐶𝑂,𝐴(𝑟, 𝑧, 0) = 𝑆𝑀 at 0<r<R1 and 0<z<L,  (32) 
and 
 𝐶𝑂,𝐵(𝑟, 𝑧, 0) = 𝑆𝑃𝐷𝑀𝑆 at R1<r<R2 and 0<z<L.  (33) 
 
 
The reactor is filled with cell culture medium initially so that 
 
 𝐶𝐺(𝑟, 𝑧, 0) = 𝐶𝑖𝑛,𝐺 at 0<r<R1 and 0<z<L, (34) 
and 
 𝐶𝐿(𝑟, 𝑧, 0) = 𝐶𝑖𝑛,𝐿 at 0<r<R1 and 0<z<L.  (35) 
 
 
 
Table 5 summarises the input parameters for the model, with * representing a 
measure value from our experiments.  
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Table 5 Model parameters and values used in model 
Parameter Description Value Units Ref 
Bioreactor Parameters 
R1 Inner wall radius 0.75 cm * 
R2 Outer wall radius 1.25 cm * 
L Scaffold length 7.5 cm * 
 Growth area of scaffold 158.8 cm2 * 
 Scaffold volume 13.25 cm3  
𝜺 Voidage 0.47 - * 
𝚽 Porosity 0.47 - * 
a Surface area to volume ratio of the scaffold 12.013 cm-1 * 
n Number of particles per volume of packed 
bed 
36 cm-3 * 
dp Particle diameter (equivalent to a sphere) 0.304 cm * 
Q Medium flow rate 0.208 cm3/h * 
Wall Properties 
SPDMS Solubility of oxygen in PDMS 1.3 mM [339] 
DPDMS Oxygen diffusion coefficient in PDMS 5x10-5 cm2/s [326] 
Fluid Properties 
Sm Solubility of oxygen in medium 0.2 mM * 
Cin,G Initial glucose concentration 4.81 mM * 
Cin,L Initial lactate concentration 1.63 mM * 
Dm,O Oxygen diffusion coefficient in medium 3.290x10
-5 cm2/s [326] 
Dm,G Glucose diffusion coefficient in medium 5.4x10
-6 cm2/s [340] 
Dm,L Lactate diffusion coefficient in medium 1.1x10
-5 cm2/s [341] 
𝝆 Density of water @ 37°C 0.9933 g/cm3 [338] 
𝝁 Viscosity of water @ 37°C 0.00692 kg/(m.s) [338] 
Cell Properties 
Nmax Maximum cell density 23,000 cells/cm2 * 
Ni Initial cell value 12013 cells/cm3  
DN Diffusion coefficient for cell movement 1.38x10-10 cm2/s [342] 
Vmax,O Maximum uptake rate of oxygen 100 fmol/h/cell [334] 
Vmax,G Maximum uptake rate of glucose 272 fmol/h/cell [334] 
YL/G Yield of lactate from glucose 2.0 - [318] 
Km,O Michaelis-Menten constant for oxygen 
uptake 
4.05x10-9 mol/cm3 [343] 
Km,G Michaelis-Menten constant for glucose 
uptake 
3.5x10-7 mol/cm3 [344] 
Kmax Max growth rate 0.02631 h-1 * 
KO Oxygen Michaelis-Menten growth 
constant 
0.001 mM [345] 
KG Glucose Michaelis-Menten growth 
constant 
0.006 mM [345] 
KL Lactate Michaelis-Menten growth 
constant 
43 mM [318] 
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4.1.4 Solution Method 
 
The model consists of five partial differential equations representing fluid flow 
through the scaffold (1), nutrient transport of glucose (6), lactate (7), oxygen (15 & 
16) and the cell density (24). Due to the complexities of the system, an analytical 
solution cannot be found. The commercially available finite element software 
COMSOL (vers. 4.4) was used to solve the governing equation.  
 
A free triangular mesh was generated and refined successively until a convergent 
result was achieved (Appendix 4). The refined mesh consisted of 9,628 elements with 
500 boundary elements. The dependent variables are approximated by a quadratic 
shape function and the system was solved for 43,493 degrees of freedom. The time 
step was set to 0.1 hr for a total of 8 days (192 hr). 
 
4.2 RESULTS AND DISCUSSION 
 
4.2.1 Base Case- Decoupling the Oxygen Supply from the Bulk Medium is 
Superior to a Traditional Packed Bed Bioreactor 
 
In experimental studies of the packed bed bioreactor, a significant reduction in 
the MSC growth in the bioreactor compared to cells grown in a traditional T175 flask 
was observed in Chapters 2 and 3. The axial symmetric model of the bioreactor was 
developed to explore this phenomenon and to further develop and optimise this 
bioreactor design. 
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Figure 18 Model results: heat map of (A) cell density, (B) glucose, (C) lactate and (D) oxygen 
concentration in the wall and in the vessel on day 7. The white arrow on the oxygen concentration heat 
map represents the direction of total flux of oxygen while the black arrow represents the direction of 
the diffusive flux.  
 
In the small scale experiments, medium was perfused at a flow rate of 0.208 
mL/hr, as this flow rate was assumed to provide enough glucose to prevent depletion, 
and that enough oxygen was supplied by radial diffusion through the bioreactor wall. 
An initial uniform cell distribution resulted in a final non-uniform cell distribution by 
the end of the culture period (Figure 18A). For an understanding of how to read the 
heat map figures and explanation of an axial symmetric model refer to Appendix 5. It 
was concluded that the cell density gradient is driven strongly by glucose or lactate 
concentrations, rather than by oxygen, as there is a large difference in the cell density 
between the inlet and outlet with only a small difference in the cell density in the radial 
A
C D
B
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direction. These concentration differences and cell gradients increased over time, 
driven by cell growth, consumption of nutrients and production of lactate (Appendix 
6, Appendix 7, Appendix 8 and Appendix 9). There was a 51% reduction in the glucose 
concentration at the outlet compared to the inlet (Figure 18 B) and a similar increase 
in the lactate concentration (Figure 18 C). Nevertheless, the model supports the 
hypothesis that radial diffusion of oxygen is sufficient to support the cell growth in the 
bioreactor without depleting oxygen in the centre of the bioreactor (Figure 18 D).  
 
When the model was modified to explore the increasing the wall thickness, it 
was found that the wall offered little resistance to the diffusive flux of oxygen 
(Appendix 10), and had little overall effect on the cell density (Figure 19 A). When 
the base model was adjusted to represent a traditional packed bed bioreactor (Figure 
19 B) by removing the oxygen equation for the wall expression 16 and replacing the 
boundary condition equations (17-20) with the boundary condition of no oxygen flux 
through the wall, that is 
 
 𝜕𝐶𝑂,𝐴
𝜕𝑟
= 0 at r=R1, 0<z<L. (36) 
 
The flow rate used in the experiments (0.208 ml/hr) was not adequate to support 
the cell growth in a traditional packed bed reactor. A flow rate of 1.5 ml/min was 
required to achieve a similar cell growth as in the base model (Figure 19 B).  
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Figure 19 (A) The average cell density change as a result of increasing the wall thickness from 0.1 to 5 
cm. (B) A bioreactor model average cell density without wall diffusion requires a higher medium flow 
rate compared to our bioreactor with wall diffusion (Base model). (C) The average cell densities 
achieved experimentally from T175 flask and bioreactor expanded cells were compared to base model 
output. Note that only final cell numbers were measured for the bioreactor expanded cells; the curve 
represents exponential approximations of the previous days based on the overall growth rate from the 
experiment. (D) Predicted average cell density at different flow rates in a gas permeable wall packed 
bed bioreactor.  
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The model fits well to the traditional T175 flask expanded cell results but not to 
the results obtained in bioreactor expansion (Figure 19 C). The base model was 
modified to explore why the bioreactor growth is significantly less than that of the 
traditional flask expanded cells. Increasing the model flow rate to 0.5, 1, 1.5, 3 and 4 
mL/hr results in only a minor increase in the average cell density (Figure 19 D). 
Although the cells became more evenly distributed (Figure 20A-C) as a result of the 
improved removal of lactate (Figure 20D-F) and the increased supply of oxygen 
(Figure 20G-I), this does suggest that the flow rate used in the experiments (0.208 
ml/hr) was near optimal. The shear stress acting on the cells was also significantly less 
at all flow rates than the 0.015 Pa shown to cause osteogenic differentiation of MSCs 
(Appendix 11) [218-221]. 
 
 
Figure 20 Heat maps of (A-C) cell density distribution (D-F) lactate concentration (G-I) and oxygen 
concentration at 0.5, 1.5, 3 cm3/hr respectively. 
A B C
D E F
G H I
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To determine if the 0.208 ml/hr flow rate used experimental in the small-scale 
bioreactor was adequate, and to also determine which nutrient or if the waste product 
was limiting the growth rate, the intrinsic growth rate was modified in the cell balance 
expression (24). This allows the investigation of the dependence of the average cell 
density on each nutrient as well as the cell contact inhibition, as presented in equations 
in Table 6. Other than cell contact inhibition, lactate showed the largest effect in 
reducing cell growth (Figure 21 A). This suggested that glucose and oxygen were both 
in sufficient supply in our bioreactor, and the retarded cell growth resulted from the 
compromised removal of lactate due to the low flow rate. It was concluded that, lactate 
is the main driving force in developing the cell gradient across the length of the reactor. 
The KL value, which is the concentration of lactate to reduce the growth rate by half, 
is only 26 times larger than the initial concentration of lactate whereas the Ko is 200 
times smaller than the initial oxygen concentration. As a consequence, the final cell 
number is much more sensitive to changes in lactate concentration than it is to the 
changes in the oxygen concentration. This is the case even if the oxygen concentration 
is reduced by a factor of two below the current inlet value. 
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Table 6 Cell growth rate equations adjusted to account for different limitations in nutrient 
concentrations and cell contact inhibition. 
Condition Cell density equation 
Base case 
𝜕𝑁
𝜕𝑡
= 𝐾𝑚𝑎𝑥(
𝐶𝐺
𝐾𝐺 + 𝐶𝐺
𝐶𝑂,𝐴
𝐾𝑂 + 𝐶𝑂,𝐴
𝐾𝐿
𝐾𝐿 + 𝐶𝐿
)𝑁 (1 −
𝑁
𝑁𝑚𝑎𝑥
) + 𝐷𝑁∇
2𝑁 
Cell contact 
inhibition 
𝜕𝑁
𝜕𝑡
= 𝑁 (1 −
𝑁
𝑁𝑚𝑎𝑥
) + 𝐷𝑁∇
2𝑁 
Oxygen  
𝜕𝑁
𝜕𝑡
= 𝐾𝑚𝑎𝑥(
𝐶𝑂,𝐴
𝐾𝑂 + 𝐶𝑂,𝐴
)𝑁 (1 −
𝑁
𝑁𝑚𝑎𝑥
) + 𝐷𝑁∇
2𝑁 
Glucose 
𝜕𝑁
𝜕𝑡
= 𝐾𝑚𝑎𝑥(
𝐶𝐺
𝐾𝐺 + 𝐶𝐺
)𝑁 (1 −
𝑁
𝑁𝑚𝑎𝑥
) + 𝐷𝑁∇
2𝑁 
Lactate  
𝜕𝑁
𝜕𝑡
= 𝐾𝑚𝑎𝑥(
𝐾𝐿
𝐾𝐿 + 𝐶𝐿
)𝑁 (1 −
𝑁
𝑁𝑚𝑎𝑥
) + 𝐷𝑁∇
2𝑁 
Oxygen and 
glucose 
𝜕𝑁
𝜕𝑡
= 𝐾𝑚𝑎𝑥(
𝐶𝐺
𝐾𝐺 + 𝐶𝐺
𝐶𝑂,𝐴
𝐾𝑂 + 𝐶𝑂,𝐴
)𝑁 (1 −
𝑁
𝑁𝑚𝑎𝑥
) + 𝐷𝑁∇
2𝑁 
Oxygen and 
lactate 
𝜕𝑁
𝜕𝑡
= 𝐾𝑚𝑎𝑥(
𝐶𝑂,𝐴
𝐾𝑂 + 𝐶𝑂,𝐴
𝐾𝐿
𝐾𝐿 + 𝐶𝐿
)𝑁 (1 −
𝑁
𝑁𝑚𝑎𝑥
) + 𝐷𝑁∇
2𝑁 
Glucose and 
lactate 
𝜕𝑁
𝜕𝑡
= 𝐾𝑚𝑎𝑥(
𝐶𝐺
𝐾𝐺 + 𝐶𝐺
𝐾𝐿
𝐾𝐿 + 𝐶𝐿
)𝑁 (1 −
𝑁
𝑁𝑚𝑎𝑥
) + 𝐷𝑁∇
2𝑁 
Oxygen, 
glucose and 
lactate only 
𝜕𝑁
𝜕𝑡
= 𝐾𝑚𝑎𝑥(
𝐶𝐺
𝐾𝐺 + 𝐶𝐺
𝐶𝑂,𝐴
𝐾𝑂 + 𝐶𝑂,𝐴
𝐾𝐿
𝐾𝐿 + 𝐶𝐿
)𝑁 + 𝐷𝑁∇
2𝑁 
 
The oxygen supply would need to be close to depletion for it to strongly affect 
the MSC growth rate. This result should be interpreted carefully, as the oxygen 
sensitivity can vary depending upon the cell type. MSCs prefer anaerobic respiration, 
but other cell types that prefer aerobic respiration result in a far higher Ko [334]. Given 
that the lactate/oxygen yield YL/G ≈ 2 for most cell types and culture conditions, the 
removal of waste products is more important than the supply of nutrients 
[261,334,346]. Adding glucose to the medium without increasing the flow rate could 
lead to accumulation of lactate in the reactor, thereby diminishing the cell growth rate. 
Nevertheless, in our bioreactor system these simulations suggest that nutrient 
limitations are only a minor influence in the reduction of the experimental growth rate 
observed in the bioreactor. Therefore, other factors must be taken into account to 
explain the experimental cell growth in the packed bed bioreactor. 
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Figure 21 (A) The average cell density with different cell growth rate equations defined in Table 6. (B) 
The average cell density with the initial homogeneous cell distribution adjusted from 500 cell/cm2 to 
1000 cell/cm2 (base model). 
 
4.2.2 Investigating the Effect of Cell Distribution on Growth 
 
In this treatment it was assumed that, initially, all the cells were attached to the 
scaffold with a homogeneous distribution. However, this is almost impossible to 
achieve. It is more likely that the cell seeding method would naturally give rise to a 
heterogeneous cell distribution. Although having fewer cells attached to the scaffold 
reduces the final cell number (Figure 21 B). However, this was not observed to be 
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experimentally significant (see Chapter 3, Figure 9 A). The cell seeding method 
strongly influenced the cell distribution heterogeneity and the cell viability [347].  
 
To model a heterogeneous cell distribution, but while still maintain same total 
cell number. The initial cell distribution was assumed to linearly decrease in either the 
axial (z) or radial (r) direction by specifying either the inlet or centre cell density (Nin) 
between 0 cell/cm2 to 2000 cell/cm2 (note that this is converted to a volume 
concentration by multiplying by the factor, a, for the simulation). This is to represent 
poor seeding efficiency with cells getting trapped at the inlet or settling to the 
bioreactor wall during the rocker roller seeding process. The linear equations represent 
this are as follows: 
 
𝑁𝑖𝑧 = 𝑁𝑖𝑛 + (𝑝 − 𝑁𝑖𝑛)
𝑧
𝐿
 at 0<r<R1 and 0<z<L, (37) 
 
for a z-direction linear cell distribution and 
 
𝑁𝑖𝑟 = 𝑁𝑖𝑛 + (𝑝𝑝 − 𝑁𝑖𝑛)
𝑟
𝑅1
 at 0<r<R1 and 0<z<L, (38) 
 
for the r-direction linear cell distribution. 
 
For both the cell distribution the constants variable p & pp have to be found to 
ensure the total cell number, T, remain fixed. T=1000 cells/cm2 x 158.8 cm2 ≈ 158,800 
cells. Expression (37) needed to be integrated between z=0 cm to z=L for πR12Niz=T, 
therefore 
𝑇
𝜋𝑅1
2 = ∫ [𝑁𝑖𝑛 + (𝑝 − 𝑁𝑖𝑛)
𝑧
𝐿
] dz 
𝐿
0
, (39) 
 
or 
 
𝑝 =
2𝑇
𝜋𝑅1
2𝐿
− 𝑁𝑖𝑛. (40) 
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To solve pp, expression (38) needs to be integrated between r= 0 and r= R1 with 
2πR1LNiz=T, therefore 
 
𝑇
2𝜋𝑅1 𝐿
= ∫ 𝑁𝑖𝑛 + (𝑝𝑝 − 𝑁𝑖𝑛)
𝑟
𝑅1
dz 
𝑅1
0
, (41) 
 
or 
 
𝑝𝑝 = 3 (
𝑇
2𝜋𝑅1
2𝑙
−
𝑁𝑖𝑛
6
)at 0<r<R1 and 0<z<L. (42) 
 
The initial cell distribution as given by (37) and (38) can be seen in Figure 22A 
& D, respectively.   
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Figure 22 (A) Cell density heat map of linear cell distribution in the z direction at day 0 and with an 
inlet concentration of 2000 cell/cm2. (B) Cell distribution at day 7 with Nin=2000 cell/cm2 with a linear 
cell distribution in the z direction. (C) Lactate concentration at day 7 with a Nin=2000 cell/cm2 with a 
linear cell distribution in the z direction. (D) The initial cell density of linear cell distribution in the r 
direction with a centre concentration of 2000 cell/cm2. (E) Cell density of linear cell distribution in the 
r direction at day 7 with Nin=2000 cell/cm2. (F) Lactate concentration for linear cell distribution in the 
r direction with Nin=2000 cell/cm2 at day 7.  
 
A linear heterogeneous cell distribution strongly impacts the final average cell 
density, more so in the z-direction than in the r-direction (Figure 23 A & Figure 24 A). 
This is shown in the cell density heat maps where a larger final cell distribution is 
developed in the z-direction. The cell density in the inlet half of the bioreactor almost 
reaches confluence, while the outlet half has a cell density of 114 cell/cm2 (Figure 22 
A B
C D
E F
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B). Conversely, the cell density gradient is reduced with an initial non-uniform linear 
cell distribution in the r direction, with a difference of 2x104 cells/cm2 in the centre of 
the bioreactor compared to 1.35x104 cells/cm2 at the reactor wall (Figure 22 E). This 
difference is firstly due to the fact that the initial distribution in the r direction is smaller 
than in the z-direction (Figure 22 A & D). However, the main driver of a large cell 
density gradient is the lactate build-up inhibiting the cell growth, which is more 
significant when the initial cell distribution in the z-direction is non-uniform. Although 
the lactate concentration does not reach as high a level in the z-direction heterogeneous 
seeding, a larger volume of the bioreactor is exposed to a higher lactate concentration 
(Figure 22 C & F). This results in a reduced growth rate for the cells located closer to 
the outlet. When this effect was observed in the heterogeneous initial cell distribution 
in the r direction, a cell density gradient developed along the length of the reactor 
(Figure 22 E).  
 
We concluded that a heterogeneous initial cell distribution alone is insufficient 
to cause the significant difference that was observed between the cell yield in the 
experimental bioreactor expansion and the traditional flask culture. However, 24 to 48 
hour delay in the cell growth was consistently observed in all experimental expansions, 
consistent with literature reports [199,223,239]. The quantified cell density measured 
on day two illustrates this lag in the experimental static bioreactor expansion growth 
curve (Figure 25). We hypothesise that this represents a phase in which the cells were 
recovering from extra handling and stress during the seeding process. We investigated 
the effect of a time lag on cell proliferation by examining 2 cases (24 hr and 48 hr). 
For the first 24 hr (48 hr) the cells could migrate but not proliferate. The growth term 
in equation (25) was modified as follows: 
 
𝑘 = 𝐻 (𝐾𝑚𝑎𝑥 (
𝐶𝐺
𝐾𝐺+𝐶𝐺
𝐶𝑂,𝐴
𝐾𝑂+𝐶𝑂,𝐴
𝐾𝐿
𝐾𝐿+𝐶𝐿
)). (43) 
 
H is the Heaviside step function 
 
 
𝐻[𝑡] = {
0, 𝑡 < 24 (48) ℎ𝑟
1, 𝑡 ≥ 24 (48) ℎ𝑟.
 (44) 
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Figure 23 Heterogeneous cell distribution are modelled as a linear function in the z direction, setting 
the cell concentration at the inlet (z= 0 cm) between 0 to 2000 cell/cm2with (A) 0 hr, (B) 24 hr and (C) 
48 hr cell quiescence. Note that the total initial cell number is the same in all conditions (158,800 cells). 
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Figure 24 Heterogeneous cell distribution modelled as a linear function in the r direction by setting the 
centre cell density (r=0) between 0 to 2000 cell/cm2 with 0 hr (F), 24 hr (G) and 48 hr (H) cell 
quiescence. Note that the total initial cell number is the same in all conditions (158,800 cells) 
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The modification to the model resulted in a better fit with the experimental 
bioreactor growth data (Figure 23 B & C, Figure 24 B & C). This suggests that a 
combination of a non-uniform initial cell distribution in the axial direction and an 
initial time lag in cell proliferation may explain the reduced cell yield seen in the 
bioreactor compared with the yield in the traditional flask culture.  Thus, distributing 
cells uniformly during the seeding process while minimising stress to the cells is the 
most important factor in achieving efficient cell expansion in a 3D culture device such 
as a bioreactor. This is very difficult to achieve in practice. While many seeding 
methods have been reported [296-298,347,348], inhomogeneity and cell stress have 
greatly affected the overall cell expansion in each.  
 
4.2.3 Modelling a Batch Bioreactor 
 
The model was modified to a batch reactor configuration, to investigate whether 
the cell distribution and cell growth lag was the main factor in bioreactor reduced 
growth rate compared to a flask culture. To do this, the terms involving the fluid flow 
through the scaffold were removed, and the mass balance equations for glucose (6), 
lactate (7) and oxygen (15) were modified as follows, 
 
 𝜕𝐶𝐺
𝜕𝑡
= ∇. (𝐷𝐺∇𝐶𝐺) −
𝑉𝑚𝑎𝑥,𝐺𝑁𝐶𝐺
𝐾𝑚,𝐺+𝐶𝐺
, (45) 
and 
 𝜕𝐶𝐿
𝜕𝑡
= ∇. (𝐷𝐿∇𝐶𝐿) + 𝑌𝐿/𝐶
𝑉𝑚𝑎𝑥,𝐺𝑁𝐶𝐺
𝐾𝑚,𝐺+𝐶𝐺
, (46) 
and 
 𝜕𝐶𝑂,𝐴
𝜕𝑡
= ∇. (𝐷𝑂∇𝐶𝑂,𝐴) −
𝑉𝑚𝑎𝑥,𝑂𝑁𝐶𝑂,𝐴
𝐾𝑚,𝑂+𝐶𝑂,𝐴
 for 0<r<R1. (47) 
 
The source boundary conditions (11) and (21) were also removed, with the 
addition of no flux boundary condition at the inlet for glucose, lactate and oxygen, 
defined as  
 
 𝜕𝐶𝑖
𝜕𝑧
= 0 at z=0, 0<r<R1. (48) 
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In the experimental protocol, a full volume medium exchange was performed 
every two days. To model this, the simulation was run for 48 hours. The cell density 
output was used as the initial cell distribution for the next simulation of 48 hours. This 
was repeated for the required 8 days of cell growth.  
 
 
Figure 25 Experimental and model average cell densities of a batch bioreactor with a full volume 
exchange every two days, exploring the effect of no medium exchange, cell death with every medium 
exchange, quiescence due to cell shock and heterogeneous cell distribution  
 
The cell growth in a batch reactor system was close to predicted for the perfusion 
bioreactor. The batch reactor had a similar growth rate even with no medium 
exchanges (Figure 25). However, the batch bioreactor experimental results were 
significantly less than the experimental perfusion results. This was likely due to the 
process of measuring the cells every two days, which required multiple full-volume 
medium exchanges as the metabolic probe in the medium was used to infer the cell 
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numbers. The resulting stress to the cells possibly killed or detached and washed away 
some of the cells. To explore this hypothesis, the model was modified so that this was 
reduced by 10% to 15% when the output cell density from the previous time period 
was used as the initial value. A heterogeneous initial cell distribution and lag phase 
was also added in order to produce a model output that fitted the static bioreactor 
expansion. This further confirmed that heterogeneous cell distribution and a lag phase 
are the main driving factors of the reduced growth in the bioreactor. The output 
confirms that measuring the cell numbers after each medium exchange was killing or 
detaching a proportion of the cells. These data support the change in protocol for the 
perfusion bioreactor expansion to cell quantification only at the end of the culture 
period. 
 
4.2.4 Using the Model to Investigate Scaling Up 
 
A packed bed bioreactor can be scaled-up in two ways by either increasing the 
dimensions of the reactor itself, or by reducing the size of individual packing material 
to increase the surface area. In chapter 2, scaled-up of the bioreactor to increase the 
reactor volume while retaining the same pellet size was achieved using GFP-mMSCs. 
However, equipment limitations prevented us from optimising the flow rate. A cyclic 
perfusion system was employed, rather than the preferred single pass circuit, and the 
lowest flow rate available was 30 ml/hr. In order to direct further scale up experiments 
and their optimisation, simulations were performed using the model that has been 
developed.  
 
The geometry of the model was changed to represent the bioreactor used in the 
trial scale-up experiments. The radius was adjusted so that the scaffold radius, R1= 2.5 
cm while the wall thickness remained at 0.5 cm, therefore R2= 3 cm. The length was 
increased to L=12 cm, which increased the reactor volume to 235.6 cm2. With the same 
pellet size as the base model this increased the reactor surface area to 2830 cm2. 
Assuming a cell density of 20,000 cells/cm2, this surface area is enough to support 
5.66x107 cells.  
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Figure 26 (A) Average cell density comparing scaled-up bioreactor R1=2.5 cm, R2= 3 cm and L= 12 cm 
with bioreactor design that includes wall diffusion, no wall diffusion, wall diffusion with additional 
central capillary providing oxygen. (B) Shear stress at different flow rates.  
 
The average cell density achieved in the scaled up bioreactor was similar to that 
obtained in the base model with a medium perfusion rate of 15 ml/hr (Figure 26 A). 
The shear stress was significantly below the 0.015 Pa which induces osteogenic 
differentiation at all flow rates (Figure 26 B). However, below 15 ml/hr it was apparent 
that the radial oxygen diffusion may not be enough to support cell growth, with the 
oxygen concentration coming close to depletion (Figure 27 A & D). This suggests that 
additional oxygen sources are required if the diffusion length is greater than 1 cm. 
Nevertheless, the design superiority of the wall diffusion bioreactor over the traditional 
packed bed bioreactor, with no oxygen sources other than through medium perfusion, 
is more apparent in the scaled up bioreactor. With medium perfusion flow rates below 
20 ml/hr one starts to observe a decrease in the average cell density (Figure 26 A). At 
flow rates of 15ml/hr there is an increasing region of oxygen depletion at the bioreactor 
outlet resulting in a decreased cell density at the outlet in the traditional packed bed 
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bioreactor (Figure 27 B & E). At the higher flowrates required for the scale up version, 
the lactate is removed at sufficiently rapid rate to ensure that its concentration does not 
reach a level to cause a significant deleterious effect (Appendix 12). 
 
To counteract this oxygen depletion and allow for lower flow rates to be used, 
the model was extended to include additional oxygen sources in the form of capillaries 
running through the bioreactor. Due to the limitations inherent in the axial symmetric 
model only one capillary could be added at the centre of the reactor. This is because 
axial symmetric model gives a 3D approximation of the 2D model by the rotation 
around the central axis of the rectangular geometry. The additions of a capillary a 
quarter of the way through the radius will actual result in an annulus, which is not an 
accurate representation and will require a full 3D model to do this accurately.  The 
geometry is outlined in (Figure 17 D). The lumen radius, Rc is 0.02 cm with the 
capillary wall outer radius wall, Rw is 0.12 cm, the vessel radius R1 is 2.62 cm and the 
outer wall R2 is 3.12 cm, the reactor length L=12 cm. We assumed that the capillary 
wall is composed of polymer with the same properties as PDMS. The boundary 
conditions for the oxygen transport within the vessel needed to be modified because 
of oxygen diffusion through the central wall. Therefore, the concentration of oxygen 
within the capillary wall (CO,C) is given by 
 
 𝜕𝐶𝑂,𝐶
𝜕𝑡
= 𝐷𝑃𝐷𝑀𝑆∇
2𝐶𝑂,𝐶  for Rc<r<Rw. (49) 
 
The same boundary conditions are applied at the outer vessel wall and for the 
capillary. There was zero flux of oxygen through the inlet and the outlet. 
 
𝜕𝐶𝑂,𝐵
𝜕𝑧
= 0 at z=0, L, Rc<r<Rw, (50) 
 
It was assumed that that there is constant oxygen concentration at the capillary 
lumen wall 
 
 𝐶𝑂,𝐶 = 𝑆𝑃𝐷𝑀𝑆 at r=Rc, 0<z<L. (51) 
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At the interface between the capillary wall and the medium, the boundary 
condition equation (23) is now replaced by 
 
 𝐷𝑂
𝜕𝐶𝑂,𝐴
𝜕𝑟
= 𝐷𝑃𝐷𝑀𝑆
𝜕𝐶𝑂,𝐶
𝜕𝑟
 at r=Rw, 0<z<L (52) 
and 
 𝐶𝑂,𝐴
𝑆𝑀
=
𝐶𝑂,𝐶
𝑆𝑃𝐷𝑀𝑆
 at r=Rw, 0<z<L. (53) 
 
This design change to the bioreactor model results in superior cell expansion at 
lower flow rates allowing the medium to be perfused at 10ml/hr resulting in a similar 
growth rate to the base model (Figure 26 A). There is no depletion of oxygen at the 
outlet of the bioreactor (Figure 27 F). However, the oxygen concentration is 10 fold 
less than the Michaelis-Menten oxygen growth constant KO. These results in a slower 
growth rate in at r= 1.25 cm in the bioreactor (Figure 27 C). Nevertheless, this concept 
warrants further investigation in the future. Further modelling analyses could be 
carried out using a three dimensional geometric models to allow for the addition of 
more oxygen providing capillaries the optimal since distance between capillaries needs 
to be determined.   
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Figure 27 Cell density heat map of bioreactor with (A) oxygen provided by diffusion through the wall, 
(B) no wall diffusion and (C) oxygen provided by both diffusion through the wall and central capillary 
at day 7 at a flow rate 15 ml/hr. Oxygen concentration with (D) oxygen provided by diffusion through 
the wall, (E) no wall diffusion and (F) oxygen provided by both diffusion through the wall and central 
capillary at day 7. 
 
A decrease in the particle size of the pellets further increases the available 
surface area. By decreasing the cylindrical pellet size to 1mm diameter by 1mm in 
length the reactor surface area increases to 7,493 cm2 which is enough to support 
1.5x108 MSCs. By further decreasing the cylinder pellet size to 0.5 mm diameter by 
0.5 mm in length the surface area increases to 14,985 cm2 which can support 3x108 
A D
B E
C F
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MSCs. The probable improvement in yield can be explored by modifying the current 
model. 
 
The simulations show that the average cell density is significantly less with both 
smaller pellet bioreactor designs with or without wall diffusion, unless the flow rate is 
increased to 50 ml/hr for the 1mm by 1mm pellets when the average cell density 
reaches 19000 cells/cm2 (Figure 28 A & B). Both designs with or without wall 
diffusion failed to support a pellet size of 0.5mm by 0.5mm because of oxygen 
depletion unless there is a significant increase in flow rate. The increased flow rate is 
possible as the shear stress acting is still below the threshold 0.015 Pa even with a flow 
rate of 90ml/hr (Figure 29 C). This high flow rate requires an increase in medium with 
consequent increased cost. A decrease in flow rate requires adding capillaries to 
provide additional oxygen sources to allow sufficient growth rate (Figure 28C). To 
further decrease the flow rate would require additional oxygen sources beyond the 
single central capillary.  
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Figure 28 Average cell density in the larger R1=2.5 and L=12 cm bioreactor with different pellet and 
flow rate for a bioreactor design that includes wall diffusion (A), no wall diffusion (B), wall diffusion 
with additional central capillary providing oxygen (C). 
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Figure 29 (A) Average cell density of the bioreactor design that provides oxygen by diffusion through 
the wall and central capillary using 0.5 mm pellets with different bioreactor geometries with the same 
reactor volume and surface area as a R1=2.5 and L=12 cm bioreactor with a flow rate of 30 ml/hr. (B) 
Average cell density of the bioreactor providing oxygen through the wall and central capillary at 
different flow rate rates. (C) Shear stresses of different pellet size and different flow rates. Shear stresses 
of different bioreactor geometries and flow rate (D). 
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Another way to reduce the flow rate without increasing the number of capillaries 
providing oxygen into the reactor is by changing the reactor shape. To explore this 
alternative, the model reactor dimensions were changed while the reactor volume 
remained constant. Figure 29 A shows the average cell density bioreactor with oxygen 
supplied through the wall and centre maintaining a reactor volume of 235.6 cm3 filled 
with 0.5 mm by 0.5mm cylindrical pellets changing the geometry of the reactor by 
adjusting the radius, R1 and the length, L. While still maintaining a medium perfusion 
rate at 30 ml/hr. It is clear that the long thin bioreactor performs the best, while the 
short fat reactor requires a higher flow rate to achieve the same growth rate. This is 
because oxygen is able to diffuse through to the centre of the long, thin vessel. This 
suggests that the maximum distance between oxygen sources should be between 0.75 
cm to 1 cm. In this way the flow rate can to be reduced without a significant effect on 
the cell growth rate (Figure 29 B). And since the shear stresses for the long thin reactor 
are above the threshold of 0.015 Pa if the flow rate is above 15 ml/hr this provides a 
suitable alternative reactor design (Figure 29 D).  
 
The modelling of this bioreactor type supports that this packed bed bioreactor 
design is superior over a traditional packed bed device, allowing for a reduced medium 
flow rate to be used, thus decreasing the cost of the cell expansion. Furthermore, the 
model gave further insight into future development and scale-up of the bioreactor 
design with the addition of diffusive oxygen sources. Moreover, the model provided 
an insight into the experimental results by highlighting the importance of the initial 
cell distribution on the final cell number achievable within the bioreactor.  
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Chapter 5: Summary of Findings and 
Future Directions 
For MSC based therapy to become routinely used in the clinic, the manufacture 
of the MSCs needs to become more efficient by replacing manual culture methods with 
an automated bioreactor system [224]. Bioreactors must have a large surface area for 
cell attachment and be optimised for the mass transport of nutrients and the elimination 
of waste [227].  
 
To provide the large surface area for MSC expansion a packed bed bioreactor 
design was selected over other high surface area devices that use microcarriers such as 
stirred tank and wave bag bioreactors. As these devices have no connectivity between 
individual micro-carriers, and empty micro-carriers do not contribute to the total 
surface area available to the culture. As a result, some micro-carriers rapidly reach 
confluence, whilst others remain empty; this requires frequent passaging to overcome 
localized space limitations [231,264]. Serum coated glass beads were first used as a 
packing material as they allowed for easier sterilisation of the device. However, the 
cell attachment to the beads was very weak, and the cells were easily delaminated. 
Thus, the scaffold material was changed to 2.5 mm radius by 3 mm in length 
cylindrical polystyrene pellets. This was due to material availability, ideally smaller 
500 µm spherical particles would have been better suited to be the bioreactor scaffold. 
As spheres have the largest surface area to volume ratio compared to cylinders also a 
smaller size gives a larger surface area in the same reactor volume. However, 
additional issue observed in the experiments using glass packing was the beads move 
during the seeding process could damage the cells. To prevent this the polystyrene 
cylinders were fused together to give one continuous scaffold that could easily be 
scaled up from 1.5 cm diameter by 7.5 cm length for the small scale bioreactor, 
providing 160cm2 of surface area to a 5 cm diameter by 12 cm length providing 2830 
cm2 of surface. This larger bioreactor size successfully expanded 1.12x108 GFP-
mMSCs and theoretically this could support up to 5.6x107 human MSCs.  
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Due to the hydrophobic nature and exhibit low surface energy of polystyrene, 
the scaffold surface needed to be modified to allow cell attachment spread and 
proliferation [263,266-268]. Rotary air plasma treatment was selected method to 
modify the scaffold surface as it provides similar growth surface chemistry to 
commercial TCP [265], which was observed experimentally Figure 7. In addition, this 
surface modification is scalable and is suitable to modify scaffold and the small 
particle size necessary for increasing the bioreactor surface area [269,274,287,288]. 
Air plasma surface was selected as surface characteristics are known to influence cell 
growth and behaviour or exhibit toxicity [260,349-353]. So that any experimental 
abnormalities observed in the bioreactor would be independent of the surface 
chemistry. See Appendix 1for the importance of testing modified surfaces for their 
effect on cell culture.  
 
Many other surface modifications are available using polymer coats that add 
more functionality to the bioreactor scaffold. Polymers such as poly-(N-isopropyl 
acrylamide) (pNIPAM), which changes the surface charge as a function of temperature 
allowing for non-enzymatic detachment of cells would be ideal candidate for the next 
evolution of the packed bed bioreactor design [354,355]. As this surface modification 
allows for better recovery of the cells as the process is less harsh [354,355]. A 
modification like this will enable better cell redistribution partway through the 
isolation and expansion process to redistribute the cell colonies to a more 
homogeneous distribution, which will greatly improve the final cell numbers harvest 
from the bioreactor. In addition to plasma polymerisation onto surfaces, by changing 
the surface topology, charge, chemical composition or hydrophilicity, stem cell fate 
can be directed to help maintain MSC phenotype and multipotency through physical 
actions through the interaction with Nano patterns or functional moieties can be 
subsequently used to immobilise proteins or other biomolecules to the surface once the 
plasma treated [288,290,353,354,356-361]. 
 
The other problem that a bioreactor design needs to take into account is the 
limiting metabolite oxygen due to its low solubility in the culture medium. Traditional 
bioreactors require high flow and mixing rates to provide an adequate oxygen supply. 
However, for MSC expansion, one of the main known limitations of perfusion 
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bioreactors is shear stress, as a force of 0.015 Pa has been shown to up-regulate the 
osteogenic pathways in human bmMSCs [218-221]. This shear stress threshold greatly 
limits the scalability of bioreactor devices that provide oxygen through the bulk media 
flow. To counteract this problem, the packed bed bioreactor design incorporated gas 
permeable wall made from gas permeable polymer PDMS that allows gas to diffuse 
radially into the bioreactor that enables the decoupling of oxygen from the bulk 
nutrient supply. This allowed a lower medium flow rate to be used in the experiments 
than has been previously been reported [226,228,231,295]. Through the development 
of 2D axial symmetric model in COMSOL in Chapter 4, showed that the flow rates 
used in the bioreactor experiments were below the shear stress threshold of 0.015 Pa, 
and that oxygen diffusion through the wall was sufficient to support MSC growth even 
when the bioreactor was scaled up. In addition, the model supported the hypothesis 
that decoupling the oxygen supply through the bulk nutrient flow by allowing oxygen 
to diffuse through the wall allows a lower perfusion rate. When a traditional packed 
bed bioreactor (without a gas permeable wall) was modelled, a 5 times higher flow 
rate of the medium was required to achieve a similar growth rate to our packed bed 
bioreactor. This difference represents a significant potential cost saving in the 
manufacturing process, especially if the medium is changed to a more expensive fully-
defined xeno-free medium.  
 
To further develop the bioreactor design, the scaled-up 2830cm2 bioreactor was 
modelled. The model did show a depletion of oxygen in the centre of the large scale 
bioreactor at lower flow rates, suggesting that oxygen diffusion through the wall alone 
could not keep up with the cell consumption at larger scale. To mitigate this, an 
additional diffusive source of oxygen was added to the bioreactor model in the form 
of a gas permeable capillary running through the centre of the bioreactor. The model 
predicts that this addition prevents oxygen depletion in the bioreactor. Furthermore, 
by scaling-up the bioreactor by changing the geometry of the bioreactor and decreasing 
the particle size, sufficient oxygen was provided by diffusion through the wall and the 
central capillary. A bioreactor modelled with a volume of 235.6 cm3 was able to 
support a cell number of 3x108 cells. Although a 2D axisymmetric model provided 
insight to the observed experimental results and helped to direct the design by 
demonstrating that additional diffusive oxygen sources can provide adequate oxygen 
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to the cells in the scaffold. A full 3D model is required to find the optimal geometry 
and placement of the oxygen delivery capillaries that will eliminate oxygen gradients 
in the bioreactor at high cell densities. This will potentially help to design a higher 
surface area bioreactor device that will allow 1010 MSCs to be manufactured, which is 
enough for approximately 100 doses. Limitations in the current model included the 
assumption that the dissolution of oxygen was instantaneous and that the concentration 
of oxygen at the wall-air interface was constant. The rate of oxygen diffusion from the 
air to the wall and from the wall to the medium will greatly affect the penetration of 
the oxygen into the bioreactor and the amount of oxygen available to the cells. Any 
new model must include the rates of dissolution of oxygen in the PDMS wall and into 
the medium, which is described by the Noyes-Whitney equation [362]. Ultimately, this 
will likely require additional oxygen capillaries due to an increase in time for the 
oxygen to diffuse through the membrane and will not be able to keep up with the rate 
of consumption especially at high cell densities. However, the experiments and 
modelling done in the thesis have been performed in normoxia. Hypoxic conditions 
have been reported to support MSC expansion and to maintain their stemness [200-
203,223]. Under hypoxic conditions, the highest oxygen concentration available 
would be 0.05 mM. Hypoxia would be very difficult to achieve while maintaining a 
shear stress below the 0.015 Pa threshold in a traditional packed bed bioreactor without 
a decoupled oxygen supply. It is essential that future scale-up experiments of the 
isolation and expansion of pMSCs will have to be performed in hypoxia in a packed 
bed bioreactor designed directed by 3D model incorporating many capillaries to 
provide additional diffusive sources of oxygen in addition to wall source, in order to 
expand MSCs in their preferred environment. 
 
Although adequate nutrients were supplied to the cells in the bioreactor, the 
model indicated that lactate impacted the cell growth in the small scale bioreactor. This 
highlighted the importance of waste product removal in low flow rate devices, 
especially in micro devices were very low flow rates are used at very high cell 
densities. An additional problem with the lower flow rate used in the bioreactor with 
the removal of the non-attached cells and debris that may have induced osteogenic 
differentiation [317] that was observed in the small scale experiments in the isolation 
and expansion of pMSCs in Chapter 3. Through the addition of process control will 
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allow for a better process to remove the cell debris from the bioreactor during the 
isolation process. As this process was done manually by a syringe which resulted in 
discontinuous flow and low flow rate, due to no controls in place to prevent detaching 
the MSCs. Automation of this process will allow the flow rate to be controlled so that 
it will be under the 0.015 Pa shear stress threshold and the flow will be continuous to 
better wash away the cell debris to prevent the osteogenic differentiation. The addition 
of temperature, pH, glucose, oxygen and flow rate probes would allow further control 
to of the environment to help maintain the required MSC phenotype. Furthermore, 
automation of the isolation of the pMSCs from placenta is possible which allows for 
the construction of a fully closed system bioreactor device for the isolation and 
expansion of pMSCs [210]. Due to limitations the regulation of medical devices, which 
stipulates that all components of such a device requires approval by governmental 
regulatory authority, it would be prudent to adapt the bioreactor to be incorporated into 
approved bioreactor control system and circuitry that is currently on the market, such 
as Quatum® Cell Expansion System (TerumoBCT) or FlexAct® (Sartorius stedim 
biotech). This will greatly reduce the registration cost and bring this packed bed 
bioreactor quicker to the market. 
 
The packed bed bioreactor system developed was able to achieve a growth rate 
for human pMSCs growing similar to that reported in the literature for other perfusion 
bioreactor devices [226,228,231,242,295]. In addition, we observed no dramatic 
difference in MSCs’ ability to differentiate after being expanded in the bioreactor 
compared to traditional flasks cultures. However, based on observations in both scales 
of bioreactor and with two cells types (GFP-mMSCs (Chapter 2) and human pMSCs 
(Chapter 3)), the growth rate of the cells expanding in the bioreactor was observed to 
be significantly less than in traditional flask cultures. This suggests that the reduced 
growth observed in our bioreactor is a common phenomenon among perfusion 
bioreactors and are unlikely to be due to the surface chemistry or culture conditions 
that are unique to our packed bed bioreactor. The finite element modelling in 
COMSOL showed that the reduced growth rate might be caused by a non-uniform cell 
distribution, most likely in the axial direction, with a cell lag phase of between 24 to 
48 hours due to the handling of the cells during the seeding method. This model output 
highlights the importance of achieving homogeneous cell distribution, while limiting 
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the stress on the cells during the seeding process. This was further supported when the 
bioreactor was modelled under static conditions, as it suggested that the MSCs were 
sensitive to manual manipulation.  The reduced growth rate observed in the MSCs 
grown under static compared to perfusion conditions were predicted by a model that 
included cell death during the medium exchanges. With the higher flow rates used in 
the scaled-up bioreactor, the lactate concentration did not cause the decrease in the 
growth rate that had previously been observed in the smaller reactor. Modelling could 
help in directing the development of a better method of cell seeding through use of 
particle settling and cell adhesion kinetics [363,364]. However, given the number of 
seeding methods currently in the literature, a homogeneous cell distribution is probably 
not achievable, and this should  be considered the trade off when expanding cells in a 
bioreactor [239,296,297,300,365,366]. 
 
pMSCs were selected over the more traditional source, bmMSCs, as a source of 
allogeneic MSCs to expand as a single placenta (500-700 g tissue) is sufficient for 
manufacturing several thousand units of allogeneic MSCs once expanded [231]. 
Furthermore, placental tissue can be harvested aseptically during a Caesarean section 
with no added risk to the mother or child. Although the ability for pMSCs to undergo 
trilineage mesoderm differentiation was significantly less than bmMSCs, the ability 
for both cell types conditioned medium to promote HaCaT growth was the equivalent. 
No correlation was observed between passage number and the MSCs’ ability to 
promote HaCaT growth, but this was largely due to data inconstancy. The conditioned 
medium derived from MSC aggregates was more consistent in promoting HaCaT 
growth, suggesting that modifying the cell culture to promote a specific phenotype 
may result in better and more consistent outcomes [7,203,367]. 
 
The difficulty in promoting HaCaT growth with MSC conditioned medium was 
the reproducibility, as no consistent result could be achieved. This was frustrating since 
the literature was showing that MSCs could support cell growth and promote tissue 
regeneration in animals and in lower level clinical trials. However, higher level clinical 
results have been published recently showing mixed results overall; there is no 
significant improvement when treating a wide range of conditions with MSC therapy 
[22,56,74,140,368]. In the case of ischemic heart repair there was no difference in 
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recovery between MSC treatment and placebo in clinical outcomes [129,369]. By 
reviewing our understanding of what defines a MSC and determining the function and 
mechanism of action, we can see that there are very large knowledge gaps. By far the 
largest deficiency is that there is no set of definitive marker. Where even selecting a 
more robust set of markers such as STRO-1, CD49a, CD105, CD133, CD146, CD271, 
SSEA-4 it is still no better than just relying on tissue culture plastic adherence to 
isolating a multipotent self-renewal MSCs [44,48,56,74,370]. This means that we are 
still dealing with a heterogeneous cell population that can change during culture 
[44,158,370]. This may explain the inconsistent results observed in the work presented 
here and the failure to achieve significant clinical outcomes. Also it has been assumed 
that MSCs are immune privileged, however they do activate the innate immune system 
meaning that intravenous injections of MSCs will be killed within 24 hours especially 
at high dosages [75,94]. In addition, when MSCs start to differentiate, they begin to 
express MHC receptors meaning that the use of allogenic MSCs for bone or cartilage 
repair is not ideal [371,372]. Most of the characterisation of MSCs have been done in 
vitro, which gives a false impression of their biological function, given that even 
fibroblasts can undergo trilineage mesodermal differentiation under the same protocol 
[56,372,373]. Many clinical applications are reliant on the “injury drug store” function 
of MSCs[8]. However, one cannot hope that the injected MSCs would respond to an 
injured or inflamed environment by secreting the right kind of cytokines as well as 
modulating the immune system; this suggests that this approach is neither evidence 
based nor scientific. Intravenous injected MSCs are embolised in the lungs which 
results in endothelial damage due to the activation of the innate immune system.  As 
previously stated the paracrine effect that is said to happen, must occur in a matter of 
hours, and it could even be related to cell death processes [56,105,197]. It is also noted 
that neural repair cannot happen without the presence of the peripheral immune system 
[374]. This all indicates that the tissue repair mechanism has more to do with activating 
the immune system than any direct regeneration by MSCs. Knowing the true 
mechanism of action of how MSCs respond in such an environment and discovering 
the true function of MSCs is paramount. 
 
Although this thesis has focused on expanding MSCs in the packed bed 
bioreactor, this bioreactor can be used for expansion or production of other cell types 
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such as platelets, or the production of protein, anti-bodies or other biological product 
production that requires adherent cells [375]. As MSCs conditioned medium can 
potentially promote tissue repair, the bioreactor can be used as a “conditioned medium 
factory”, as the large surface area and low rates our bioreactor can achieve allows for 
a more concentrated product requiring less downstream manipulation. The packed bed 
bioreactor could be used as a platform for an artificial liver [376-378]. With the 
advantage of an independent oxygen supply, the culture environment is better 
controlled with our device, meaning that this device is superior to the traditional 
packed bed bioreactor. 
 
In summation this thesis demonstrates that a packed bed bioreactor that has a gas 
permeable wall which allows for the decoupling of oxygen from the bulk nutrient flow 
can be used to isolate and expand pMSCs. This bioreactor is scalable, and finite 
element modelling of the bioreactor provided further direction to scale-up and improve 
future bioreactor designs. The model highlighted the most important factor in the cell 
growth in the bioreactor is the seeding distribution. Although the growth rate of 
pMSCs in the bioreactor was less than the cells grown in traditional on tissue culture 
flasks, the few extra days required for MSCs to reach confluence in the packed bed 
bioreactor represents an acceptable trade-off to have the potential for an automatable 
method to digest, isolate and expand pMSCs in a single closed bioreactor system.  
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Appendices 
Appendix 1 
Biological testing of plasma modified surfaces 
 
 
As part of our collaboration with Prof. Hans Griesser and Thomas Michl, from 
the University of South Australia and to further understand plasma surface 
modification. A method was developed to characterise two types of antibacterial 
surfaces, which were obtained from our collaborators, who performed the plasma 
surface modification of the bioreactor scaffolds. These surfaces released either nitric 
oxide (NOX) or chlorine (TCE) to inhibit bacterial growth. The main mechanisms of 
the antibacterial properties of nitric oxide is through the damage of DNA by reactive 
nitric oxide species that were generated by the autoxidation of nitric oxide, inhibition 
of DNA repair mechanisms, and increase generation of alkylating agents and hydrogen 
peroxide [379]. Chlorine has long been used as an antiseptic and disinfectant, through 
its action as an oxidising agent [380]. For potential medical application these surfaces 
must be assessed for human cell toxicity. Some of the data presented here, have been 
published in two of their papers [381,382]. 
 
As each cell type and application design is different, all modified surfaces must 
be tested for their biological properties and toxicities to ensure that they are suitable 
for the specific purpose. Cell adherence, cell morphology and cell growth in adherent 
cell lines are standard testing parameters [383-385]. Of course, these are not suitable 
for an application that demands non-adherent surfaces. In addition, it is difficult to 
correlate an observed reduced growth rate on a surface with surface characteristics that 
are known to either influence cell growth and behaviour or exhibit toxicity [260,349-
353]. Standards used to evaluate these surfaces must also address the potential 
depletion of essential media components, such as growth factors, proteins or lipids that 
are required for cell growth, which could be absorbed by the scaffold [386,387]. 
Finally, the use of serum supplemented media can complicate the analysis by either 
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contributing to or inhibiting the cytotoxic effects of the material being tested 
[388,389].  
 
In our system, a non-adherent myeloid leukemic cell line KG1a grown in a fully 
defined serum-free medium (X-VIVO 15) was used to evaluate the toxicity of a test 
surface independently of cell adhesion and complications due to serum. To test the 
biocompatibility of the surfaces, the cells were cultured in either direct contact with 
the test surface, cultured with the test surface but without direct cell contact, or in a 
24-hour conditioned medium away from the test surface. In addition to ethanol as a 
toxicity standard, a standard dilution of PBS was used to determine if any medium 
components were depleted. This pre-screening process determined if an observed 
reduced growth rate or cell depth on a test surface resulted from a toxic effect or a 
surface chemistry difference when compared to traditional tissue culture plastic. For 
surfaces that passed this screening, primary human bmMSCs were subsequently used 
to study the growth and morphology of adherent cells growing on such surfaces.  
 
Methods 
 
Cell Culture 
 
To isolate bone marrow MSCs, human bone marrow aspirates were obtained 
from volunteer donors. Written consent and ethical approval for these studies was 
granted by the Mater Health Services Human Research Ethics Committee (Ethics 
number: 1541A) and the Queensland University of Technology Human Research 
Ethics Committee in accordance with the Australian National Statement on Ethical 
Conduct in Human Research. Every 5 ml bone marrow aspirate was diluted to 35 ml 
with Phosphate buffer saline (PBS, Invitrogen). The mononuclear cells were isolated 
using Ficoll-Paque (GE Healthcare) density gradient at 400g for 20 minutes. The buffy 
layer was removed and washed in PBS and re-suspended in low glucose DMEM 
(Invitrogen) supplemented with 10% fetal bovine serum (Thermofisher), 100 units/mL 
penicillin, and 100 µg/mL streptomycin (Life Technologies), referred to as DMEM 
10% FBS from here on, and seeded into a single T175 flask (Nunc). The cells were 
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then incubated in 20% oxygen, 5% CO2 at 37 ⁰C for 24 hours to allow adherent cells 
to attach. The medium was then replaced with fresh medium and the flask was placed 
into a hypoxic incubator (2% oxygen and 5% CO2 at 37 ⁰C). The medium was replaced 
twice a week until the monolayer was 80-90% confluent before passaging. 
 
Kg1a myeloid leukaemia cell line was sourced from ATCC and was maintained 
in RPMI (Invitrogen) supplemented with 10% fetal bovine serum and 100 units/mL 
penicillin, and 100 µg/mL streptomycin (referred to RPMI 10% FBS from here on) in 
a T25 flask and incubated at standard cell culture conditions (5% CO2 at 37 ⁰C). The 
medium was changed twice weekly and the cells were passaged when they reached 
80-90% confluent.  
 
Surface Preparation 
 
Isopentyl nitrate that produces nitric oxide upon contact with water and is 
sufficiently volatile to be plasma polymerised onto a polyethylene terephthalate 
surface to give rise to the NOX surface. 1,1,1-Trichlorethane can be plasma 
polymerised due to volatility and release Cl- and Cl2
- ion in contact with water. The 
surfaces were either unwashed (dry), rinsed with 1 ml of distilled water for 15 minutes 
(wet) or repeating the wet process 20 times (washed). The method for plasma 
modification of the surfaces has been previously described by others [381,382]. The 
surface composition was unknown when the biological testing was performed. 
 
MSC Cytotoxicity Assay 
 
Passage 4 MSCs were seeded at 2000 cells/cm2 suspended in DMEM 10% FBS 
in a 24 well plate that had the surface modified (n=4). For the controls the 2000 
cell/cm2 were seeded into a normal tissue culture treated 24 well plate suspended in 
DMEM 10% FBS for the positive growth control (n=4) and serum free DMEM for the 
negative control (n=4). For the non-surface contact controls, 2000 cells/cm2 were 
seeded in DMEM 10% FBS into a normal tissue culture plate but with the surface 
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modified insert placed vertically into the well (n=4) and 2000 cell/cm2 were seeded in 
conditioned DMEM 10% FBS that has been in contact with the modified surface for 
24 hours in an incubator (5% CO2 at 37 ⁰C) (n=4). The cells were allowed to grow for 
4 days in standard tissue culture conditions (37⁰C and 5% CO2). The cells were 
quantified by the metabolic probe AlamarBlue (Invitrogen). The medium was replaced 
with a 1:50 dilution of AlamarBlue in DMEM 10% FBS and incubated for 3 hours. 
The fluorescence signal of the AlamarBlue in media was measured in a plate reader 
(FLUOstar Omega, BMG Labtech, Germany) along with a cell titration to infer cell 
numbers using excitation and emission filters of 544 and 590. 
 
KG1a Cytotoxicity Assay 
 
Kg1a cells were seeded at 20,000 cells/ml suspended in serum free media X-
VIVO 15 (Lonza) in a 24 well plate that had the surface modified (n=4). For the 
controls the 20,000 cells/ml were seeded into a normal tissue culture treated 24 well 
plate suspended in X-VIVO 15 for the positive growth control (n=4) and serum free 
RPMI for the negative control (n=4). For the non-contact controls, 20,000 cells/ml 
were seeded in X-VIVO 15 into a normal tissue culture plate but with the surface 
modified insert placed vertically into the well (n=4) and were seeded in conditioned 
X-VIVO 15 that had been in contact with the modified surface for 24 hours (n=4). The 
cells were grown for 4 days under standard tissue culture conditions (37⁰C and 5% 
CO2). The cells were counted by flow cytometry (FC500, Beckman Coulter, USA) 
using Flow-CountTM Fluorospheres (Beckman Coulter) with 3 µM propidium iodide 
to gate out the dead cells. 
 
Cytotoxicity Standards 
 
The MSCs 2000 cells/cm2 suspended in DMEM 10% FBS in a 24 well plate 
were titrated with PBS and ethanol (200 proof, >99.5%) to give a dilution and toxicity 
curve. For the KG1a cells, the cells were seeded at 20,000 cells/ml suspended in X-
VIVO 15 or RPMI 10% FBS and were titrated with PBS and ethanol. The cells were 
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allowed to grow for 4 days and the cell numbers were quantified by the AlamarBlue 
method for the MSCs and by flow cytometry for the KG1a cells. 
 
MSC Morphology on Modified Surfaces 
 
The medium was removed and the cells washed before being fixed with 4% 
paraformide in PBS for 10 minutes and then washed with PBS. The MSCs were 
permeabilised by 0.1% TRITON X-100 (Invitrogen) in PBS and washed again in PBS. 
The cells were stained with 50 µg/ml of phalloidin (Invitrogen) solution in 1% bovine 
serum albumin (BSA, Sigma) and PBS for 20 minutes at room temperature. The cells 
were washed again and stained with 5 µg/ml DAPI for 5 minutes. The cells were then 
washed with PBS and imaged with an ECLIPSE Ti epifluorescent microscope (Nikon, 
Japan).  
 
Statistics 
 
Refer to section 2.1.15. 
 
  
 148 Appendices 
Results 
 
Cytotoxicity Standards  
 
KG1a cell growth was first compared in different media types to demonstrate 
that XVIVO-15 medium did not adversely affect growth. No difference was observed 
between XVIVO-15 and the standard RPMI 10% FBS, even when XVIVO-15 was 
supplemented with FBS (Figure 30). However, non-supplemented RPMI did not 
support KG1a cell growth. 
 
 
Figure 30 KG1a cell growth after four days with different medium types. * indicates P<0.01. 
 
Increasing concentrations of ethanol were used as toxicity standards. For the 
KG1a cell standard, a difference in the level of toxicity between the two media types 
used was observed, with the ethanol having a greater toxic effect at lower 
concentration in the XVIVO 15 with a AC50 of 0.275 %vol/vol compared to the serum-
containing medium with a AC50 of 3x10-10 %vol/vol (Figure 31A). The cell type used 
is also an important consideration, as bmMSCs are far more resistant to the toxic 
effects of ethanol than KG1a cells with an AC50 of 1.55 % vol/vol (Figure 31 C). PBS 
dilution reduced the cell growth rate, but did not induce cell death, thus demonstrating 
that it is a suitable model for nutrient depletion (Figure 31 B&D). However, there was 
no significant reduction observed in final KG1a cell number until 80% vol/vol dilution 
of the medium with PBS.  
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Figure 31 (A) KG1a day 4 cell concentration exposed to ethanol in RPMI 10% FBS or XVIVO 15. (B) 
KG1a day 4 cell concentration after being diluted with PBS in RPMI 10% FBS or XVIVO 15. (C) 
bmMSC cell density after 4 days growth in DMEM 10% FBS exposed to ethanol. (D) bmMSC cell 
density after 4 days growth in DMEM 10% FBS diluted with PBS.  
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Toxicity of Chlorine Surfaces 
 
 
Figure 32 (A) KG1a growth after 4 days on two different TCE surfaces n=4. (B) KG1a growth after 4 
days on a TCE surfaces that have been unwashed (Dry), washed and dry (washed), and washed and 
remained wet (wet), the cells were either in contact or grown in conditioned media n=4. (C) Human 
bmMSC grown in contact or in conditioned media on surfaces that have been unwashed (dry), rinsed 
briefly (wet) or washed by rigorous method (washed) n=4. * indicates P<0.01. 
 
The surfaces being tested were plasma polymerised 1,1,1-trichloroethane (TCE) 
onto polystyrene 48 well plates. For the non-contact surface, the TCE was polymerised 
onto a surface of polyethylene terephthalate (PET) [381]. Surfaces were tested with 
the KG1a cells that underwent a variety of different vapour pressures, input powers 
and treatment times. All surfaces showed toxicity to KG1a cells in all surface types 
compared to KG1a cells grown in XVIVO 15 on commercial TCP. Figure 32A is an 
example of such results of direct surface contact. The surfaces were washed to 
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eliminate the possibility of unreacted polymer leaching from the surface into the 
medium. However, this had no effect on the toxicity for either KG1a cells or human 
bmMSCs, as both in contact and the conditioned media killed the cells (Figure 32 
B&C).  
 
Biocompatibility of Nitric Oxide Releasing Surfaces 
 
Isopentyl nitrite was plasma polymerised to untreated 48 well polystyrene tissue 
culture plates and PET coverslips. This surface releases NO upon contact with water, 
which has a toxic effect on bacteria [382,390]. This surface is non-cytotoxic to human 
cells, and KG1a cells shows no difference in cells grown on the NOX surfaces 
compared to cells grown on tissue culture plastic (Figure 33 A). A decrease in cell 
density for bmMSCs grown on the NOX surface was observed (Figure 33 B). 
However, no difference in cell density was observed when the cells were grown on 
commercial TCP and exposed to, but do not come in contact with, the NOX surfaces 
or with the conditioned medium. This suggests that the observed reduced growth rate 
of the bmMSCs was due to surface effects, but not to cytotoxic effects. No difference 
in the morphology of the bmMSC growing on either the NOX surfaces (Figure 33 
D&E) or commercial TCP (Figure 33 F&G) was observed. However, when the NOX 
surfaces were modified to have increased NO released, a significant reduction in the 
growth rate of the bmMSCs was noted for cells grown on the surface, no contact with 
surface or the conditioned media (Figure 33 C). This suggests that NO has an effect 
on the bmMSCs at higher concentrations. Although these modified NOX surfaces 
exhibited enhanced antibacterial properties, the surface type used in Figure 33 A&B 
was considered to be the most suitable for medical applications and still had adequate 
antibacterial properties [382].  
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Figure 33 KG1a growth after 4 days exposed to NOX surface n=4 (A). Human bmMSC growth after 4 
days exposed to NOX surface n=4 (B). Human bmMSC growth after 4 days on different types NOX 
surfaces that have stronger antibacterial properties n=4 (C). Human bmMSC growing on NOX surface 
(D & E) and tissue culture plastic (F & G) stained with phalloidin to show actin filaments (red) and 
DAPI to stain the nucleus (blue). * indicates P<0.01. 
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Discussion 
 
The correct controls and method to test the cytotoxicity of biomaterials and 
modified surfaces is important for the development of functionalised surfaces in 
bioreactors to satisfactorily control culture conditions [275,283,288]. A method that 
tests for cytotoxicity independently of cell adhesion is important to establish if an 
observed reduced growth rate resulted from either surface effects or from toxicity of 
the biomaterial or surface [260,349-353]. Non-adherent cells allow for greater 
flexibility for high throughput methods for cytotoxicity testing using flow cytometry 
[349,383,391]. Because serum can mask cytotoxicity, an appropriate serum-free 
medium is necessary [388,389]. In our experiments (in Figure 31A), the serum-
containing RPMI medium masked the toxic effect of ethanol up to 0.25 %vol/vol, 
while a toxic effect could be observed at 0.1%vol/vol in the serum-free media XVIVO 
15. The cell type was also important for detecting cytotoxicity; the KG1a cells being 
far more sensitive to ethanol compared to bmMSCs (Figure 31 A&C). This has been 
observed with other cytotoxic materials and chemicals, and demonstrates the 
importance of pre-screening. It also highlights the importance of testing and optimising 
the bioreactor surface for the cell type that will be actually growing in the bioreactor 
[392-394]. 
 
In addition to the cytotoxicity standard, an absorption or deficit of important 
media components standard was assayed by diluting the medium with PBS. Although 
complete cell death was not observed, the growth rate was reduced in both the KG1a 
cells and bmMSC as a result of the reduced available nutrients and growth factors 
(Figure 31 B&D). The bmMSC showed a steady decrease in cell density, resulting in 
half the final cell numbers at 80% vol/vol dilution compared with the positive control. 
However, no significant reduction in the KG1a cell number was evident until 80% 
vol/vol dilution with PBS (Figure 31B). It should be noted that KG1a is an 
immortalised cell line that can grow in the absence of growth factors, therefore its 
growth is limited only by nutrient concentration [395]. The uptake rate of nutrients is 
higher in KG1a cells compared to bmMSCs, for example glucose uptake rate is 346 
fmol/cell/hr for KG1a cells and 200 fmol/cell/hr for bmMSCs [334,396]. In addition, 
more KG1a cells per well were observed compared to bmMSCs, resulting in a higher 
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consumption of nutrients and other medium components that could result in a reduced 
growth rate.  
 
These methods were also used to test TCE plasma polymerised surfaces, which 
release chlorine and have an anti-bacterial effect [287]. The TCE surfaces were 
cytotoxic under all conditions and cell types (Figure 32). Although the TCE surface 
cannot be used clinically, this surface modification might still prove useful for non-
fouling piping or as an antibacterial coating on surgical gowns, masks and other 
personal protection equipment.  
 
The KG1a cells grown on the NOX surface displayed no reduction in the final 
cell number (Figure 33A), indicating that the surface was non-cytotoxic. However, 
when the bmMSCs were grown on the NOX surface there was a significant reduction 
in the final cell number, compared to bmMSCs grown on commercial TCP that were 
exposed to either the conditioned medium or grown in the presence of, but not in 
contact with, the NOX surface (Figure 33B). However, there was no difference in the 
morphology of the cells grown on the NOX surface (Figure 33 D, E, F &G) relative to 
TCP, suggesting that the reduction in cell number of the bmMSCs grown on the NOX 
surface was not a result of toxicity. Surface chemistry is known to affect cell growth 
and could account for the reduction of bmMSC growth rate [260,349-353]. In addition, 
nitric oxide can affect stem cell fate by inducing mobilisation and differentiation of 
MSCs [115,397-399]. The stronger NOX surface in Figure 33C might have reduced 
the bmMSC cell growth by signalling the bmMSC to alter the cell fate. In summary, 
the NOX surface is non-cytotoxic and is suitable for clinical applications. However, 
cell function alteration through nitric oxide signalling must be considered when using 
this surface.  
 
The method described here for evaluating material surfaces is effective for 
distinguishing between true toxic effects and other phenomena, such as changing cell 
fate through nitric oxide. This will be important for further development of bioreactor 
scaffolds to either add functionality to influence cell fate or to subsequently attach 
selection molecules to the surface to help isolate a preferred cell type [265,268,269]. 
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In addition, the reduce growth of bmMSCs on the NOX surface in comparison to 
traditional tissue culture plastic, highlights the importance of the surface 
characteristics on cell growth that has to be optimised for each cell type grown in a 
bioreactor.  
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Appendix 2 
Difference in media type and conditioning time on HaCaT growth 
 
 
To determine the most suitable media type and to optimise the method for 
producing conditioned media, HaCaT cell growth was measured with different media 
types and different lengths of media conditioning. After 4 days, pMSC and bmMSC 
XVIVO 15 conditioned medium yielded greater growth characteristics comparing the 
XVIVO 15 negative control. No effect of the conditioning time was observed on 
overall cell growth (Figure 34A). However, the pMSC and bmMSC DMEM 
conditioned medium only increased cell growth over the negative control after 30 
hours of conditioning. Also significantly greater growth was achieved in the XVIVO 
15 control medium compared to the DMEM conditioned medium. 
 
After 6 days of HaCaT growth in the condition medium, only after 24 hours 
conditioning the XVIVO 15 medium with pMSCs did the HaCaT number increase was 
significantly higher than the XVIVO 15 negative control. While it took 30 hours for 
the pMSC DMEM conditioned medium to be greater than the DMEM negative control. 
For the bmMSC condition medium, all time points for the XVIVO 15 conditioned 
medium resulted in an increase in HaCaT growth after 6 days compared to the XVIVO 
15 negative control. However, the DMEM bmMSC conditioned medium had no effect 
on HaCaT growth regardless of how long the medium was conditioned (Figure 34B). 
From this result it was concluded that XVIVO 15 was the best medium to use, firstly 
because it is a fully defined medium that not only contains glucose, vitamins and 
minerals but also includes fats as compared to DMEM that is a very basic medium 
requiring the addition of serum to support MSC growth. Secondly, it appears MSCs 
are in a better state to secrete any growth factors when grown in the presence of 
XVIVO with a far better impact on the HaCaT growth. It does appear that 30 hours of 
conditioning results in the best growth in all cases, we opted to use 48 hours as it is an 
easier time point to manage and it was the conditioning time of other publications 
[101,110,175,238,312]. 
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Figure 34 HaCaT cell density in response to pMSC and bmMSC for different conditioning times and 
medium types at (A) day 4 and (B) day 6. * indicates cell density significantly greater (p<0.01) over the 
DMEM negative control, # indicates significantly greater (p<0.01) over XVIVO 15 control and ** 
indicates a significate difference (p<0.01) between XVIVO 15 and DMEM media types. 
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Appendix 3 
Repeated conditioned medium experiments 
 
Repeat experiments where performed using different donors and different 
batches of conditioned medium (Figure 35 A & B). However, the results were 
inconsistent with the degree of HaCaT growth improvement was highly variable 
between the experiments.  
 
Figure 35 (A & B) HaCaT growth in response to pMSC and bmMSC conditioned medium from different 
donors and cell aggregates two different experimental replicates after 6 days. * Significant (p<0.01) 
increase over XVIVO 15 negative control. 
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Appendix 4  
Mesh refinement, difference in final average cell density (cell/cm2) at different 
mesh sizes (cm) 
 
 
A mesh refinement study was performed to find convergence of the result while not 
using excessive computing time. The maximum mesh size was reduced from 0.1cm 
to 0.02 cm in order to reduce the error of the approximate solution. The difference 
between the average cell different from 0.02 cm mesh size and the large mesh size 
was graphed to find where the result was convergent below the acceptable tolerance 
of 0.5 cell/cm2. A mesh size of 0.05 cm was the point where the solution converged 
within the acceptable tolerance and computing time.  
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Appendix 5 
Understanding Axis symmetric models and heat map figures. 
 
 
  
Colour Scale for nutrient 
concentration: blue being low 
concentration and dark red 
being high concentration
Maximum 
concentration 
present in 
reactor 
Minimum 
concentration 
present in 
reactor 
Flux direction arrows: the black arrow shows the direction of diffusive flux 
which is towards the centre of the reactor, the white arrow represents the 
combined flux of the diffusion and convection as the medium is pumped 
through the reactor.
As the wall has a higher solubility of oxygen than the 
medium in the reactor there needs to be two scales 
for the oxygen concentration: one for the wall and 
the other for the medium in the reactor.
A 2D axial symmetric model give an approximation 
of 3D object by rotation around the axis. This 
requires less computing power to solve the 
equations compared to a full 3D model. 
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Appendix 6  
Average cell density of the base model 
 
Heat map of the cell density within the bioreactor calculated from the base model for 
every two days. It shows the development of the non-uniform cell gradient from the 
inlet to the outlet which increases over time.  
 
Cell density day (cells/cm2) day 2 
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Cell density day (cells/cm2) day 4 
 
 
Cell density (cells/cm2) day 6 
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Cell density (cells/cm2) day 8 
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Appendix 7 
Oxygen concentration (mM) in reactor vessel and PDMS wall of the base model. 
White arrows represent direction of combined diffusive and convective flux and 
the black arrow represents the direction of the diffusive flux.  
 
Oxygen concentration (mM) day 2 
 
 
Oxygen concentration (mM) day 4 
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Oxygen concentration (mM) day 6 
 
 
Oxygen concentration (mM) day 8 
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Appendix 8 
Glucose concentrate (mM) for the base model. 
 
Glucose concentration (mM) day 2 
 
 
Glucose concentration (mM) day 4 
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Glucose concentration (mM) day 6 
 
 
Glucose concentration (mM) day 8 
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Appendix 9 
Lactate concentration (mM) of the base model. 
 
Lactate concentration (mM) day 2 
 
 
Lactate concentration (mM) day 4 
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Lactate concentration (mM) day 6 
 
 
Lactate concentration (mM) day 8 
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Appendix 10 
Changing wall thickness on oxygen concentration 
 
Oxygen concentration on day 7 in the centre of the bioreactor. 
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Oxygen concentration at the wall interface 
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Appendix 11 
Shear stress with varying flow rates. 
 
From the shear force was calculated from the Darcy flow as described in 4.1.2 
Shear Stress. The base model of 0.208 ml/hr was the flow rate used in the small scale 
experiments. 
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Appendix 12 
Glucose and oxygen concentration based on different flow rates in the wall 
diffusion bioreactor. 
 
30 ml/hr Glucose concentration day 7 
 
 
30 ml/hr Oxygen concentration day 7 
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20ml/hr Glucose concentration day 7 
 
 
20 ml/hr Oxygen concentration day 7 
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15 ml/hr Glucose concentration day 7 
 
 
15 ml/hr Oxygen concentration day 7 
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10 ml/hr Glucose concentration day 7 
 
 
10 ml/hr Oxygen concentration day 7 
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Appendix 13 
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of this Agreement. No breach under this agreement shall be deemed waived or 
excused by either party unless such waiver or consent is in writing signed by 
the party 
granting such waiver or consent. The waiver by or consent of a party to a 
breach of 
any provision of this Agreement shall not operate or be construed as a waiver 
of or 
consent to any other or subsequent breach by such other party. 
This Agreement may not be assigned (including by operation of law or 
otherwise) by 
you without WILEY's prior written consent. 
Any fee required for this permission shall be nonrefundable 
after thirty (30) days 
1/20/2016 RightsLink Printable License 
https://s100.copyright.com/AppDispatchServlet 4/5 
from receipt by the CCC. 
These terms and conditions together with CCC's Billing and Payment terms 
and 
conditions (which are incorporated herein) form the entire agreement between 
you and 
WILEY concerning this licensing transaction and (in the absence of fraud) 
supersedes 
all prior agreements and representations of the parties, oral or written. This 
Agreement 
may not be amended except in writing signed by both parties. This Agreement 
shall be 
binding upon and inure to the benefit of the parties' successors, legal 
representatives, 
and authorized assigns. 
In the event of any conflict between your obligations established by these 
terms and 
conditions and those established by CCC's Billing and Payment terms and 
conditions, 
these terms and conditions shall prevail. 
WILEY expressly reserves all rights not specifically granted in the 
combination of (i) 
the license details provided by you and accepted in the course of this licensing 
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transaction, (ii) these terms and conditions and (iii) CCC's Billing and 
Payment terms 
and conditions. 
This Agreement will be void if the Type of Use, Format, Circulation, or 
Requestor 
Type was misrepresented during the licensing process. 
This Agreement shall be governed by and construed in accordance with the 
laws of 
the State of New York, USA, without regards to such state's conflict of law 
rules. Any 
legal action, suit or proceeding arising out of or relating to these Terms and 
Conditions or the breach thereof shall be instituted in a court of competent 
jurisdiction 
in New York County in the State of New York in the United States of America 
and 
each party hereby consents and submits to the personal jurisdiction of such 
court, 
waives any objection to venue in such court and consents to service of process 
by 
registered or certified mail, return receipt requested, at the last known address 
of such 
party. 
WILEY OPEN ACCESS TERMS AND CONDITIONS 
Wiley Publishes Open Access Articles in fully Open Access Journals and in 
Subscription 
journals offering Online Open. Although most of the fully Open Access 
journals publish 
open access articles under the terms of the Creative Commons Attribution (CC 
BY) License 
only, the subscription journals and a few of the Open Access Journals offer a 
choice of 
Creative Commons Licenses. The license type is clearly identified on the 
article. 
The Creative Commons Attribution License 
 
The Creative Commons Attribution License (CCBY) 
allows users to copy, distribute and 
transmit an article, adapt the article and make commercial use of the article. 
The CCBY 
license permits commercial and nonCreative 
Commons Attribution NonCommercial 
License 
The Creative Commons Attribution NonCommercial 
(CCBYNC) 
License permits use, 
 184 Appendices 
distribution and reproduction in any medium, provided the original work is 
properly cited 
and is not used for commercial purposes.(see below) 
Creative Commons AttributionNonCommercialNoDerivs 
License 
The Creative Commons Attribution NonCommercialNoDerivs 
License (CCBYNCND) 
permits use, distribution and reproduction in any medium, provided the 
original work is 
properly cited, is not used for commercial purposes and no modifications or 
adaptations are 
made. (see below) 
Use by commercial "forprofit" 
organizations 
1/20/2016 RightsLink Printable License 
https:/ 
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Figure 3 Approval 
 
JOHN WILEY AND SONS LICENSE 
TERMS AND CONDITIONS 
Jan 20, 2016 
This Agreement between Michael Osiecki ("You") and John Wiley and Sons 
("John Wiley 
and Sons") consists of your license details and the terms and conditions 
provided by John 
Wiley and Sons and Copyright Clearance Center. 
License Number 3792880565341 
License date Jan 20, 2016 
Licensed Content Publisher John Wiley and Sons 
Licensed Content Publication Journal of Chemical Technology & Biotechnology 
Licensed Content Title Design of bioreactors for mesenchymal stem cell tissue 
engineering 
Licensed Content Author Pankaj Godara,Clive D McFarland,Robert E Nordon 
Licensed Content Date Feb 18, 2008 
Pages 13 
Type of use Dissertation/Thesis 
Requestor type University/Academic 
Format Print and electronic 
Portion Figure/table 
Number of figures/tables 1 
Original Wiley figure/table 
number(s) 
figure 3 
Will you be translating? No 
Title of your thesis / 
dissertation 
ISOLATION AND EXPANSION OF PLACENTAL DERIVED 
MESENCHYMAL STROMAL CELLS IN A PACKED BED BIOREACTOR 
Expected completion date Mar 2016 
Expected size (number of 
pages) 
200 
Requestor Location Michael Osiecki 
2 George St 
Brisbane, Australia 4000 
Attn: Michael Osiecki 
Billing Type Invoice 
Billing Address Michael Osiecki 
2 George St 
Brisbane, Australia 4000 
Attn: Michael Osiecki 
TERMS AND CONDITIONS 
This copyrighted material is owned by or exclusively licensed to John Wiley 
& Sons, Inc. or 
1/20/2016 RightsLink Printable License 
https://s100.copyright.com/AppDispatchServlet 2/5 
one of its group companies (each a"Wiley Company") or handled on behalf of 
a society with 
which a Wiley Company has exclusive publishing rights in relation to a 
particular work 
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(collectively "WILEY"). By clicking "accept" in connection with completing 
this licensing 
transaction, you agree that the following terms and conditions apply to this 
transaction 
(along with the billing and payment terms and conditions established by the 
Copyright 
Clearance Center Inc., ("CCC's Billing and Payment terms and conditions"), at 
the time that 
you opened your RightsLink account (these are available at any time at 
http://myaccount.copyright.com). 
Terms and Conditions 
The materials you have requested permission to reproduce or reuse (the 
"Wiley 
Materials") are protected by copyright. 
You are hereby granted a personal, nonexclusive, 
nonsub 
licensable (on a standalone 
basis), nontransferable, 
worldwide, limited license to reproduce the Wiley 
Materials for the purpose specified in the licensing process. This license, and 
any 
CONTENT (PDF or image file) purchased as part of your order, is for a 
onetime 
use only and limited to any maximum distribution number specified in the 
license. 
The first instance of republication or reuse granted by this license must be 
completed 
within two years of the date of the grant of this license (although copies 
prepared 
before the end date may be distributed thereafter). The Wiley Materials shall 
not be 
used in any other manner or for any other purpose, beyond what is granted in 
the 
license. Permission is granted subject to an appropriate acknowledgement 
given to the 
author, title of the material/book/journal and the publisher. You shall also 
duplicate 
the copyright notice that appears in the Wiley publication in your use of the 
Wiley 
Material. Permission is also granted on the understanding that nowhere in the 
text is a 
previously published source acknowledged for all or part of this Wiley 
Material. Any 
third party content is expressly excluded from this permission. 
With respect to the Wiley Materials, all rights are reserved. Except as 
expressly 
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granted by the terms of the license, no part of the Wiley Materials may be 
copied, 
modified, adapted (except for minor reformatting required by the new 
Publication), 
translated, reproduced, transferred or distributed, in any form or by any means, 
and no 
derivative works may be made based on the Wiley Materials without the prior 
permission of the respective copyright owner.For STM Signatory Publishers 
clearing permission under the terms of the STM Permissions Guidelines only, 
the 
terms of the license are extended to include subsequent editions and for 
editions 
in other languages, provided such editions are for the work as a whole in situ 
and 
does not involve the separate exploitation of the permitted figures or extracts, 
You may not alter, remove or suppress in any manner any copyright, 
trademark or 
other notices displayed by the Wiley Materials. You may not license, rent, sell, 
loan, 
lease, pledge, offer as security, transfer or assign the Wiley Materials on a 
standalone 
basis, or any of the rights granted to you hereunder to any other person. 
The Wiley Materials and all of the intellectual property rights therein shall at 
all times 
remain the exclusive property of John Wiley & Sons Inc, the Wiley 
Companies, or 
their respective licensors, and your interest therein is only that of having 
possession of 
and the right to reproduce the Wiley Materials pursuant to Section 2 herein 
during the 
continuance of this Agreement. You agree that you own no right, title or 
interest in or 
to the Wiley Materials or any of the intellectual property rights therein. You 
shall have 
no rights hereunder other than the license as provided for above in Section 2. 
No right, 
license or interest to any trademark, trade name, service mark or other 
branding 
("Marks") of WILEY or its licensors is granted hereunder, and you agree that 
you 
1/20/2016 RightsLink Printable License 
https://s100.copyright.com/AppDispatchServlet 3/5 
shall not assert any such right, license or interest with respect thereto 
NEITHER WILEY NOR ITS LICENSORS MAKES ANY WARRANTY OR 
REPRESENTATION OF ANY KIND TO YOU OR ANY THIRD PARTY, 
EXPRESS, IMPLIED OR STATUTORY, WITH RESPECT TO THE 
MATERIALS 
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OR THE ACCURACY OF ANY INFORMATION CONTAINED IN THE 
MATERIALS, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED 
WARRANTY OF MERCHANTABILITY, ACCURACY, SATISFACTORY 
QUALITY, FITNESS FOR A PARTICULAR PURPOSE, USABILITY, 
INTEGRATION OR NONINFRINGEMENT 
AND ALL SUCH WARRANTIES 
ARE HEREBY EXCLUDED BY WILEY AND ITS LICENSORS AND 
WAIVED 
BY YOU. 
WILEY shall have the right to terminate this Agreement immediately upon 
breach of 
this Agreement by you. 
You shall indemnify, defend and hold harmless WILEY, its Licensors and 
their 
respective directors, officers, agents and employees, from and against any 
actual or 
threatened claims, demands, causes of action or proceedings arising from any 
breach 
of this Agreement by you. 
IN NO EVENT SHALL WILEY OR ITS LICENSORS BE LIABLE TO 
YOU OR 
ANY OTHER PARTY OR ANY OTHER PERSON OR ENTITY FOR ANY 
SPECIAL, CONSEQUENTIAL, INCIDENTAL, INDIRECT, EXEMPLARY 
OR 
PUNITIVE DAMAGES, HOWEVER CAUSED, ARISING OUT OF OR IN 
CONNECTION WITH THE DOWNLOADING, PROVISIONING, 
VIEWING OR 
USE OF THE MATERIALS REGARDLESS OF THE FORM OF ACTION, 
WHETHER FOR BREACH OF CONTRACT, BREACH OF WARRANTY, 
TORT, 
NEGLIGENCE, INFRINGEMENT OR OTHERWISE (INCLUDING, 
WITHOUT 
LIMITATION, DAMAGES BASED ON LOSS OF PROFITS, DATA, 
FILES, USE, 
BUSINESS OPPORTUNITY OR CLAIMS OF THIRD PARTIES), AND 
WHETHER OR NOT THE PARTY HAS BEEN ADVISED OF THE 
POSSIBILITY 
OF SUCH DAMAGES. THIS LIMITATION SHALL APPLY 
NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF 
ANY 
LIMITED REMEDY PROVIDED HEREIN. 
Should any provision of this Agreement be held by a court of competent 
jurisdiction 
to be illegal, invalid, or unenforceable, that provision shall be deemed 
amended to 
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achieve as nearly as possible the same economic effect as the original 
provision, and 
the legality, validity and enforceability of the remaining provisions of this 
Agreement 
shall not be affected or impaired thereby. 
The failure of either party to enforce any term or condition of this Agreement 
shall not 
constitute a waiver of either party's right to enforce each and every term and 
condition 
of this Agreement. No breach under this agreement shall be deemed waived or 
excused by either party unless such waiver or consent is in writing signed by 
the party 
granting such waiver or consent. The waiver by or consent of a party to a 
breach of 
any provision of this Agreement shall not operate or be construed as a waiver 
of or 
consent to any other or subsequent breach by such other party. 
This Agreement may not be assigned (including by operation of law or 
otherwise) by 
you without WILEY's prior written consent. 
Any fee required for this permission shall be nonrefundable 
after thirty (30) days 
1/20/2016 RightsLink Printable License 
https://s100.copyright.com/AppDispatchServlet 4/5 
from receipt by the CCC. 
These terms and conditions together with CCC's Billing and Payment terms 
and 
conditions (which are incorporated herein) form the entire agreement between 
you and 
WILEY concerning this licensing transaction and (in the absence of fraud) 
supersedes 
all prior agreements and representations of the parties, oral or written. This 
Agreement 
may not be amended except in writing signed by both parties. This Agreement 
shall be 
binding upon and inure to the benefit of the parties' successors, legal 
representatives, 
and authorized assigns. 
In the event of any conflict between your obligations established by these 
terms and 
conditions and those established by CCC's Billing and Payment terms and 
conditions, 
these terms and conditions shall prevail. 
WILEY expressly reserves all rights not specifically granted in the 
combination of (i) 
the license details provided by you and accepted in the course of this licensing 
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transaction, (ii) these terms and conditions and (iii) CCC's Billing and 
Payment terms 
and conditions. 
This Agreement will be void if the Type of Use, Format, Circulation, or 
Requestor 
Type was misrepresented during the licensing process. 
This Agreement shall be governed by and construed in accordance with the 
laws of 
the State of New York, USA, without regards to such state's conflict of law 
rules. Any 
legal action, suit or proceeding arising out of or relating to these Terms and 
Conditions or the breach thereof shall be instituted in a court of competent 
jurisdiction 
in New York County in the State of New York in the United States of America 
and 
each party hereby consents and submits to the personal jurisdiction of such 
court, 
waives any objection to venue in such court and consents to service of process 
by 
registered or certified mail, return receipt requested, at the last known address 
of such 
party. 
WILEY OPEN ACCESS TERMS AND CONDITIONS 
Wiley Publishes Open Access Articles in fully Open Access Journals and in 
Subscription 
journals offering Online Open. Although most of the fully Open Access 
journals publish 
open access articles under the terms of the Creative Commons Attribution (CC 
BY) License 
only, the subscription journals and a few of the Open Access Journals offer a 
choice of 
Creative Commons Licenses. The license type is clearly identified on the 
article. 
The Creative Commons Attribution License 
The Creative Commons Attribution License (CCBY) 
allows users to copy, distribute and 
transmit an article, adapt the article and make commercial use of the article. 
The CCBY 
license permits commercial and nonCreative 
Commons Attribution NonCommercial 
License 
The Creative Commons Attribution NonCommercial 
(CCBYNC) 
License permits use, 
distribution and reproduction in any medium, provided the original work is 
properly cited 
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and is not used for commercial purposes.(see below) 
Creative Commons AttributionNonCommercialNoDerivs 
License 
The Creative Commons Attribution NonCommercialNoDerivs 
License (CCBYNCND) 
permits use, distribution and reproduction in any medium, provided the 
original work is 
properly cited, is not used for commercial purposes and no modifications or 
adaptations are 
made. (see below) 
Use by commercial "forprofit" 
organizations 
1/20/2016 RightsLink Printable License 
https://s100.copyright.com/AppDispatchServlet 5/5 
Use of Wiley Open Access articles for commercial, promotional, or marketing 
purposes 
requires further explicit permission from Wiley and will be subject to a fee. 
Further details can be found on Wiley Online Library 
http://olabout.wiley.com/WileyCDA/Section/id410895. 
html 
Other Terms and Conditions: 
v1.10 Last updated September 2015 
Questions? customercare@copyright.com or +18552393415 
(toll free in the US) 
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